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Nitric oxide (NO) is known to be present in increased amounts in the breath of acute
asthmatics and evidence suggests that airway epithelial cells release NO, particularly
in response to pro -inflammatory cytokines such as tumor necrosis factor-a (TNF-a).
NO is synthesised by the conversion of L-arginine to L-Citruline by the enzyme NO
synthase (NOS), which is present in a wide range of cell types and can be both
inducible and constitutive. There is evidence that oxidative stress can induce NO
synthase (NOS) mRNA synthesis in airspace epithelial cells in vitro, through the
activation of the transcription factor NF-kB. It has been shown that NF-kB
activation is necessary for inducible NOS (iNOS) induction and NF-kB is thought to
be oxidant regulated, either directly by the oxidants themselves, or by the antioxidant
state of the cell. Cytokines, such as TNF-a, which result in increased NO release
from lung epithelial cells may act on the mitochondria, increasing mitochondrial
release of superoxide anions, which may, inturn, activate NF-kB resulting in iNOS
induction and NO release. Glutathione (GSH) is a ubiquitous low weight molecular
thiol, which is required for many cellular functions. Moreover, as a major antioxidant
it has a role in maintaining the reduction/oxidation (redox) potential of the cell and is
important in protecting the cells against oxidative damage, such as that induced by
superoxide anions. There is evidence to suggest that the ratio of oxidised GSH
(GSSG) to reduced GSH may be critical in oxidant induced NF-kB activation. The
level of GSSG is thought to be involved in the modification of proteins involved in
the cascade leading to NF-kB activation and in the degradation of IkB, the inhibitory
subunit of NF-kB. It has also been shown that NF-kB requires a reductive
environment for DNA binding and GSH levels may therefore affect NF-kB binding
to DNA. Furthermore, induction ofNO by cytokines and oxidants is associated with
a decrease in intracellular GSH in several cell types, and thus it is likely that an
oxidant/antioxidant balance is important in the regulation of NF-kB activation.The
hypothesis of this thesis is that changes in intracellular GSH redox state effect iNOS
mRNA, via NF-kB activation, in response to both cytokines and oxidants. The data
presented show that both cytokines and oxidants (H2O2) induce iNOS mRNA and
NO release in both the human Alveolar Type II epithelial cell line (A549) and the
human Bronchial Epithelial cell line (16HBE14o-) and this NO release is
concomitant with a decrease in GSH. The decrease in GSH is not, however, due to
the production of NO as shown by the use of NO inhibitors supporting a role for
GSH in NO induction. Decreasing intracellular GSH levels with BSO caused an
increase in iNOS induction and NO release suggesting that decreased GSH levels
may have a role in iNOS induction. GSH levels were increased by 4 thiol compounds
to determine if increased GSH levels could prevent or decrease iNOS induction.
Increased GSH levels decreased H2O2 induction, but not cytomix induction of
NF-kB activation and NO release. This suggests that increasing oxidant stress
directly, using an oxidant, results in NF-kB activation and iNOS induction, and this
increase can be inhibited by increasing intracellular GSH levels. However increasing
NO release and NF-kB activation with a mixture of cytokines is not, however,
decreased by increased GSH levels, suggesting an alternate pathway exists for
NF-kB activation and iNOS induction by cytomix. In conclusion, this data supports
the hypothesis that the redox status of the cell, particularly GSH is involved in the
activation of NF-kB and induction of iNOS by oxidants. GSH does not, however,
appear to play a critical role in activation of NF-kB and induction of iNOS by
cytomix suggesting iNOS induction can be achieved by different signalling
pathways. These data may be important in inflammatory disorders of the lung and
may provide information on the uses of antioxidants as a means of inhibiting NO
during lung inflammation.
DECLARATION
he work presented in this thesis was carried out solely by the author, unless
otherwise stated, under the supervision of Professor W. MacNee and Professor K.
Donaldson, Wilkie Laboratory, University of Edinburgh.
Tammy Watchorn
ACKNOWLEDGEMENTS
I wish to express my sincere thanks to the following people for all their support, help
and advice throughout this period of research.
To my parents Norah and Ken Watchorn for encouragement, moaning and financial
support.
To my 'bloke' Kevin McGlynn for encouragement, moaning and financial support.
To my brother Mark, for meaningless conversations and quality hairstyles.
To Ma McGlynn for putting up with the moaning and ranting of 'Grandpa Simpson'.
To my friends in the lab Dr Brigitte Mulier (for moaning at) and Dr Jo Murray (for
moaning at with a pint or three).
And finally to staff in the Rayne Lab for help and advice, including Dr Ellen Drost,
Dr Trevor Walker, Mark Lawson, Dr Irfan Rahman, Dr John Simpson, Dr Carol Ward
and Eileen Neal.
ABBREVIATIONS
16HBE14o"(16HBE) Human bronchial epithelial cell line
A549 Human alveolar type II cell line
AA Non-essential amino acid mixture
ABC Avidin biotinylated complex
ALF Airway lining fluid
APS Ammonium persulphate
ARE)S Adult respiratory distress syndrome
BAL Bronchoalveolar lavage
BCNU Bis 2 chloroethyl nitrosourea




CFTR Cystic fibrosis transmembrane conductance regulator
cNOS Constitutive nitric oxide synthase
CO2 Carbon dioxide
COPD Chronic Obstructive Pulmonary Disease




DMEM Dulbecco's modified eagles medium
DMSO Dimethylsulfoxide
DNA Deoxyribonucleic acid
DTNB 5,5'-Dithiobis (2-nitrobenzoic acid)
DTT Dithiothreitol
EDTA Ethylene diamine tetracetic acid
ELF Epithelial lining fluid




y-GCS Gamma glutamylcysteine synthetase





GSHMEE Glutathione monoethyl ester
GSNO Nitrosothiols





IkB Inhibitory protein kappa B
ILl-p Interleukin 1- p
iNOS Inducible nitric oxide synthase






MEM Minimal essential medium
MgCl2 Magnesium chloride
MnSOD Manganese superoxide dismutase
mRNA Messenger ribonucleic acid
NAC N-acetylcysteine
NaCl Sodium chloride
NADPH Reduced nicotinamide adenine dinucleotide phosphate
NaF Sodium fluoride
NAL N-acetylcysteine L-lysinate














PBS Phosphate buffered saline





ROS Reactive oxygen species







TEMED N' ,N' ,N' ,N' ,Tetramethylethylenediamine




Chapter 1 Introduction 4
1. THE LUNG AND ROS 5
1.1. STRUCTURE OF THE LUNGS 5
1.2 INFLAMMATORY CELLS 7
1.3 REACTIVE OXYGEN SPECIES (ROS) 8
1.4 ROS AND OXIDATIVE DAMAGE 11
2 Antioxidants 13
2.1 THE PREVENTION AND COMPARTMENTALISATION OF FREE
RADICALS 14
2.2 THE CONVERSION OF OXIDANTS TO LESS REACTIVE SPECIES 14
2.3 REPAIR OF OXIDANT INDUCED INJURY 17
2.4 EXTRACELLULAR ANTIOXIDANT DEFENCES 17
2.5 NO AS AN ANTIOXIDANT 18
3 Inflammatory Disorders Involving ROS And Antioxidants 19
3.1 ASTHMA 19
3.2 ARDS 21
3.3 OTHER RESPIRATORY DISORDERS ASSOCIATED WITH INCREASED
ROS 22
4 Nitric Oxide (NO ) 24
4.1 BACKGROUND 24
4.2. METABOLISM/BIOCHEMISTRY 25
4.3 NO AS A FREE RADICAL 28
4.4 NO AS A MESSENGER AND TOXIN 33
4.5 NO IN LUNG DISORDERS 34
5 Glutathione (L-y-glutamyl-L-Cysteinylglycine) 38
5.1 GSH METABOLISM 39
5.2 GSH AND THE LUNGS 42
6. Nuclear Factor-KappaB (NF-kB) 43
6.1 STRUCTURE 44
6.2 THE INHIBITORY SUBUNIT IKB 45
6.3 ACTIVATION OF NF-kB 46
6.4 REDOX REGULATION OF NF-KB 46
7 Hypothesis 50
8 Aims 50
8.1 SPECIFIC OBJECTIVES: 50




2.2.1 CELL CULTURE TECHNIQUES 51
2.2.2 EXPERIMENTAL TREATMENT OF CELLS 53
2.2.3 ASSAYS 54
2.2.3.1 PREPARATION OF CELLS PRIOR TO ASSAYS 54
2.2.3.2 CELL COUNTS AND CELL VIABILITY 55
2.2.3.3 NITRIC OXIDE (NO ) ASSAY 55
2.2.3.4 REDUCED GLUTATHIONE (GSH) ASSAY 56
2.2.3.5 OXIDISED GSH (GSSG) 56
2.2.3.6 MODIFICATION OF TIETZE METHOD 57
2.2.3.7 TOTAL PROTEIN ASSAY 58
2.2.4 REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION 59
2.2.4.1 RNA EXTRACTION 59
2.2.4.2 CDNA PREPARATION 59
2.2.4.3 PCR 60
2.2.4.4 ELECTROPHORETIC MOBILITY GEL SHIFT ASSAY 61
2.2.4.6 LABELLING OF THE CONSENSUS OLIGONUCLEOTIDE FOR NF-
kB 62
2.2.4.7 SAMPLE PREPARATIONS 63
2.2.5 IMMONOPEROXIDASE (ABC) CYTOKERATIN STAINING OF CELLS
FOR EPITHELILA MARKERS 63
2.2.6 STATISTICAL ANALYSIS 64
Chapter 3 Epithelial characteristics of A549 and 16HBE cells and
the role ofGSH in cell proliferation 65
3.1 INTRODUCTION 65
3.2 CHARACTERISATION OF THE EPITHELIAL CELL LINES: 65
3.3 CELL CONFLUENCY 67
3.4 REDUCED GSH LEVELS IN THE EPITHELIAL CELL LINES 69
3.5 SUMMARY 74
3.6 DISCUSSION 74
Chapter 4 Induction of Nitric Oxide in Both A549 and 16HBE Cells
and the Effect of Nitric Oxide Induction on GSH Levels 77
4.1 INTRODUCTION 77
4.2 INDUCTION OF NO AND NITRITE PRODUCTION IN EPITHELIAL
CELLS IN RESPONSE TO CYTOKINES AND LPS 77
4.3 INHIBITION OF NO RELEASE BY THE NOS INHIBITOR LN°-
MONOMETHYL-L-ARGININE (L-NMMA) 84
4.4 INDUCTION OF NO USING THE OXIDANT H202 85
4.5 INTRACELLULAR GSH LEVELS FOLLOWING CYTOMIX AND H202.89
4.6 PCR ANALYSIS OF iNOS 95
4.7 SUMMARY 98
4.8 DISCUSSION 99
Chapter 5 The Effect ofManipulating GSH Levels on NO' Induction
and Release In Both A549 and 16HBE Cells 105
2
5.1 INTRODUCTION 105
5.2 MANIPULATION OF GSH LEVELS 105
5.3 THE EFFECT OF DEPLETING INTRACELLULAR GSH WITH BSO ON
NO PRODUCTION 106
5.4 THE EFFECT OF INCREASING GSH LEVELS WITH THIOL
COMPOUNDS ON NO RELEASE 112
5.5 THE EFFECT OF PRE-TREATING CELLS WITH THIOL COMPOUNDS
ON CYTOMIX AND H202 INDUCED NO RELEASE 117




Chapter 6 The effect of cytokines, H2O2 and modulating GSH levels
on NF-kB activation 130
6.1 INTRODUCTION 130
6.2 A TYPICAL GEL SHIFT 131
6.3 THE EFFECT OF CYTOMIX, INDIVIDUAL CYTOKINES AND LPS ON
NF-KB ACTIVATION 134
6.4 THE EFFECT OF MODULATING INTRACELLULAR GSH LEVELS BY
BSO AND THIOL COMPOUNDS ON NF-KB ACTIVATION 138
6.5 THE EFFECT OF ROTENONE ON CYTOKINE AND H202 INDUCED
NF-kB ACTIVATION 146
6.6 THE EFFECT OF ROTENONE ON iNOS mRNA LEVELS 154
6.7 INTRACELLULAR GSSG:GSH RATIO IN BOTH A549 AND 16HBE
CELLS AT TIME POINTS WHEN NF-KB IS ACTIVATED 156
6.8 SUMMARY 158
6.9 DISCUSSION 159
7 Final Discussion 168
7.1 SUMMARY 168
7.2 CONCLUSIONS 169
7.3 TO CONCLUDE: 173




Oxygen was first characterised by Priestly and Lavoisier between 1772 and 1774
(Chinard, 1998) as a stable, odorless, tasteless and colourless gas. Oxygen is used in
aerobic life form to oxidise carbon and hydrogen rich substrates, resulting in the
chemical energy and heat essential for life. The major source of energy for most
aerobic life arises from the reduction of oxygen to H2O during respiration by the
addition of 4 electrons. Reduction of oxygen during respiration can result in the
formation of intermediates, which are both reactive and unstable and known as
reactive oxygen species (ROS). ROS are generally harmful to their environment, but
can be involved in physiological interactions such as the killing of micro-organisms
(Bast et al., 1991) and the regulation of smooth muscle contraction (Bast et al.,
1991).
The production ofROS is normally balanced in tissues by antioxidants, an imbalance
generally resulting in oxidant induced injury and it is widely accepted that ROS play
a role in the pathology ofmany diseases (Gutteridge, 1993).
Nitric oxide (NO) is a colourless gas and a weak reducing agent, first recognised as a
gas by Priestly in 1772 (Gutteridge, 1994). It is a noxious chemical in the
atmosphere but can be beneficial in the body in controlled doses. Recently there has
been biological interest in NO due to the observation that it is analogous to the
endothelium derived relaxing factor (EDRF) (Ignarro et al., 1987; Palmer et al.,
1987). Although a free radical, it is not as reactive as oxygen metabolites. At low
levels it is beneficial, causing bronchodilation and smooth muscle relaxation (Barnes
and Belvisi, 1993; Bast et al., 1991), but becomes cytotoxic at higher levels, forming
peroxynitrite, a ROS (Ignarro and Murad, 1995) which decomposes to form a toxic
hydroyxl-like radical (Gutteridge, 1994). NO can therefore act as both an antioxidant
and an oxidant.
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There has been widespread research in the area of oxidants and the antioxidant
defense system, as well as on the effects of NO and its metabolites. The balance
between ROS, antioxidants and NO levels are important in disease states, especially
in the bronchial and alveolar epithelium, and it is in these cells that the in vitro
studies in this thesis were carried out.
The antioxidant GSH is a major focus of this study, since it plays a central role as a
major protective intracellular and extracellular antioxidant. Its role in NO
induction/inhibition was investigated.
1. THE LUNG AND ROS.
The anatomy of the lung is important in the process of diseases due to both
exogenous and endogenous oxidants. The following paragraph describes the anatomy
of the lung.
1.1. STRUCTURE OF THE LUNGS.
The lungs are a system of symmetrical branching dichotomous tubes, starting at the
mouth and nose and terminating at the alveolus, the ultimate unit of gaseous
exchange. The airways can be divided into 2 portions, the upper airways consisting
of the nose, nasal cavities, pharynx and larynx. The larynx is considered to be the
boundary between the upper and lower respiratory tract (Jeffrey, 1998). The lower
respiratory tract begins with the trachea and branching begins by division of the main
bronchi, after which there are some 23 generations of branches before the alveoli are
reached. There is progressive loss of cartilage, which is responsible for structural
support, from the upper airways to the lower airways. The last bronchiolar divisions,
which contain much less developed ciliated lining epithelium, are the terminal
bronchi and lead into the respiratory bronchioles which have alveoli in the walls. The
terminal bronchioles are the last of the soley conducting airways, the respiratory
bronchioles and alveoli being involved in gaseous exchange. Support and elasticity
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throughout the lung is provided by connective tissue, collagen and elastin which is
found below the surface epithelium, and the presence of surfactant on the alveolar
surface assists expansion of the lung during inspiration by reducing alveolar and
bronchiolar surface tension. In the alveolar region the epithelium is in very close
contact with the blood capillaries, favouring rapid and effective passage of gasses.
The respiratory bronchioles, arising from one terminal bronchiole, together with its
alveolar ducts and sacs, are known as the respiratory acinus, the basic unit of the
lung (Jeffrey, 1998).
On average 10-15,000 litres of air pass through the lung per day (Jeffrey, 1998). The
surface is therefore susceptible to inhaled irritants, and both infective and allergic
substances. The airways therefore have protective mechanisms against such
substances and also have mechanisms to condition the air before it reaches the
respiratory portion of the lung. The conducting airways are involved in gas delivery
to the alveoli, warming, humidifying and cleansing the air. A defence mechanism
involving nervous reflexes (ie broncho-constriction or cough), ciliary action, mucous
secretion and immune responses defends the lungs against pollution including
irritants and bacteria etc (Jeffrey, 1996).
The airway and airspaces are lined by a single layer of cells, the epithelium, which
are attached to a basement membrane. There are, however, many different epithelial
cell types (Jeffrey, 1998), all having specific functions. These include ciliated cells
for the removal of particles, serous cells and goblet cells for the production of mucus
and clara cells which are important in metabolism and surfactant production. There is
a progressive change in cell type from the upper airways to the lower airspaces. The
alveoli contain two types of epithelial cells, the type I and type II pneumocytes. Most
of the alveolar surface is covered by the more dominant type I epithelial cell which
have many processes, each cell contributing to more than one alveolus. Their main
function is to provide a barrier to prevent fluid loss and to facilitate gas exchange.
Type I cells are connected to one another and to type II cells by tight junctions
providing a selectively permeable barrier for fluid, molecules and ion movement
between the interstitium and the alveolar space. Type II epithelial cells are cuboidal
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in shape, and they only cover approximately 7% of the alveolar surface (Crapo et al.,
1982). They are involved in the synthesis and secretion of the pulmonary surface
active material, surfactant, and also act as progenitors of type I cells, regenerating a
continuous epithelium after alveolar injury, such as that caused by oxidants. These
two cell types are likely to differ in their antioxidant status, due to their function, and
therefore have different susceptibility to oxidative damage (Persinger et al., 1996).
1.2 INFLAMMATORY CELLS
The experiments in this thesis use a mixture of cytokines, TNF-a, IL1—p, and
IFN-y, collectively called cytomix. These pro-inflammatory cytokines are present
during inflammation being released by both inflammatory cells and epithelial cells.
Cells that are important in the inflammatory response are present on the surface of
the airspace epithelium cells at all times. These include mononuclear migratory cells
such as intra-epithelial lymphocytes and mast cells, and alveolar macrophages
(Crapo et al., 1983). A wider variety of inflammatory cells are, however, recruited
during lung injury due to a variety of stimuli such as inhaled air pollutants (ozone,
cigarette smoke, nitrogen dioxide and particles) and infection. Part of the cellular
response to injury is the migration of leukocytes to sites of inflammation and injury,
including macrophages, lymphocytes and polymorphonulcear (PMN) cells such as
neutrophils. These inflammatory cells produce soluble mediators including proteins,
interleukins and cytokines. Additionally neutrophils degranulate releasing lysomal
enzymes and other granule products. The function of phagocytic inflammatory cells
is to kill bacteria and viruses and this is achieved, in part, by activation of the
hexomonophosphate shunt to generate NADPH. The cells then utilize NADPH for
the reduction of molecular oxygen, using the membrane bound flavoprotein
cytochrome b-245 NADPH oxidase. This results in a 'respiratory burst', and the
generation of superoxide anions, hydrogen peroxide, hydroxyl radicals and
hypochlorous acid (Barnes, 1990; Kinnula et al., 1991; Root et al., 1975; Sedgwick
et al., 1990), which are powerful anti-microbial agents.
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Although inflammation is a defence mechanism against microbial infection, chronic
inflammation has been associated with chronic lung disorders including asthma and
adult respiratory distress syndrome (ARDS) (see later). Inflammatory cells are able
to induce lung damage as well as being bactericidal, and a side effect of the
respiratory burst, is an increase in oxidants which can damage lung cells as well as
bacteria and viruses. In addition to an increase in oxidants, the low pH produced
locally by phagocytes during inflammation may contribute to the release of transition
metals, which enhance formation of the highly destructive hydroxyl radical (see
later) (Halliwell et al., 1992). Hydrogen peroxide concentrations are also enhanced,
being produced by lymphocytes, macrophages and PMNs. H2O2 is important not
only as an oxidant but as a secondary messenger, activating immunologically
important transcription factors such as NF-kB, which switches on many genes for
pro-inflammatory cytokines (Droge et al., 1994b; Winrow et al., 1993).
Degranulation of neutrophils can also induce lung damage due to the release of
elastases, which can cause lung damage if a protease/antiprotease imbalance occurs
(Tetley, 1993). Inflammatory lung disorders are discussed in more detail later (see
section 3 on inflammatory disorders).
1.3 REACTIVE OXYGEN SPECIES (ROS)
The effects of oxidants are examined in this study, in particular H2O2, (which is
present in the lower respiratory tract during inflammation), to determine their effects
on NO induction and NF-kB activation.
ROS are metabolites of molecular oxygen O2, and many of these oxidants are also
free radicals. A free radical is defined chemically as any species capable of
independent existence that contains one or more unpaired electrons (Halliwell,
1991a). Free radicals are usually unstable, reacting with a wide variety of compounds
by either extracting or donating electrons, which results in stability of the radical, or
by reacting with other free radicals, resulting in the formation of a covalent bond
(Halliwell et al., 1992).
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Respiration involves the reduction of bimolecular oxygen to water by a sequential 4-
step addition of electrons.
02 + 4H+ + 4e~ ► 2H20
A metabolic by product of respiration is the partial reduction of oxygen, by one
electron, resulting in the formation of the superoxide anion (02"):
02 + e ► 02
The superoxide anion is also produced by the enzyme xanthine oxidase (XO), which
converts water and xanthine in the presence of oxygen to uric acid and superoxide.
XO
Xanthine + 02 ► uric acid + 02"
Recruitment and activation of inflammatory cells such as neutrophils and phagocytes
also generate the superoxide anion during the respiratory burst.
The superoxide anion is rapidly converted to H202 by the enzyme, superoxide
dismutase (SOD).
SOD
202" + 2H+ ► H202 + 02
Hydrogen peroxide can also be formed by the action of the ferric iron on the
superoxide anion (known as the Haber Weiss reaction).
Fe3+ + 2H+ + 02" ► H202 + Fe2+
Generation of H202 can result in the formation of the hydroxyl radical (OH) non-
• • o |
enzymatically in the presence of Fe in a secondary reaction, known as the Fenton
reaction.
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H202 + Fe2+ > 02" + OH + Fe3+
Neutrophils also produce the enzyme, myeloperoxidase, which converts hydrogen
peroxide and chloride to hypochlorous acid (HOC1).
Myeloperoxidase
H202 + CI" ► HOC1 + OH"
These oxidants, H202, OH, 02 " and HOC1 are typical of those produced during
inflammation by migratory leukocytes such as macrophages and neutrophils and are
important in the process of bacterial killing by phagocytes.
Another oxidant which may be present in the lung during inflammation, is NO and
its metabolites. NO, a free radical, can be induced by cytokines and released by both
epithelial cells (Adcock et al., 1994; Felley-Bosco et al., 1994; Robbins et al., 1994)
and inflammatory cells such as neutrophils and macrophages, (Kinnula et al., 1995;
Marietta et al., 1997). It can react readily with the superoxide anion resulting in the
formation of peroxynitrite (ONOO") a highly toxic free radical (Kinnula et al., 1995).
NO+02" ► ONOO"
Peroxynitrite can then decompose into other oxidants, to release hydroxyl like
radicals, independent ofmetal catalysis.
ONOO" + H+ ► OH +N02
Lung epithelial cells also generate oxidants but the action of these oxidants is
normally limited within the cell by antioxidants, which effectively remove oxidants
before they cause intracellular damage (Kinnula et al., 1992; Kinnula et al., 1991).
They are therefore not generally released, unlike inflammatory cells, which release
oxidants in order to kill bacteria. However, some epithelial cells do release oxidants
into the extracellular space of the lung, such as alveolar type II cells, which release
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H2O2 (Barnes, 1990). H2O2 is fairly stable and not particularly damaging to normal
tissue and acts as a secondary messenger in the activation of the transcription factor
NF-kB (see later). The injurious potential of hydrogen peroxide is, however,
amplified by conversion to the hydroxyl radical which is a potent oxidant, capable of
causing damage to other cells. The presence of the superoxide anion further
potentates this reaction, by converting ferric iron (Fe3+) to ferrous iron (Fe2+) in the
Haber Weiss reaction, thus enabling the Fenton reaction to occur.
1.4 ROS AND OXIDATIVE DAMAGE.
Oxidative stress results from an imbalance in the oxidant/antioxidant equilibrium in
favour of oxidants and relevant reactive oxygen species (ROS). In the lung ROS
include, O2OH', H2O2 HOC1 and ONOO", all of which are important players in cell
and tissue injury during inflammation, being produced by several types of
inflammatory cells (Barnes, 1990; Halliwell et al., 1992). ROS have been implicated
in several lung diseases such as asthma (Barnes, 1990), chronic obstructive
pulmonary disease (COPD) (Kinnula et al., 1995), smoking related emphysema
(Heffner and Repine, 1989) and the alveolar disease adult respiratory disorder
(ARDS) (Brigham, 1990), where they cause both tissue and cell damage.
ROS can exert different toxic effects during oxidative stress causing injury to the
airways in a number of ways (Barnes, 1990). These include modification of receptor
activity and signaling (Cochrane, 1991) by oxidisation of amino acids such as
methionine and cysteine; release of endogenous mediators of inflammation by acting
as signaling mediators, (Baeuerle et al., 1996; Pahl and Baeuerle, 1994) resulting in
the over expression of normal physiological processes; and acute cell death and
tissue injury, which is often mediated by the hydroxyl radical (Farber et al., 1990). It
has also been suggested that oxidants and the redox status of the cell are important in
the mechanisms of cell death by both apoptosis and necrosis (Kazzaz et al., 1996).
Both cellular and plasma proteins can be damaged undergoing cross-linking and
aggregation (Wolff et al., 1986) in the presence of free radicals. The cell membrane
undergoes lipid peroxidation due to a high content of polyunsaturated fatty acids
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which provides an electron rich environment which is highly susceptible to oxidative
attack. Lipid peroxidation causes a decrease in the fluidity of the membrane,
destabilising membrane receptors and products of lipid peroxidation, primarily
aldehyde derivatives, which can inhibit protein synthesis, block macrophage action
and cause changes in chemotaxis and enzymatic activity (Bast et ah, 1991). Lipid
peroxidation also occurs in the mitochondrial membrane resulting in loss of energy
and cellular stores of ATP, and damage of mitochondrial DNA (Schraufstatter et al.,
1986). Both single and double stranded DNA is damaged, accompanied by
hydroxylation of bases following oxidant or radical attack (Halliwell and Arouma,
1991b) (Ryrfeldt et al., 1993). Oxidant stress within the cell also causes a change in
the redox state of the cell, in particular glutathione, which is oxidised (to GSSG), and
can cause damage resulting in the release of calcium from its intracellular stores
(Wefers and Sies, 1989). A vicious circle of injury occurs on release of iron and
other transition metals due to oxidative stress, which enhances hydroxyl radical
formation. Figure 1 shows a schematic diagram of the formation of ROS, and the
damage they can cause.
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2 Antioxidants
This section describes the antioxidant systems which allow the protection of cells
against oxidant induced injury. GSH is discussed in more detail separately, since this
was the antioxidant studied in this thesis.
An antioxidant is defined as any substance that, when present at low concentrations
compared to those of the oxidisable substrate, significantly delays or inhibits the
oxidation of that substrate (Gutteridge, 1994). There are different categories of
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antioxidant effects (Heffner and Repine, 1989), which often have overlapping
properties:-
1. The prevention and compartmentalisation of free radical formation.
2. The conversion of oxidants to less reactive species
3. The repair of oxidant-induced injury.
2.1 THE PREVENTION AND COMPARTMENTALISATION OF FREE
RADICALS.
The prevention and compartmentalisation of free radicals is primarily achieved by
the 4 electron reduction of oxygen to water by cytochrome oxidase in the
mitochondria. The mitochondria utilise more than 90% of the oxygen in lung cells
and metabolise it in a way to avoid significant free radical formation (Heffner and
Repine, 1989).
2.2 THE CONVERSION OF OXIDANTS TO LESS REACTIVE SPECIES.
Oxidants are converted to less reactive species by 3 major intracellular and
extracellular enzymes which provide a critical defence mechanism (Heffner and
Repine, 1989; Kinnulaet al., 1995) including:
• Catalase, which catalyses the degradation of hydrogen peroxide to water and
oxygen, mainly within peroxisomes.
• Superoxide dismutases which catalyse the dismutation of superoxide anion to
hydrogen peroxide. The superoxide dismutases are a family of enzymes with
different intra and extracellular distributions. They include copper zinc SOD
(CuZnSOD), which is found mainly in the cytosol, but also is found in the
nucleus and manganese SOD (MnSOD), which exists in the mitochondria,
eliminating superoxide anions produced during electron transport. The
extracellular copper SOD (ECSOD), is found in the epithelial lining fluid of the
lower respiratory tract. The SODs are thought to play a protective role in cells
that produce both superoxide anion and nitric oxide since by dismutating the
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superoxide anion they also prevent the formation of the toxic peroxynitrite, by
preventing superoxide anions from reacting with NO, and thus prolong the
bioavailability ofNO as an antioxidant (see 2.5) (Beckman et ah, 1990).
• Glutathione peroxidase (GPx), which reduces hydroperoxides to water, using
GSH as a reducing substrate, which is, itself, oxidised to a GSH dimer, GSSG.
GPx is part of the GSH redox system (figure 2) having a central role in the
reduction of intracellular hydroperoxides, complementing catalase in lowering
H2O2 levels. GPx is also able to eliminate hydroperoxides such as lipid peroxide,
formed during lipid peroxidation. GSH is the reducing substrate for the enzyme
and GSSG is the product, GSSG is then reduced by glutathione reductase (GR)
using NADPH as a reducing agent. NADPH is supplied via the activity of
glucose-6-phosphate in the hexomonophosphate shunt.










As well as these enzyme systems, there are a whole array of molecules which act as
sacrificial antioxidants by scavenging free radicals directly. Examples are given in
table 1 (Heffner and Repine, 1989)
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Table 1: Oxidant And Free Radical Scavengers (Heffner and Repine, 1989).
Scavenger Structure Tissue site Actions
Vitamin E Fat soluble vitamin Lipid membranes,
extracellular fluids
Converts 02 ~, OH and
lipid peroxyl radicals
to less reactive forms,
breaks lipid chain
reactions
B-Carotene Metabolic precursor to
vitamin A





Bloodstream, tissue Chain breaking
antioxidant, reacts with
ROO
Vitamin C Water soluble vitamin Wide distribution -
intracellular and
extracellular








Glucose Carbohydrate Wide distribution Scavenges OH.




Cysteamine Amino acid Wide distribution Same as cysteine
Taurine B-amino acid Radical generation Conjugates
xenobiotics, reacts
with HOC1






Wide distribution Scavenges inhaled
oxidants
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2.3 REPAIR OF OXIDANT INDUCED INJURY
Repair of oxidant induced injury by antioxidants is not well understood but involves
removal of injured cellular components, activation of nuclear enzymes for DNA
repair and induction of cellular proliferation (Heffner and Repine, 1989).
2.4 EXTRACELLULAR ANTIOXIDANT DEFENCES.
Both conducting and respiratory airways have a liquid covered surface, and the
integrity of the fluid balance of this surface layer is necessary for maintaining a
protective environment as well as maintaining optimal gas exchange. In the
respiratory epithelium, this layer of fluid is referred to as the epithelial lining fluid
(ELF), which is rich in antioxidants. These include Vitamin E and C, ceruloplasmin,
transferrin, ascorbate, albumin, methionine and GSH (Cantin et al., 1987; Davis and
Pacht, 1998; Matalon et al., 1990). The lung is unique in that the extracellular milieu
at the alveolar epithelial surface, the ELF, is rich in GSH (Cantin et al., 1987). GSH
and other antioxidants are thought to either, be secreted by cells (Cantin et al., 1987)
or to diffuse from the blood (Heffner and Repine, 1989), platelets and erythrocytes
being rich in antioxidants and having the potential to be recruited during
inflammation. Certain lung cells are capable of exporting GSH (Cantin and Begin,
1991; Deneke and Fanburg, 1989) and the alveolar macrophage is also a candidate,
containing 9 times more GSH than other lung cells (Cantin and Begin, 1991; Horton
et al., 1987). Macrophages contain high levels of GSH in order to protect themselves
against the hydrogen peroxide they release during phagocytosis (Root et al., 1975). A
striking feature of the ELF are the surprisingly low levels of oxidised GSH, GSSG,
despite the potentially large oxidant burden, thus implying an effective mechanism,
possibly involving y-GT, for removal of GSSG by degradation, reduction or both
(Cantin and Begin, 1991). Both macrophages and type II alveolar cells exhibit y-GT
activity (Liu et al., 1996), which is possibly involved in the degradation of GSSG and
the uptake of its corresponding amino acids for de novo synthesis of GSH within the
cell (see section 5).
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Table 2 shows the concentrations of antioxidants in the ELF and compares them to
both the plasma and the nasal lining fluid.
Table 2: A comparison of antioxidants present in the plasma, the ELF and the
nasal lining fluid (Cross et al., 1994)
Antioxidant Plasma pM ELF pM Nasal lining fluid pM
Ascorbic acid 40 100 40
Glutathione 1.5 100 40
Uric acid 300 90 160
a-Tocopherol 25 2.5 -
Albumin SH 500 70 10
2.5 NO AS AN ANTIOXIDANT.
NO , is a small, relatively unstable, free radical, that readily crosses lipid membranes
where it interacts with specific targets for cell signaling. It can exert both beneficial
and deleterious effects in different tissues under different conditions, being able to
act as both an oxidant and an antioxidant. NO can be produced by 2 different
enzymes, one is constitutive and the other inducible (Ignarro and Murad, 1995).
Constitutive NO is produced in regulated amounts and is likely to act as an
antioxidant. The endothelium derived relaxing factor now recognised as NO, relaxes
smooth muscle by activation of soluble guanylyl cyclase in adjacent cells and has
been shown to inhibit leukocyte adhesion, a rate limiting step in inflammation,
possibly by scavenging superoxide anion (Barnes, 1993; Granger and Kubes, 1996).
NO can react rapidly with hyrdroperoxyl radicals, and therefore prevent lipid
peroxidation (Rubbo et al., 1994). It is highly lipid soluble and can partition into the
membrane where it can act as a chain terminator of radical-mediated lipid
peroxidation. Virtually any radical species formed in or near the lipid membrane can
react with NO (Crow and Beckman, 1995). NO has also been shown to inhibit
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superoxide anion production by neutrophils (Clancy et al., 1992). This is not due to
its scavenging properties, but due to direct effects on the membrane component of
NADPH oxidase thus preventing the respiratory burst. This is likely to occur
following cytokine induced NO release by cells such as macrophages at sites of
inflammation, so protecting against tissue injury. NO can therefore act as an
antioxidant, but becomes pro-oxidant after reacting with the superoxide anion,
resulting in peroxynitrite, which is produced in great amounts during inflammation
(Rubbo et al., 1994).
3 Inflammatory Disorders Involving ROS And Antioxidants.
Oxidants are thus increased during inflammation and a variety of antioxidants are
present in both lung cells, and the ELF, that are important in the safe removal of
oxidants. However, in cases of extreme oxidative stress, such as that produced during
the respiratory burst, an oxidant/antioxidant imbalance may occur, resulting in both
cell and tissue injury. Several lung disorders are associated with increased
inflammation, and it is thought that oxidants play a role in lung damage in these
disorders. It is therefore possible that an oxidant/antioxidant imbalance is occurring
in several of these disorders which are described below.
3.1 ASTHMA
Asthma is a chronic inflammatory disease of the conducting airways, and can be
characterised by:
• Variable and reversible airflow obstruction,
• Bronchial hyperresponsiveness, defined as an excessive airway narrowing in
response to various stimuli.
The earliest reported histological features of asthma (Dunhill, 1960) are epithelial
damage, thickening of the reticular basement membrane and infiltration of the airway
wall by mononuclear cells and eosinophils. More recently broncho-alveolar lavage
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studies indicate that asthmatic airways undergo an inflammatory response involving
activated T-helper cells, lymphocytes, eosinophils and mast cells (Azzawi et ah,
1990; Azzawi et ah, 1992; Holgate, 1993). The disordered function is due to the
secretion of an array of vaso-bronchoacitve mediators (Busse et ah, 1993), which
interact in a complex way, resulting in the pathophysiology of asthma. Epithelial
cells are also a source of pro-inflammatory cytokines and other mediators such as
NO (Barnes, 1996), which contribute to the disease. Thus it has become clear that an
inflammatory response is a key element in the development of asthma. Airway
narrowing and airflow obstruction, which are reversible either spontaneously or by
treatment, result in the symptoms of dyspnoea and wheezing and increase airway
responsiveness to a variety of stimuli (Holgate, 1993). Airway hyperreactivity or
hyperresponsiveness, although not unique to asthma, is therefore a hallmark of
asthma.
An increased oxidant burden, in particular from the release of superoxide anions
from activated macrophages (Calhoun et ah, 1992) and hypodense eosinophils
(Sedgwick et al., 1990) has been detected in asthmatic patients following an allergen
challenge. Both alveolar macrophages and BAL from asthmatic patients release more
free radicals compared to control patients' (Kinnula et al., 1995), and this increased
oxidant burden may contribute to airway injury. Free radical generation correlates
negatively with lung function (Kinnula et al., 1995) and epithelial loss correlates
with airway reactivity in asthmatics (Jeffrey et al., 1989). Moderate to severe
asthmatic patients have decreased levels of antioxidants (Novak et al., 1991), such as
catalase and GSH in plasma and red blood cells, but mild asthmatics have increased
antioxidant defences in their BAL, possibly to counterbalance an increase in oxidant
generation and prevent airway injury (Smith et al., 1993).
NO has also been detected in the breath of asthmatics in higher levels than those
found in normal subjects (Byrnes et al., 1997; Massaro et al., 1995) and has been
suggested as a clinical marker for airway inflammation. Although much of the
exhaled NO is thought be a product of the nasal passage, it has been shown that
increased NO in the breath of asthmatics arises from the lower airways (Kharitonov
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et al., 1996). Inhalation of an inhibitor of the inducible nitric oxide synthase (iNOS)
in asthmatics decreases exhaled NO, suggesting that increased NO in the breath is
due to induction of iNOS (Yates et al., 1996). mRNA for NOS has been found in
airway epithelial cells, macrophages, neutrophils, eosinophils and mast cells (del
Pozo et al., 1997; Gaston et al., 1994), and iNOS is synthesised on stimulation with
inflammatory cytokines (Barnes and Belvisi, 1993) (see later). Although NO can be
beneficial to the airways in small amounts, causing relaxation of vascular and airway
smooth muscle, it can become cytotoxic at higher levels. NO can react with the
superoxide anion resulting in the formation of the oxidant peroxynitrite (ONOO-),
which although it contributes as a defence mechanism, being cytotoxic to bacteria, it
also contributes to the oxidant burden, causing cell damage. Thus it is established
that an increased oxidant burden is present in asthmatics and that bronchial epithelial
damage is a component of the injurious inflammatory response (Jeffrey et al., 1989).
The antioxidant status of the bronchial epithelium may therefore be an influencing
factor in the susceptibility of individuals to the effects of an inflammatory response
following exposure to allergens and thus the subsequent development of an asthma
attack. Thus antioxidants should have a role in the prevention or treatment of the
condition.
3.2 ARDS
ARDS, which was first recognised 30 years ago (Ashbaugh et al., 1967), is a disorder
which affects the gaseous exchanging region of the lung, the alveolar capillary
membrane, resulting in acute lung injury and respiratory failure. It is a condition that
is associated with mortality as high as 60%. It is characterised pathologically
(Cochrane et al., 1983) by an influx of neutrophils into the lungs, alveolar damage,
hypoxaemia, and bilateral pulmonary infiltrates on chest x-ray associated with
increased alveolar and capillary permeability, non-cardiogenic pulmonary oedema
and decreased lung compliance. It may occur due to insults to the lung, such as
pneumonia, but may also result from an extra pulmonary cause of shock, such as
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trauma and sepsis. Death is often due to non-pulmonary causes as a result of sepsis
and multi organ failure (Dantzker, 1990).
There is evidence that ARDS is associated with oxidative stress, leading to an
oxidant/antioxidant imbalance (Brigham, 1990; Cochrane et ah, 1983). Increased
oxidants are also thought to cause inactivation of antiproteases in the alveolar space
(Cochrane et al., 1983), producing the potential for proteolytic injury. Decreased
levels of antioxidants such as GSH and higher levels of GSSG are found in the
alveolar ELF of patients with ARDS (Bunnel and Pacht, 1993; Pacht et al., 1991),
suggesting that oxidant stress has occurred in the lower respiratory tract. A
deficiency in GSH is thus thought to be important in the pathogenesis of the disease.
Increased NO levels have been found in the broncho-alveolar lavage, in animal
models of ARDS, following exposure to endotoxin (Pheng et al., 1995). iNOS
mRNA has also been found in human lung biopsies and in the lungs at autopsies of
ARDS patients (Sachdev et al., 1997). The level of nitrotyrosine residues (produced
by the action of peroxynitrite) have been monitored in ARDS patients and these
residues were found to be increased with increased disease severity (Kooy et al.,
1995; Royall. and Kooy, 1997). The presence of NO and peroxynitrite in ARDS in
humans is controversial, but is likely to be present during severe inflammation. NO
is, however, often used, in low doses, in the treatment of ARDS, to improve
oxygenation (Johannigman et al., 1997; Yoshida et al., 1997), but this treatment,
along with oxygen treatment, may only be supportive, and may potentate further
injury.
3.3 OTHER RESPIRATORY DISORDERS ASSOCIATED WITH
INCREASED ROS.
There are several other respiratory disorders which have been reported to be due, at
least in part, to an increased oxidant burden caused by the inflammatory response
and an imbalance in the oxidant/antioxidant status of the lung. These include:
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• Idiopathic Pulmonary Fibrosis (IFF) is characterised by an accumulation of
alveolar macrophages and neutrophils in the lower respiratory tract, cell injury,
fibrosis of the alveolar wall and a loss of lung architecture (Crystal, 1991; Saleh
et al., 1997). A 4-5 fold increase in inflammatory cells is observed in
bronchoalveolar lavage (macrophages, neutrophils), as are increases in
cytochrome b-245, resulting in an increased oxidative burst which mediates the
process of cell injury (Saleh et al., 1997). There is a 3-fold decrease in GSH in
the ELF, thus adding to the antioxidant/oxidant imbalance. Both iNOS and eNOS
have been observed by immunohistochemistry in lung biopsies of IPF patients at
levels much higher than those observed in normal lungs (Saleh et al., 1997). IPF
is also associated with increases in nitrotyrosine, as observed by immunostaining
of lung biopsies from both IPF and normal lungs (Saleh et al., 1997). Increased
nitrotyrosine residues were observed in airway epithelium, alveolar epithelium,
macrophages and neutrophils. This suggests that increased production ofNO' and
peroxynitrite may be partly responsible for the damage observed in this disease.
• Cystic fibrosis (CF) is a genetic disease, which mainly affects the lungs and
gastrointestinal tract. In CF the lung contains thick, infected mucus, and there is
chronic inflammation dominated by neutrophils and macrophages. Injury is
thought to occur due to the increased oxidant burden caused by chronic infections
(Crystal, 1991), eventually resulting in respiratory failure. Increased NO' levels
are not observed in the breath of cystic fibrosis, but this is possibly due to the
thickness of mucus preventing NO' diffusion (Balfour-Lynn et al., 1996), which
is further supported by the fact that nasal NO' in CF patients is decreased
compared to normal subjects (Lundberg et al., 1996).
• Chronic obstructive pulmonary disease (COPD) results largely from the
inhalation of cigarette smoke, which contains 1017 oxidants/puff (Pryor et al.,
1976). Chronic bronchitis and emphysema are the major conditions that make up
COPD (Jeffrey, 1992). Both disorders are associated with increased alveolar
macrophage and neutrophil recruitment in the BAL. Emphysema is associated
with an increase in the size of the alveolar spaces distal to the terminal
bronchioles (Flenley et al., 1986) due to the degradation of elastin by proteases
such as elastase, or oxidants which are found in cigarette smoke or released by
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the influx of inflammatory cells (Riley and Kerr, 1998). Cigarette smoke also
leads to further recruitment of PMNs, which release proteolytic enzymes such as
elastases (Flenley et al., 1986). There is therefore an increase in oxidant burden
from both inhaled oxidants and oxidant release from inflammatory cells. These
oxidants are thought to inactivate anti-proteases such as a i-antitrypsin, causing a
protease/antiprotease imbalance leading to proteolytic damage to matrix
structures such as elastin in the alveolar walls resulting in the airspace
enlargement that is emphysema (Tetley, 1993). An oxidant/antioxidant imbalance
is also thought to occur in this condition (Rahman and MacNee, 1996) and it is
likely that NO and peroxynitrite also play a role.
Evidence thus suggests that inflammatory lung diseases are associated with increased
oxidative stress (Cochrane et ah, 1983; Crystal, 1991) resulting from an
oxidant/antioxidant imbalance. Administration of compounds to augment the
antioxidants found in the ELF may therefore be beneficial in preventing oxidant-
induced damage.
4 Nitric Oxide (NO)
The main focus of this thesis is the induction of nitric oxide by a variety of stimuli
including cytokines and oxidants, and the effect of the redox state of the cell,
particularly glutathione, on this induction. This section provides background
information on NO , its induction and molecular regulation and the effect of NO on
its environment.
4.1 BACKGROUND
In 1992, the journal Science declared NO to be molecule of the year (Culotta and
Koshland, 1992). NO is unusual in that it is a noxious chemical in the atmosphere
but in controlled concentrations in the body it can be beneficial. It is a relatively
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unstable, uncharged free radical that reacts readily with acceptor molecules. A role
for NO in biological reactions was discovered in 1987 by Ignarro and colleagues
(Ignarro et al., 1987) and Palmer and colleagues (Palmer et al., 1987) when it was
shown to have the same biological properties as endothelium derived relaxing factor
(EDRF), the endogenous stimulator of guanylate cyclase. EDRF was discovered in
1980 by Fuchagott and Zadwadzki (Furchgott and Zawadzki, 1980) when it was
demonstrated that vascular relaxation induced by acetylcholine (ACh) depended on
the presence of the endothelium, providing evidence that this effect was mediated by
a labile humoral factor, which was called EDRF. EDRF was shown to be activated
by a variety of stimuli such as acetylcholine, thrombin, bradykinin and hypoxia
(Furchgott and Zawadzki, 1980). However agents such as nitrovasodilators and
P-adrenergic agonists also stimulated EDRF independent of the presence of the
endothelium (Ignarro et al., 1987). EDRF was shown to be NO using a
chemiluminecense assay and its release was proportional to the amount of bradykinin
required for EDRF activation (Ignarro et al., 1987). Further comparisons of the
effects of EDRF and NO using vascular strips provided evidence that the two were
indistinguishable (Marietta, 1989; Moncada et al., 1991). Superoxide anions appear
to contribute to the instability of EDRF since the effects ofNO could be prolonged
by the addition of superoxide dismutase (SOD) (Gryglewski et al., 1986) which
dismutates superoxide anions to hydrogen peroxide, thus preventing the creation of
NO with the superoxide anion. Simultaneously with the discovery that EDRF was
analogous to NO', two groups investigating the mechanisms of murine macrophage-
induced cytotoxicity attributed this activity to NO (Hibbs et al., 1987; Iyengar et al.,
1987).
4.2. METABOLISM/BIOCHEMISTRY
NO is formed by the conversion of L-arginine to L-citrulline, requiring bi-molecular
oxygen and NADPH. The requirement of L-arginine for NO formation was
discovered in macrophages by Hibbs and colleagues (Hibbs et al., 1987), when it was
shown that the cytotoxic effects of macrophages on DNA synthesis and
mitochondrial respiration was due to NO and was dependant on L-arginine. This
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was further supported by Palmer and colleagues in 1988 (Palmer et al., 1988) who
showed that NO release from endothelial cells required L-arginine. The enzyme
responsible for NO production is known as nitric oxide synthase (NOS) and there
are three types; Neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial
constitutive NOS (ecNOS) (Ignarro and Murad, 1995) all of which are highly
homologous to each other. There are, however differences in expression and
activation. Both nNOS and eNOS are constitutively expressed proteins that require
enzyme activation by a calcium/calmodulin signaling pathway, an increase in
calcium levels resulting in the binding of calcium to calmodulin on the enzyme
followed by activation of the enzyme. iNOS, however, requires de novo mRNA and
protein synthesis. The enzyme causes the release of massive amounts of NO',
independent of calcium levels. It is the inducible enzyme that is of interest in this
thesis since we are inducing NO in cells by cytokines and oxidants.
Inducible NOS is a homodimeric protein which shares homology in its C terminal
with the heme protein NADPH cytochrome P-450 reductase (CPR) (White and
Marietta, 1992). NOS catalyses the production ofNO by a five electron oxidation of
the terminal guanidino nitrogen of L-arginine (Stamler et al., 1992). Arginine
oxidation by NOS consists of 2 monoxygenation reactions resulting in an
intermediate NO-hydroxyl-L-arginine. The enzyme consumes 2 moles of O2 and 1.5
moles ofNADPH per mole ofNO formed. Therefore for catalysis, NOS must bind
and activate oxygen twice, in tight proximity to the L-arginine binding active site,
using electrons derived from NADPH. Figure 3 shows the steps involved in NO
production (Marietta, 1993)
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Figure 3: Schematic view of NOS, the interaction of the flavin reductase and
oxidative heme domain (Marietta, 1993).
NADPH —. Domain
Reductase Oxidase
Domain L-arginine + O2
NADP+ L-Citrulline + NO
Nitric Oxide Synthase
The formation of NO is both achieved and regulated by 5 bound cofactors and
prosthetic groups present on the enzyme. These include FAD (flavin adenine
dinucleotide), FMN (flavin mononucleotide), a heme group (iron protophoryphin
IX), BH4 (tetrahydrobiopterin) and calmodulin. NOS contains both a reductase and
an oxidase domain. The reductase domain serves two purposes; as a conduit for
delivering single electrons to molecular O2 from NADPH ie electrons flow from
NADPH to FAD to FMN, and to act as an electron reservoir. Between the two
domains there is an interdomain which contains a calmodulin binding sequence. In
iNOS this sequence has an extremely high avidity for calmodulin, ensuring that
calmodulin is virtually always bound to the enzyme, independent of calcium levels.
Calmodulin binding to iNOS is able to regulate enzyme activity by triggering an
electron flux from FMN to the heme group ie it couples the oxidase and reductase
domains. Both arginine and BH4 bind to the oxygenase domain, BH4 is thought to be
an active cofactor, activating O2 for catalysis (Marietta, 1993).
iNOS is induced in almost every tissue and cell type. Its predominate mechanism of
induction is by transcriptional regulation. Low basal rates of inducible NO
formation are enhanced by cytokines and/or LPS but maximal induction occurs with
a synegistic combination of the proinflammatory cytokines such as TNF-a, IL1—P,
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IFN-y and LPS in many cell types including epithelial cells, endothelial cells,
hepatocytes and kupffer cells (Ignarro and Murad, 1995).
iNOS is found on chromosome 17, consists of 26exons, 25introns and is a 37KB
genomic DNA (Chartrain et al., 1994). Sequence analysis of the 5' flanking region
revealed consensus sequences important in cytokine modulation of gene expression,
including NF-kB, IRF-1, the IFN-y responsive element, NF-interleukin 6 (IL6), and
TNF-RE like sites (Chartrain et ah, 1994; De Vera et ah, 1996). The promoter region
for the gene has been shown to interact with NF-kB (Xie et ah, 1994) (Ignarro and
Murad, 1995) which is thought to be critical in the induction if iNOS. More distal
regions of the promoter may however be involved in IFN-y stimulation of iNOS
induction. These include the IRF-1 cis region of the DNA since IRF-1 knockout mice
do not exhibit an iNOS response (Ignarro and Murad, 1995) suggesting that although
NF-kB activation is necessary for NO induction, interaction with other transcription
factors may be required (Salkowski et ah, 1996).
4.3 NO AS A FREE RADICAL.
NO is a small hydrophobic molecule, being more soluble in hydrophobic solvents
than in aqueous solutions, and is therefore suitable to be both an intra- and
extracellular messenger. NO is able to move by random motion, having a half-life of
between 5-15 seconds and can reach the cell membrane within 2-30 milli seconds.
NO can react in the cell in two ways; by autoxidation (+ O2) and by reacting with
major cell species such as metal ions and superoxide. As NO is synthesised, it
spreads out until the rate of appearance (synthesis and diffusion) and disappearance
(e.g. autoxidation) counterbalance each other, a steady state being reached in about
20 seconds.
NO is uncharged but has an unpaired electron and as such is a free radical. It
therefore reacts with other species having unpaired electrons, resulting in secondary
products which are often more reactive. NO reacts rapidly with bi-molecular oxygen
in a process of autoxidation:
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2 NO + 02 > 2N02
Nitrogen dioxide (N02) further reacts with NO to give dinitrogen trioxide (N203).
2N02 + NO' ► 2N203
N203 further reacts to give nitrite (N02"):
2N203 + 2H20 ► 4N02" + 4H+
NO also reacts with transition metals and other free radicals such as the superoxide
anion:
NO + 02" ► ONOO"
Peroxynitrite is relatively stable but will be protonated at physiological pH to yield
peroxynitrous acid (ONOOH), which is unstable and will rapidly decompose to yield
N03" via the formation of an intermediate with hydroxyl like properties:
ONOO" + H+ ► ONOOH ► 'OH' + 'N02' ► N03"
Thus NO release can result in the formation of the fairly stable and unreactive nitrate
(N03") and Nitrite (N02"), the very reactive peroxynitrite (ONOO") and nitrogen
dioxide (N02). These products of NO induction and release result in a variety of
effects, including nitrosation of amines, thiol containing peptides and proteins, lipid
peroxidation, and the formation of complexes with transition metals, such as
metalloproteins and haemoglobins (Ignarro and Murad, 1995; Robbins and Grisham,
1997).
Nitrite and nitrate are relatively unreactive end-products of NO oxidation, but
intermediates such as nitrogen dioxides and peroxynitrite, can be involved in lipid
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peroxidation and nitrosation, which would account for the high concentrations of RS-
NO products found in the lungs during inflammation (Gaston et ah, 1993) (Stamler,
1997). Nitrosation involves the reaction or transfer of NO+ and forms a relatively
stable product. NO is able to react with GSH in aerobic conditions forming S-
nitrosothiols, (GSNO) (Hogg et al., 1996). One of the main products of nitrosation
are nitrosothiols, the S and N providing stability. Formation of nitrosothiols provide
a means of stabilising NO in a bioactive form for transport within tissues and
organs, especially the lungs, and also decreases the toxicity of NO by acting as a
reservoir for the slow release of NO and therefore preventing the formation of
peroxynitrite (Gaston et al., 1994; Meyer et al., 1994; Ohara et al., 1995; Stamler,
1994). Nitrosothiols (RSNO) are the most predominant redox form of NO in the
plasma. The most abundant thiol in plasma is albumin, which serves as a source and
sink ofNO buffering the concentrations of free NO . Alteration of the redox state of
thiols by addition of NO may also serve as a method of signaling by NO . There is
speculation that nitrosothiols participate in smooth muscle relaxation as opposed to
NO itself (Ignarro et al., 1981). Drugs used in the activation of guanylate cyclase,
such as amyl nitrite and glyceryl trinitrite, induce smooth muscle relaxation, but
require the presence of SH groups in the form of added thiols. The drugs then react
with the cysteine group of the thiol, forming S-nitrosocysteine, which activates
guanylate cyclase and increases cGMP levels to levels necessary for relaxation
(Ignarro et al., 1981). The vasodilatory properties ofNO are therefore likely, at least
in part, be due to the formation of the intermediate S-nitrosothiol (Ignarro et al.,
1981).
Interaction of NO with either free iron or heme and metalloprotiens, is also an
important biological reaction, being involved in at least 3 physiological systems
including - the effector mechanisms of guanylate cyclase activation; the inhibitory
action of haemoglobin in systems in which NO is generated; and the nitrosylation of
iron-sulfur centered proteins in macrophage cidal reactions (Gaston et al., 1994). NO
has also been shown to react with, and in some cases modify the function of a variety
of other biological metaloproteins, such as myoglobin, cytochrome c, catalase and
succinate dehydrogenase (Gaston et al., 1994; Stamler, 1997) and has been shown to
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play a part in the upregulation of activity and mRNA synthesis of y-GCS, the rate
limiting enzyme in GSH synthesis (Kuo et ah, 1996b).
Figure 4 gives an overview of the formation of NO, its products and some of the
functions ofNO.
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Figure 4: Biological function of NO (Robbins and Grisham, 1997).




















A; NO is formed by the enzyme NOS from arginine. B; NO can stimulate guanyl
cyclase, causing an increase in cGMP formation, which in turn, relaxes smooth
muscle, such as vascular smooth muscle, producing a decrease in blood pressure.
This is possibly achieved by the formation of S-nitrosothiols, which release NO to
the iron group of the guanyl cyclase enzyme. C; NO can act as a neurotransmitter
by stimulating NMDA receptors. D; NO and its oxides can produce bactericidal or
cytotoxic effects. They can also nitrosate proteins and thiols altering function. E; NO
can modulate inflammation, producing both anti-inflammatory effects, such as
decreases in lymphocyte activation, or pro-inflammatory effects, such as increase in
leukocyte migration.
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4.4 NO AS A MESSENGER AND TOXIN.
NO can therefore act as both an oxidant and an antioxidant. In some cells NO is
cytotoxic and others cytostatic suggesting sensitivity to NO varies from one cell to
another (Vandeputte et ah, 1994). Small amounts ofNO, such as those produced by
cNOS are sufficient to activate known NO sensitive enzymes and participate in NO
signaling. Larger amounts, exceeding a critical concentration, such as those produced
by iNOS during inflammation, inhibit the action of certain enzymes, such as those
containing iron centres, resulting in inhibition of DNA synthesis, protein synthesis
and mitochondrial enzymes (Nussier and Billiar, 1993). Table 3 shows the effects of
NO' as both a messenger and a toxin (Schmidt and Walter, 1994).
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Table 3: The effects of NO (Schmidt and Walter, 1994).
Tissue Messenger Toxin
Blood vessels EDRF, antithrombic, ischemic
protection, antiatherosclerotic,






























Pancreas Endocrine/exocrine secretion (3 cell destruction




Immune system Antimicrobial, antitumour Anti-allograff, graft versus host
disease, inflammation,
septicshock, tissue damage
4.5 NO IN LUNG DISORDERS
As previously described in Section 3, NO has been implicated in lung disorders
associated with inflammation such as asthma, ARDS, cystic fibrosis, IPF and COPD.
NO is increased in the breath of asthmatics at higher levels than normal, as is iNOS
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expression, (Hamid et al., 1993; Robbins et al., 1994) and this increase can be
decreased by inhalation of inhibitors of iNOS (Barnes and Liew, 1995; Yates et al.,
1996). NO is therefore likely to have a detrimental role in asthma since
inflammatory cells present in asthmatics, such as neutrophils, release oxidants
during the respiratory burst, which react with NO resulting in the formation of
peroxynitrite. Lung biopsies of patients with ARDS, have been found to have
increased levels of iNOS protein and increased levels of nitrotyrosine residues, both
shown by immunohistochemistry. Increased nitrosylation of tyrosine residues in
ARDS patients was shown to be associated with severity of the disease (Kooy et al.,
1995; Royall.JA. and Kooy, 1997; Saleh et al., 1997). Both NO and peroxynitrite
are also thought to play a role in the pathophysiology of idiopathic pulmonary
fibrosis (Saleh et al., 1997), cystic fibrosis (Balfour-Lynn et al., 1996), (although
increased NO is not observed in the breath of patients with cystic fibrosis, possibly
due to the thickness of the mucus (Balfour-Lynn et al., 1996; Saleh et al., 1997)) and
chronic obstructive pulmonary disorder, induced by smoking (Flenley et al., 1986;
Jeffrey, 1992).
Continuous expression of iNOS mRNA has been shown in airway epithelial cells in
vivo, but once cells are cultured in vitro they lose the ability to continually express
iNOS (Guo et al., 1995) and there must therefore be factors of the airway, which
contribute to iNOS expression. It is likely that respiratory epithelial cells are key
inflammatory cells in the airway, having a function in host defence and also playing
a role in airway inflammation. INOS mRNA can be induced in airway epithelial cells
by a mixture of cytokines such as IL1—(3, TNF-a, IFN-y and LPS (Geller et al.,
1993; Maier et al., 1994), however iNOS expression is present, in vivo, in the
absence of cytokines and LPS (Nathan and Xie, 1994).
NO can act as an anti-inflammatory agent in the lungs by increasing ciliary motility,
thus enhancing muco-ciliary clearance and can also mediate cytotoxicity against
bacteria etc (Schmidt and Walter, 1994), both of which are important features of host
defence. Epithelial cells may therefore regulate an inflammatory response in the
normal lung, since they have the ability to produce cytotoxic NO levels. Cytotoxic
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levels of NO have been shown to inhibit superoxide production by neutrophils
(Clancy et al., 1992) and inhibit leukocyte adhesion (Barnes, 1993; Granger and
Kubes, 1996; Li et al., 1995), suggesting that epithelial cells are critical effector cells
of the immune defense system in the lungs (Guo et al., 1995). Figure 5 shows the
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5 Glutathione (L-y-glutamyl-L-Cysteinylglycine)
The aim of this study was to determine the role of GSH in NO induction and to
examine the effect of intracellular GSH redox state on NO levels and nuclear factor
kappa B (NF-kB) activation.
GSH is a low molecular weight tri-peptide consisting of 3 amino acids; glutamine,
cysteine and glycine. It was first described over 100 years ago, and its structure was
established in 1935 (Morris and Bernard, 1994). The N-terminal glutamate is linked
to the cysteine via a non-a peptidyl bond. Its reduction site is the reduced sulfhydryl
group on the cysteine moiety and the '/-glutamyl linkage provides internal stability
of GSH in the cell. GSH makes up ninety percent of all intracellular non-protein
thiols. Thus, it is a key intracellular reducing agent, (Morris and Bernard, 1994) and
protects cells against oxidants and xenobiotics.
The versatility of GSH includes its functions as; an antioxidant, a cysteine storage
molecule, and a transport molecule. It is involved in the conjugation and
detoxification of endogenous and foreign electrophilic compounds, and is necessary
for the synthesis of many cellular compounds and is important in immunological
modulation (Morris and Bernard, 1994). Due to its suphydryl group it is able to
scavenge free radicals by donation of its hydrogen atom, resulting in the formation of
the stable disulphide, GSSG. It can also act as a co-substrate in the reduction of H2O2
and other hydroperoxides by gluthathione peroxidase (see 2.2). GSH is able to
conjugate with a variety of compounds, via its sulphide bond or through the action of
the glutathione S-transferases, a group of enzymes which are important in the
detoxification of xenobiotics (Moldeus and Jernstrom, 1983). It also plays a major
role in many metabolic pathways such as the reduction of disulphide linkages of
proteins and DNA precursors as well as activation of enzymes and regulation of
immune responses (Meister and Anderson, 1983).
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GSH is therefore one of the primary cellular defences against electrophillic
compounds, not only as an antioxidant but by playing a role in maintaining normal
physiological function.
5.1 GSH METABOLISM
Cellular turnover of GSH occurs constantly, the oxidised form of GSH, GSSG, is
removed from the cell due to its toxicity to the cell. Intracellular GSH is regulated
by the externally membrane bound y-Glutamyl transpeptidase (y-GT),
y-Glutamylcysteine synthetase (y-GCS) and glutathione synthase (GS). y-GT is
involved in the breakdown of extracellular GSH, into its constituent amino acids,
which are transported into the cell and resynthesised into intracellular GSH by
y-GCS and GS. The enzymes are represented by the y-Glutamyl cycle (figure 6
below) (Cantin and Begin, 1991; Meister and Anderson, 1983).
2+GSH synthesis requires y-GCS, GS, ATP, Mg and the relevant amino acids. The
major organs involved in GSH synthesis are the liver and the kidney. GSH is then
either used in various cellular metabolic pathways or exported out of the cell. The
mechanism for exporting GSH is still not fully understood but is thought to either
involve y-GT, (Tate and Meister, 1981) or occur via a sodium transport system
which may also be responsible for the uptake of intact GSH in certain epithelial cells
(Burrowski et ah, 1995; Hagen et ah, 1988; Hagen and Jones, 1987). In the presence
of an oxidative stress, GSH is oxidised to GSSG, which is highly toxic to the cells
and either exported, possibly by an active transport system (Meister and Anderson,
1983) or reduced to GSH by glutathione reductase and NADPH in the GSH redox
cycle (see 2.2 Figure 1).
The breakdown of both GSH and GSSG extracellularly, involves the outer
membrane bound y-GT, which catalyses the transfer of the y-Glutamyl moiety to
acceptor molecules such as amino acids (cystine, glutamine, methionine), dipeptides
and other y-Glutamyl compounds (GSH) (Tate and Meister, 1981). y-GT is
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prevalent in secretory cells such as kidney epithelial cells, the epididymus and
bronchial cells, but it also occurs in alveolar type I and II cells and in alveolar
macrophages (Dinsdale et al., 1992). y-GT consists of 2 sub-units, the
cysteinylglycine moiety binding to the heavy sub-unit, and the active site for transfer
of the y-Glutamyl moiety to an acceptor molecule being in the light subunit (Tate
and Meister, 1981). The remaining L-cysteinylglycine from GSH is then cleaved by
dipeptides on the cell surface to release the 2 amino acids cysteine and glycine. The
amino acids are then transported back into the cell. This is known as the y-Glutamyl
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De novo synthesis ofGSH intracellularly is a 2 step process:
• Glutamic acid and cysteine are combined in a step catalysed by y-GCS. This is
both the first and the rate limiting step of GSH synthesis. The active site of the
enzyme can bind the y-Glutamyl moiety of GSH and glutamate, and hence
feedback inhibition of y-GCS can occur by GSH itself and glutamate. The first
step is also rate limited by the availability of cysteine. Cysteine and cystine are 2
non-essential amino acids, which are synthesised in the liver, cysteine is obtained
by reduction of cystine, which is more stable in the oxidative environment of
plasma. Cystine is the most active acceptor of the y-Glutamyl moiety and
therefore is taken up readily by y-GT, it can then be reduced in the cell to
cysteine and used for GSH synthesis. The availability of cystine, cysteine and a
reductive environment are therefore critical to this rate-limiting step in GSH
synthesis. Eighty percent of y-GCS is inactive in the cell since it is bound to
GSH. Depletion of GSH within the cell therefore results in GSH release from
y-GCS, resulting in increased GSH synthesis. mRNA for y-GCS and y-GT are
also increased following oxidant exposure and depletion of GSH (Liu et ah,
1996).
• The addition of glycine to y-Glutamylcysteine is achieved by the enzyme GSH
synthetase (GS). This is not a rate limiting step, and probably plays a less
important role than y-GCS in an oxidant response.
5.2 GSH AND THE LUNGS
As already discussed in the section on antioxidants, the ELF of the normal lung
contains high concentrations of GSH (Cantin et al., 1987) since the lung is exposed
to potentially toxic oxidation from various sources. GSH levels in the ELF of a
normal individual are approximately 100 times greater than plasma levels, and it is
thought that alveolar macrophages play a major part in releasing GSH since they
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contain high levels of GSH (9 times more than alveolar type II cells) and they have
an active y-GT cycle (Cantin and Begin, 1991; Horton et ah, 1987; Liu et al., 1996).
GSH is able to protect the cell membrane against oxidative damage by maintaining
SH groups and reducing compounds in the immediate environment of the cell and
can prevent the oxidation of antiproteases (Morris and Bernard, 1994).
GSH is likely to be critically involved in the negative control of pro-inflammatory
cytokines and NO production (Gaiter et al., 1997; Hayashi et al., 1993; Liu et al.,
1996; Staal et al., 1990). An increased oxidant burden, which results in alterations in
the GSH redox state of the cell, results in the activation of NF-kB, a transcription
factor which switches on pro-inflammatory cytokines such as TNF-a and IL8 and
NO production (Fujihara et al., 1994; Jany et al., 1995; Mellits et al., 1993; Newton
et al., 1997; Sen and Packer, 1996).
6. Nuclear Factor-KappaB (NF-kB)
NF-kB has been shown to induce mRNA for iNOS in many cell types and multiple
putative NF-kB sites in the promoter region of iNOS have been shown to be critical
for iNOS induction in response to stimuli such as cytokines (Chartrain et al., 1994;
Natoli et al., 1997). Activation ofNF-kB is thought to be redox regulated, having an
oxidant step in its activation that is inhibitable by thiols (Flohe et al., 1997; Sen and
Packer, 1996). NF-kB nuclear binding has been studied in this thesis in response to
various stimuli such as cytokines and oxidants, and the effects of thiols on NF-kB
induction have also been investigated. This section covers the structure and
activation ofNF-kB and discusses the controversy surrounding NF-kB activation. It
also covers the role of NF-kB in the pro-inflammatory processes in lung
inflammatory disease.
Acute and chronic alveolar and bronchial inflammation is a central feature of the
pathology of lung disorders such as asthma, COPD, ARJDS and IPF. All of these
disorders lead to the recruitment to, and activation of immune and inflammatory cells
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in the lungs. These inflammatory cells release cytokines, oxidants and other
inflammatory mediators. Epithelial cells also secrete pro-inflammatory mediators,
including NO, oxidants and cytokines, which contribute to a chronic inflammatory
response which can cause lung injury (Rahman and MacNee, 1998). NF-kB is a
major regulator of pathogen and inflammatory cytokine-inducible gene regulation
(Baeuerle and Baichwal, 1997; Flohe et al., 1997; Rahman and MacNee, 1998)
NF-kB binding sites serve as inducible transcriptional regulatory elements that
respond to immunological stimuli such as TNF-a, LPS and IL1—(3. Inducers ofNF-
kB, however, are not exclusively immunological, but also include an array of
substrates such as oxidants, growth factors, viral infection and UV light. NF-kB is
associated with an IkB subunit in the cytoplasm, release of which causes rapid
translocation of NF-kB into the nucleus, activating genes within minutes. There is
increasing evidence to support the occurrence of interactions between NF-kB and
other transcription factors resulting in the regulation of gene expression in a selective
manner (Hecker et al., 1996a; Lincoln et al., 1996; Salkowski et al., 1996). Synergy
with other transcription factors may determine cell type specific expression of genes,
an example being interferon regulatory factor-1 (IRF-1), which is inducible by IFN-y
treatment and physically interacts with NF-kB subunits (Baldwin, 1996; Salkowski
et al., 1996). Activation of IRF-1 by IFN-y, although not essential, is thought to be
required for optimal expression of the iNOS gene (Salkowski et al., 1996). NF-kB
activation is therefore necessary, but not necessarily sufficient for inducible
expression of particular genes. A great degree of specificity can therefore be
achieved by the synergistic interactions of NF-kB with other factors in gene
regulation (Baeuerle and Baichwal, 1997; Hecker et al., 1996a).
6.1 STRUCTURE
The NF-kB subunits and IkB proteins belong to larger protein families. Among the
NF-kB subunits, 5 rel proteins have been recognised and characterised, and all
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contain the Rel homology domain (RHD), a highly conserved protein involved in
immune regulation in insects (Warner et ah, 1995). The 5 rel proteins are; cRel, RelA
(p65), relB, NF-kB 1 and NF-kB 2. The rel homology domain functions in DNA
binding, dimerization and interactions with IkB. Active forms ofNF-kB include the
p50/p65 (relA) heterodimer and the p65/p65 (RelA/cRel) homodimer. Different
dimers are able to recognise different DNA consensus targets, thereby increasing the
ability ofNF-kB subunits to differentially regulate gene expression (Baldwin, 1996).
The p50/p65 heterodimer plays a critical role as a potent transcriptional activator that
is most frequently found in inducible complexes of various immune and non-immune
cell types. In the nucleus the p50 subunit facilitates binding to DNA whereas the p65
subunit is required for transactivation. A p50 homodimer also exists and this is able
to bind DNA and inhibit transcription (Baldwin, 1996; Rahman and MacNee, 1998).
6.2 THE INHIBITORY SUBUNIT IkB
There are several forms of IkB including IkB-cc and IkB~P, and their purpose is to
inactivate NF-kB by masking the nuclear binding sequence. A feature of IkB is the
presence of ankyrin repeats, and since both NF-kB 1 and 2 contain these ankyrin
repeats it is assumed that they contain an intramolecular IkB. NF-kB 1 and 2 are
thought to be precursor molecules for the p50 and p52, subunits of NF-kB, which
bind DNA. IkB-oc, the most studied inhibitor of NF-kB activation, is often
associated with the cRel and RelA dimers. The ankyrin repeats, present in all IkB
subunits, are required for binding to the Rel homology domain of NF-kB subunits.
The IkBa protein contains 3 domains, the N domain, C domain and an intermediate
domain. Experiments to remove or inactivate the N and C domain did not inhibit
IkBoc interaction with NF-kB. However on removal of the C terminal, NF-kB was
able to bind to DNA indicating that the C terminal is involved in masking of the
DNA binding site on NF-kB. The intermediate domain contains the ankyrin repeats
and mutations in this region prevents IkB binding to NF-kB. IkBP is similar to IkBcc
but is targeted by different stimuli (Baldwin, 1996).
45
6.3 ACTIVATION OF NF-kB
NF-kB is activated by the phosphorylation and ubiquitination of IkB, resulting in
degradation of the subunit. This can be demonstrated by the use of protease
inhibitors which block activation ofNF-kB (Mellits et ah, 1993). Protease inhibitors
inhibit the processing and degradation of IkB but phosphorylation still occurs
(Mellits et al, 1993), suggesting that a further step, the ubiquitination step, is
required for the degradation of IkB. The IkB gene is activated by NF-kB itself, and
is regenerated one hour after NF-kB activation, re-entering the cytosol and
inactivating NF-kB. IkB is therefore important in repression after induction.
Phosphorylation of IkB is thought to be achieved by a single kinase since mutations
of serine residues on IkB inhibit both TNF-a and LPS activation of NF-kB
(Baldwin, 1996). This kinase has recently been identified as the NF-kB inducing
kinase (NIK) (Reginier et al., 1997). However, it is likely that this kinase may itself
be activated by multiple pathways (Baeuerle and Baichwal, 1997).
Secondary messengers are also thought to be involved in NF-kB activation. These
include TNF-a activated ceramide, (which is thought to activate kinases which in
turn phosphorylate IkB), and ROS, (since H2O2 has been shown to increase NF-kB
activation) (Kretx-Remy et al., 1996; Schreck et al., 1991). TNF-a itself, results in
increased ROS release from the mitochondria, which is dismutated by SOD into
H2O2. There is conflicting evidence that ROS are important in the activation of NF-
kB, (Brennan and O'Neill, 1994; Flohe et al., 1997; Sen and Packer, 1996) and it is
likely that different systems occur in different cell types.
6.4 REDOX REGULATION OF NF-kB.
NF-kB can thus be activated by H2O2, TNF-a, and other cytokines (Fujihara et al.,
1994; Jany et al., 1995; Mellits et al., 1993; Newton et al., 1997) and there appears to
be a common link in the activation of NF-kB, by ROS which can be blocked by
antioxidants such as NAC (Blackwelll et al., 1996; Hecker et al., 1996a; Schenk et
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al., 1994; Schreck et al., 1991). There are, however, several reports showing that
oxidants are not necessary for NF-kB activation, particularly by TNF-a and IL1-P
(Brennan and O'Neill, 1994). Moreover, antioxidants are also able to activate NF-kB
(Kumuda et al., 1995; Toledano and Leonard, 1991). The involvement of ROS in
NF-kB activation has been assumed to be due to an oxidant step in the cascade
leading to NF-kB activation, possibly by modification of a protein. There are several
reports however, suggesting that oxidants are not directly involved in NF-kB, but
that the redox status of the cell is important, in particular, GSH, GSSG and
thioredoxin (Trx) (Gaiter et al., 1997; Hayashi et al., 1993; Staal et al., 1990). A
potent inducer of NF-kB activation is tertradecanoyl-phorbol-13-acetate (TPA),
which has been shown to increase GSSG levels, altering the GSHrGSSG ratio (Droge
et al., 1994a; Fidelus, 1998). NF-kB activation can be inhibited by BSO, a
compound that inhibits GSH synthesis (Meister and Anderson, 1983), and
augmented by BCNU, a compound that inhibits GR and reduction of GSSG (Gaiter
et al., 1997), thereby increasing GSSG. GSSG has an important role in protein
disulphide formation and protein folding, and may be necessary in forming a
disulphide bond in the NF-kB cascade (Droge et al., 1994). It has also been shown
that GSSG is necessary for both induction and nuclear translocation, but excess
GSSG inhibits DNA binding (Droge et al., 1994; Gaiter et al., 1997). Evidence thus
suggests that the level of GSSG in the cell is critical in both NF-kB activation and
inhibition (Droge et al., 1994a). Oxidative conditions have been shown to inhibit
DNA binding ofNF-kB (Gaiter et al., 1997). NF-kB has a sequence motif containing
cysteine and arginine in the DNA binding region (Matthews et al., 1992). The
cysteine residue is highly reactive and susceptible to oxidation, and binding can be
inhibited by modification of the cysteine residue, or enhanced by reducing agents.
Optimal activity ofNF-kB may be sensitive to an oxidant/antioxidant balance in the
cell, and may also depend on optimal levels of GSSG. Low GSSG levels prevent
NF-kB activation, and high GSSG levels inhibit NF-kB binding to DNA (Droge et
al., 1994a; Gaiter et al., 1997). Alternate pathways may also exist for some cytokines
such as TNF-a and IFN-y, which have been shown to activate NF-kB in the presence
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of antioxidants (Brennan and O'Neill, 1994). It is likely, however that the reductive
state of the nucleus is vital in the binding ofNF-kB to DNA due to the presence of
cysteine residues in the binding site (Matthews et al., 1992).
Figure 7 shows a schematic view of the systems possibly involved in NO induction,
including an oxidant/antioxidant pathway for NF-kB activation as well as an
alternative pathway independent of oxidants.
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Figure 7: A schematic view of NO induction via NF-kB activation.
Cytokines (TNF-a,
IL1-P,IFN-Y)
A: Pro-inflammatory cytokines such as TNF-a bind to receptors on the cell surface, causing protein kinase phosphorylation and superoxide
anion release from the mitochondria. B: Addition of H2O2 to the cell mimics the effect of superoxide anion release from the mitochondria. C:
Superoxide anions are converted to H2O2 (by SOD), which is broken down 1o water by glutathione peroxidase (GPx) and GSH. D: H2O2, GSSG
and cytokines may all have effects on phosphorylation of NF-kB either directly or by phosphorylation of protein kinases, GSSG in particular
may be involved in ubiquitination. This results in degradation of the IkB subunit and activation and translocation ofNF-kB to the nucleus. E: A
reductive environment is required in the nucleus for NF-kB binding to DNA. Binding may be prevented by too high concentrations ofGSSG. F:
NF-kB binds to DNA, switching on transcription of the gene for iNOS. NO is formed by the enzyme iNOS and L-arginine.
7 Hypothesis
The redox status of the cell, particularly that ofGSH is critical to the induction ofNF-
kB activation by cytokines and oxidants, which subsequently involves the induction
of iNOS and NO production. Increasing intracellular GSF1 by exogenous thiol
compounds will thus prevent NO induction.
8 Aims
The studies herein were designed to induce iNOS and NO production through the
activation of NF-kB by pro-inflammatory cytokines and oxidants (H2O2), in 2 cell
lines, in vitro, and to determine the role of intracellular GSH in this induction.
8.1 SPECIFIC OBJECTIVES:
• To measure nitrite release, as an indication of NO production and iNOS mRNA
levels upon stimulation of cells with a mixture of pro-inflammatory cytokines,
LPS and H202.
• To determine the effect ofNO induction on GSH levels of the cell.
• To determine the effect of depleting GSH levels with BSO, on NO induction
• To increase intracellular GSH levels using four exogenous thiol compounds NAC,
NAL, GSH, and GSHMEE.
• To determine the effect of increased intracellular GSH levels on the induction of
NO and iNOS mRNA, by cytokines and H2O2.
• To determine the effect of cytokines and H2O2 on NF-kB activation
• To determine the effect ofmodulating GSH levels, by BSO and thiol compounds,
on cytokine and H2O2 activation of NF-kB.
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2.2.1 CELL CULTURE TECHNIQUES.
Two cell lines representative of bronchial and alveolar cells were used throughout
this project: a human type II alveolar-like cell line, A549, and a human bronchial
epithelial cell line, 16HBE140-.
The A549 cell line has been recently proposed as a typical lower respiratory airway
cell and is derived from a single patient with a pulmonary adenocarcinoma (Lieber et
al, 1976). The cells were obtained from the American Type for Cell Culture,
(ATCC).
Dr. D.Greunert of the University of California kindly donated the bronchial epithelial
cell line, 16HBE140-. These cells were clone 16 derived from bronchial tissue of a
healthy male. The nomenclature 0- indicates they were transformed by the SV40
virus and the 14 stands for the 14th sample. These cells have been shown to possess
cilia (Cozens et ah, 1994) and express the chloride channel gene CFTR, which has
been shown to be defective in cystic fibrosis.
Both cells were grown in monolayers in 160mm flasks. Once they reached 95%
confluency they were passaged using phosphate buffered saline (PBS),
trypsin/EDTA and complete medium, all at 37°C. Confluency throughout this
project is defined in terms of percentage of plastic (wells/flasks) covered by cells,
and is assessed visually, although cells were also counted. Cells were normally
treated at 70% confluency for a maximum of 24 hours at which point cells had
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reached 95-99% confluency, defined as greater than 95% of the culture dish covered
by the cells. A549 cells were grown in Dulbeco's modified eagles medium (DMEM),
supplemented with 10% foetal bovine serum (FBS), lOOmM penicillin (P) and
lOOOu/ml of streptomycin (S) (known as the penicillin/streptomycin mixture (P/S))
and 2mM 1-glutamine (L-G) hence forth referred to as A549 complete medium. The
16HBE cells were grown, in contrast to the A549 cells, in minimum essential
medium (MEM), supplemented with 10% FBS, P/S, L-G and 1% non-essential
amino acid mixture (AA) and is henceforth be referred to as 16HBE complete
medium.
To passage the cells, medium was aspirated from the flasks and the cell monolayer
rinsed in warm sterile PBS. Cells were detached from the flask by the addition of
7ml of warm trypsin/EDTA, A549 cells requiring 5 minutes incubation at 37°C and
16EIBE cells requiring 10 minutes incubation at 37°C. Once detached 20ml of
complete medium was added to the flask to inactivate the trypsin, and the resultant
cell suspension was transferred to a sterile 50ml falcon tube. Trypsin/EDTA was
removed by centrifugation at 1 OOOrpm for 5 minutes at room temperature (RT) and
the cell pellet was resuspended in the volume of complete medium necessary for the
next stage. Generally cells were resuspended in; 20ml of complete medium for
propagation, 5ml of the suspension being transferred to a sterile flask along with
20ml of complete medium, or 24ml of complete medium for experimental purposes,
lml of suspension being transferred to a well in a 6 well plate along with 2ml of
complete medium. Cell cultures were maintained at 37°C, 5% CO2. Flasks for
propagation were left until cells required further passaging with a change of medium
every 2 days. Cells for experimental use were incubated until they reached 70%
confluency (approximately 1.4 x 106 cells/well of a 6 well plate), usually the
following day, and were then treated.
All cell culture work was performed in a uni-directional laminar flow Class II safety
cabinet. The surface of the cabinet was sprayed with isopropanol as was all bottle
caps and flasks caps prior to opening inside the cabinet. The appropriate protective
clothing (lab coat and disposable gloves) were worn on all occasions. All waterbaths
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and incubator humidifiers were cleaned on a weekly basis to reduce the risk of
bacterial contamination. On rare occasions when infection occurred, cells and
medium were destroyed and cells from frozen stock were seeded in new medium. All
cells were regularly checked for mycoplasma contamination and the cells used were
mycoplasma free.
Vials of both cell types were frozen down at regular intervals to ensure a sufficient
reserve in case of infection as mentioned above. This process involves removal of
cells from the flasks using trypsin/EDTA as described above. However cells were
resuspended in 1ml of freezing solution, (80% complete medium plus an extra 10%
FBS and 10% dimethylsulfoxide (DMSO)), and transferred to a cryogenic sterile 2ml
vial. DMSO inhibits the formation of ice crystals within the cells during the
freezing process since ice crystals occupy more space than water and would
therefore lead to cell disruption. However, DMSO is toxic to cells at room
temperature and it is therefore important to freeze the cells immediately. The vials
were wrapped in tissue paper and placed at -80°C for 48 hours and then transferred to
a liquid nitrogen storage unit (-130°C) for long term storage. The process of freezing
down slowly using 2 temperature stages also helps minimise the formation of ice
crystals (Morgan and Darling, 1996).
Likewise when cells were required from stock they were thawed out rapidly by
placing them at 37°C until they had thawed out. They were then aseptically
transferred to 10ml of warm sterile complete medium, washed by centrifugation at
1 OOOrpm, 25°c, for 5 minutes and the pellet resuspended in 10ml of fresh complete
medium before seeding into a 160mm flask. Once the cells had adhered, the
medium was replaced to remove any remaining traces ofDMSO.
2.2.2 EXPERIMENTAL TREATMENT OF CELLS
All cells were treated in phenol red free medium supplemented with 2% bovine
serum albumin (BSA), P/S, L-glutamine with 1% non-essential amino acids for the
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16HBE cells, hence forth referred to as 2% medium. Cells were washed twice in
PBS when 70% confluent (approximately 1.4 x 106 cells per well of a 6 well plate),
treated with bolus additions of appropriate treatment at the correct concentrations and
incubated for the appropriate time at 37°C, 5% CO2.
Concentrations of treatments and dilutions of compounds used throughout were as
follows:
Cytomix (TNF-a lOng/ml, IFN-y lOng/ml, IL-ip lOng/ml), cytokines were
dissolved in PBS containing 1% BSA and diluted to a storage concentration of
10pg/ml and stored at -70°C. Cytokines were diluted to lOng/ml in 2% medium for
experimental use.
LPS (from E.Coli serotype OIII:B4, y-irradiated) was diluted to lmg/ml in PBS and
stored at -20°C. LPS was diluted to lpg/ml in 2% medium and sonicated for 10
minutes before treatment of cells.
H202 (lpM), BSO (50pM), L-NMMA (50pM), NAC (5mM), NAL (5mM), GSH
(5mM) and GSHMEE (5mM) were all diluted in 2% medium for experimental use.
Rotenone was dissolved in chloroform at O.lpg/ml.
2.2.3 ASSAYS.
2.2.3.1 PREPARATION OF CELLS PRIOR TO ASSAYS.
Various assays were performed on both cell medium and cell lysates. Following
treatments and incubation, medium was removed from the cells and stored on ice for
nitrite measurement. Cells were subsequently removed from the wells as described
above by washing in warm PBS and incubation at 37°C for 5-10 minutes in 0.5ml of
trypsin/EDTA. Cell suspensions were aspirated from the wells, placed in 2ml
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Eppendorfs with 1ml ofwarm complete medium to wash the cells and centrifuged at
lOOOrpm for 5 minutes at room temperature. The supernatant was removed and cells
were resuspended in 1ml PBS. An aliquot (20pl) of the cell suspension was
removed to determine cell numbers and to check viability, and the remaining cells
were re-spun at lOOOrpm, 37°C for 5 minutes. The supernatant was removed and
cells were homogenised in 1ml of 0.6% Sulfosalicylic acid (SSA), 0.1% triton in
PBS using a mini-teflon. Samples were then spun at 2500rpm for 10 minutes at 4°C
and kept on ice or stored at -20°C for GSH measurements.
2.2.3.2 CELL COUNTS AND CELL VIABILITY.
Cells were counted using a standard haemocytometer and trypan blue. Trypan blue
exclusion was used as an indication of cell viability.
2.2.3.3 NITRIC OXIDE (NO) ASSAY.
Nitric oxide (NO ) released into the medium rapidly converts to nitrite (NO2").
Nitrite was measured using the Griess reagent (Green et ah, 1982) which involves
the diazotization of sulfanilimide and subsequent coupling to the chromophore N-(l-
napthyl)-ethanediamine. This results in a colour change which was measured
spectrophotometrically at 550nm on a Dynatech 3000 plate reader. In order to
observe the colour change, phenol red free medium was used to measure nitrite,
100pl of cell medium was placed into a 96 well flat bottom plate and lOOp.1 of Griess
reagent (1% sulfanilomide, 0.1% N-(l-napthyl)-ethanediamine and 2.5% H3PO4)
was added to the plate which was incubated at room temperature for 10 minutes. A
standard was established using sodium nitrite, diluted in distilled water (dE^O) in the
range of 0.098pM to 50pM. The results were expressed per million cells.
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2.2.3.4 REDUCED GLUTATHIONE (GSH) ASSAY.
GSH was measured using the Tietze assay (Tietze, 1969), which involves the
glutathione redox cycle i.e. oxidised GSH (GSSG) is reduced by glutathione
reductase (GR) and NADPH. To detect GSH the compound 5,5'dithio-bis-(2-
Nitrobenzoic acid) (DTNB) is used which binds to thiol groups and forms a complex
with an absorbance at 412nm. The rate of formation of the DTNB-GSH complex is
directly dependent on the concentration of GSH present in the sample. This assay
measures total GSH and does not distinguish between oxidised (GSSG) and reduced
glutathione (GSH) since GSSG is recycled to GSH.
For the assay 680-690pl phosphate buffer (PB) (pH 7.5, containing 5mM of EDTA),
lOOpl GR (lOunits/ml PB), lOOpl DTNB (5mM in PB), and 10-20pl of sample are
placed into a 1ml cuvette and left at room temperature for 1 minute. One hundred pi
of NADPH (2.4mM in PB) was added and the rate of the GSH-DTNB complex
formation followed at 412nm for 1 minute. A standard curve was established using
GSH, made up in 0.6% SSA and 0.01% triton-XlOO, in the range of 0.02nmoles to
2.6nmoles and results were expressed per million cells.
2.2.3.5 OXIDISED GSH (GSSG).
GSSG was also measured using the Tietze method (Tietze, 1969) with an additional
step that first removed GSH (Griffith, 1980). Two hundred pi of sample was
transferred into an eppendorf to which 4pl of 2-vinylpyridine (2-VP) was added, the
mixture vortexed and incubated for 1 hour at RT. 2-VP binds specifically to
reduced GSH, thus ensuring that only GSSG will be measured subsequently in the
Tietze assay. After 1 hour 6pl of 1:3 Triethanolamine (TEA) is added which inhibits
the action of 2-VP. At this point the pH of the samples is important in the assay, but
due to the small volumes used it was not feasible to measure the pH. There were
therefore variations within the pH levels of different experiments resulting in
variation between experiments, and therefore statistical analysis was not possible.
However in the results shown, the trends for each experiment were the same,
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allowing the data to be meaned and therefore provide some evidence for changes
following certain treatments. One hundred pi of the sample was added to lOOpl GR,
lOOpl DNTB and 600pl PB as for the measurement of total GSH and incubated at
RT for 1 minute. One hundred pi ofNADPH was added and the absorbance read at
412nm for 2 minutes. A standard curve was established using GSSG in the range of
0.02nmoles to 2.6nmoles, which was treated in the same manner as the samples.
2.2.3.6 MODIFICATION OF TIETZE METHOD.
The Tietze method was modified during the project to enable the measurement of
GSH/GSSG to be carried out on a plate reader. The same concentrations of reagents
were used but scaled down by l/5th of the original volume. However as a 412nm
filter was not available for the plate reader a 410nm filter was used. Comparisons of
the two wavelengths were carried out on the spectrophotometer (figure 1) and no
significant difference between either wavelength was observed between control and
treated cells. This method has since been published, (Vandeputte et al., 1994)
although enzyme concentrations were different to the ones used in our assay. The
difference observed between control cells and cytomix treated cells in figure 1 is
explained in further detail in chapter 4.
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Fig 1: The effect of cytomix on GSH levels in A549 cells. There is a significant
difference between control cells and cytomix treated cells at both 410 and 412nm.
There is no significant difference between the two wavelengths in either control cells
or cytomix treated cells. Histograms represent means and bars represent SEMs of 3
samples measured in duplicate. (**p<0.01 compared to relevant control)
2.2.3.7 TOTAL PROTEIN ASSAY.
Total protein was measured using bicinchonic acid which forms a colour complex
with proteins at 570nm (Smith et ah, 1985). In this assay lOpl of sample is incubated
with 200pl of dilute bicinochoic acid (1:50) in a 96 well plate for 30 minutes at 37°C.
Absorbance is measured at 562nm using a standard of pure bovine serum albumin in
the range of 0.1-0.6 mg/ml. Pierce and Warriner, Chester, UK provided a protein
assay kit containing both the standard and acid.
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2.2.4 REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION.
2.2.4.1 RNA EXTRACTION.
Cells were passaged as previously described and seeded in 100mm petri dishes at a
density of 4xl06 cells per dish. The cells were treated when 70% confluent for the
specified time. Following treatment the medium was removed and discarded. One
ml of TRIzol reagent was added to the plate for 5 minutes at room temperature to
lyse the cells. TRIzol reagent is used since it maintains the integrity of RNA whilst
disrupting cells and dissolving cellular components. Cell lysates were removed and
transferred to sterile, RNAse free, 2ml Eppendorfs. Phase separation of RNA, DNA
and protein was achieved by addition of 0.2ml of chloroform followed by vortexing
for 30 seconds and incubation at room temperature for 2 minutes. Chloroform
separates the sample into an aqueous phase and an organic phase, with RNA
remaining in the upper aqueous phase. Samples were centrifuged at 12,000rpm for
15 minutes at 4°C and the aqueous phase was transferred to a sterile, RNAse free,
2ml eppendorf. 0.5ml of isopropanol was added to precipitate the RNA from the
aqueous phase extract, samples were incubated on ice for 10 minutes and centrifuged
at 12,000rpm for a further 10 minutes at 4°C. The supernatant was discarded and the
RNA pellet washed in 75% ethanol (200pl). Samples were vortexed and spun at
7,500rpm for 5 minutes at 4°C. The ethanol was removed and the cell pellets
allowed to air dry on the bench for 10 minutes. Pellets were dissolved in 50pl dH20
at 55°C for 5 minutes. Samples were either used for cDNA preparation immediately
or stored at -70°C.
2.2.4.2 CDNA PREPARATION.
The total RNA concentration of the samples was determined spectrophotometrically
at 260nm in a quartz cuvette. 1 pi of sample was diluted into 1ml dH20 and the RNA
concentration determined. RNA/protein ratio was also determined to give an
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indication of RNA purity. Table 4 explains which components are necessary for the
synthesis of first strand cDNA.
Table 4 The Components for First Strand cDNA
Components Final concentration Final Volumes
RNA 5pg 1 Opl (approximately)
5x First strand buffer lx 5pi
DTT(lOOmM) lOmM 2.5pl
Oligo dT (lOOpg/ml) 1 Opg/ml 2.5pl
DNTPs (lOmM) 0.5mM 1.25 pi




dh2o - 1.75pl (approximately)
This cDNA mixture was incubated on a PCR block for 60 minutes at 37°C after
which reverse transcriptase was heat inactivated at 95°C for 5 minutes.
2.2.4.3 PCR.
For detection of mRNA using the reverse transcriptase method, 5pi of cDNA stock
was added to 50pl of PCR mixture in a 0.5ml Eppendorf. PCR mixture consists of
PCR buffer (50mM KC1, lOmM TrisCl pH 8.4, 2.5mM MgCk, 0.2mM dNTPS) and
lpM each of the appropriate primers for the particular mRNA required. Primers
were used for both iNOS and GAPDH mRNA. The latter as a housekeeping gene to
ensure that the PCR reaction is working and also to compare with the iNOS mRNA.
Primer pairs for GAPDH were:
5' CCA CCC ATG GCA AAT TCC ATG GCA 3'
5' TCT AGA CGG CAG GTC AGG TCC ACC 3'
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Primer pairs for iNOS were:
5' GTG AGG ATC AAA AAC TGG GG 3'
5' ACC TGC AGG TTG GAC CAC 3'
2 drops of mineral oil was added to the Eppendorfs to ensure evaporation did not
occur during the PCR cycles. The samples were placed in the PCR thermal cycler
and heated to 98°C for 10 minutes. lUnit of Taq DNA Polymerase was added after
the first 5 minutes, a feature known as 'Hot Start'. 'Hot Start' ensures that there is no
non-specific binding of the primers to the cDNA as they may anneal at room
temperature since Taq polymerase works at both room temperature and higher
temperatures. The samples were then run on the correct program for either iNOS or
GAPDH. Amplification of iNOS consists of 35 cycles of 94°C for 2 minutes, 58°C
for 2 minutes, 72°C for 2 minutes and finally 1 cycle of 72°C for 10 minutes.
Amplification of GAPDH consists of 35 cycles of 94°C for 1 minute, 55°C for 1
minute, 72°C for 1 minute and finally one cycle of 72°C for 5 minutes. A positive
control for iNOS was provided by Dr Serpil Erzurm of the Cleveland Clinic
Foundation. The amplified products were resolved by agarose gel electrophoresis in
a 1.6% agarose in 0.5% TBE buffer (0.45M TrisBorate and 0.01M EDTA(Na),
visualised by ethidium bromide and photographed.
2.2.4.4 ELECTROPHORETIC MOBILITY GEL SHIFT ASSAY.
This assay detects DNA binding proteins such as sequence specific transcription
factors. The principal of the assay is based on the migration of protein-DNA
complexes through a denaturing polyacrylamide gel in which unbound DNA
fragments or double stranded oligonuclotides migrate at different rates to protein-
DNA complexes. The complex can be observed by the use of 32P end labeled DNA
fragments, which contain the putative protein-binding site. A gel shift assay core
system was obtained from Promega for this assay.
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2.2.4.5 NUCLEAR PROTEIN EXTRACTION (Andrew and Faller, 1991).
Nuclear protein extraction involves the use of 3 separate buffers;
Buffer A contains: 10mM HEPES pH7, lOmM KC1, 2mM MgCl2, ImM
DTT, O.lmM EDTA, 0.2mM NaF, 0.2mM sodium orthovanadate, 0.8mM PMSF and
0.3mg/ml leupeptin.
Buffer B consists of 10% Noidet P 40 diluted in distilled water.
Buffer C contains: 50mM HEPES pH7.5, 50mM KC1. 300mM NaCl, O.lmM
EDTA, ImM DTT, 10% glycerol, 0.2mM NaF, 0.2mM sodium orthovandate and
0.6mM PMSF.
In both buffers A and C, anti-proteases (PMSF and leupeptin) were added at the last
minute.
Cells were grown in 100mm petri dishes until 70% confluent and treated for the
appropriate time. The cells were washed in PBS, scraped into 1ml PBS, transferred to
a 2ml Eppendorf and centrifuged at 1400rpm for 1 minute at 4°C. The supernatant
was discarded, the pellet resuspended in 0.4ml of buffer A and the samples were
incubated on ice for 15 minutes. Buffer B (25pi) was added, the samples vortexed
and centrifuged at 14000rpm for 1 minute at 4°C. The supernatant was again
discarded, the pellet resuspended in 50pl buffer C and samples incubated on a
rotating table for 20 minutes at 4°C. The samples were centrifuged at 14000rpm for 5
minutes at 4°C, the supernatant was removed, total protein concentration was
determined in the supernatant (using the protein assay described above) and the
supernatant samples were stored at -20°C.
2.2.4.6 LABELLING OF THE CONSENSUS OLIGONUCLEOTIDE FOR NF-
kB
The NF-kB oligonucleotide (supplied by Promega) was labeled using [y32P] ATP.
Two pi ofNF-kB oligonucleotide sequence (at 1.75pmol/ml) was incubated with lpl
10xT4 polynucleotide kinase buffer, lpl [y32P] ATP (3000Ci/ml), 5pl dH20 and lpl
T4 polynucleotide kinase (5-10U/ml) for 10 minutes at room temperature. The
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reaction was terminated by the addition of lpl 0.5M EDTA, the reaction mixture was
made up to lOOpl with TE buffer (lOmM Tris pH 8, ImM EDTA, pH 8) and the
labeled oligonucleotide could be stored at -20°C for up to 2 weeks.
2.2.4.7 SAMPLE PREPARATIONS
Nuclear extract proteins were diluted to 1 pg/ml with dEEO and 2pg was incubated in
5pi dEEO, 2pi gel shift binding 5x buffer (supplemented with 0.25mg/ml sheared
salmon sperm DNA) for 5 minutes at room temperature. A positive control from
EleLa nuclear extract was used (provided by Promega) and a negative control tube
was set up with dEEO. One pi of the labeled oligo NF-kB was added to the samples
followed by a 20 minute incubation at room temperature. The reaction was
terminated by the addition of lpl lOx gel loading buffer (20mM EGEPES, 0.1%
bromophenol blue, 20% glycerol). Samples were then run on a 5% acrylamide gel
which is prepared by using 10ml of 30% (w/v) acrylamide/bis solution (37.5:1)
diluted with lx TBE, 50pl of N',N',N',N', Tetramethylethylenediamine (TEMED)
and 50pl of 25% ammonium persulphate (APS). Samples were loaded once the gel
had set and run at 100 volts for 2 hours. Gels were placed onto Whatman filter paper,
vacuum dried for 30 minutes and autoradiographed.
2.2.5 IMMONOPEROXIDASE (ABC) CYTOKERATIN STAINING OF
CELLS FOR EPITHELIAL MARKERS.
Cells were seeded at 0.5 x 106 cells/ml onto sterile cover slips which were placed in
petri dishes and cultured until they reached 70% confluency. Medium was removed
and cells were washed in warm PBS, and then fixed using 3% paraformaldehyde
(diluted in PBS without calcium/magnesium) for 4 minutes. Coverslips were then
rinsed 3 times in PBS and ImM EDTA/PBS was added to the petri dish. Cells were
permeabilised by placing them in a microwave for 30 seconds (Morgan and Darling,
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1996). Petri dishes were then placed in a humid chamber, cells face up, and
incubated with 200pl of the Dako monoclonal mouse anti-human cytokeratin
antibody at a dilution of 1 in 50 in EDTA/PBS and left for 1 hour at room
temperature. Coverslips were washed with EDTA/PBS 3 times and subsequently
incubated with 200pi of the secondary biotinylated antibody, rabbit anti-mouse
(RAM) at a dilution of 1 in 300 in EDTA/PBS for 45 minutes in a humid container.
Coverslips were rinsed in PBS, incubated with 200pl of the avidin biotinylated
complex (ABC), containing horseradish peroxidase, (which is supplied in kit form
from Dako), and incubated for 45 minutes. Cells were developed in
diaminobenzedine (DAB) for 7 minutes, and rinsed with PBS. The nuclei were
stained by addition of 10ml of nuclear fast red (filtered) to the coverslips for 5
minutes followed by rinsing in distilled water.
2.2.6 STATISTICAL ANALYSIS
All experiments were carried out a minimum of 3 times, each experiment was
performed in triplicate and all assay measurements performed in duplicate. Data was
analysed for skewness followed by a one way analysis of variance (ANOVA), and
subsequently by Tukeys T test for unpaired samples. The histograms in the figures
represent means and the bars standard errors of between 3 and 5 experiments carried
out in triplicate.
Since GSH levels often varied between experiments, due to cell culture conditions,
the results were therefore normalised to control level before analysis was carried out.
In these cases, the control levels therefore have no standard error.
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Chapter 3 Epithelial characteristics of A549 and 16HBE cells and
the role of GSH in cell proliferation.
3.1 INTRODUCTION
The two cell types used throughout this thesis were the A549 and the 16HBE cell
lines. A549 cells are a tumour cell line (Lieber et ah, 1976), initiated from a human
alveolar cell carcinoma, and were originally shown to have properties typical of
human alveolar type II cells. These include the presence of multilamellar
cytoplasmic inclusion bodies and the ability to produce surfactant. It has recently
been shown, however that they no longer retain the ability to produce surfactant (Li
et ah, 1995). A549 cells are thus only used as a model of 'alveolar-like' cells which,
when grown in culture, still retain the characteristic cobble shape. 16HBE cells are
SV40 transformed primary bronchial cultured epithelial cells and have been shown to
retain differential epithelial morphology. Monolayers of these cells have been shown
(Cozens et al., 1994) to generate transepithelial resistance, have tight junctions and
cells grown in a liquid/air interface retain the ability to generate cilia, properties
typical of human bronchial cells. 16HBE cells when grown in culture also retain the
characteristic cobble shape, but unlike the A549 cells, which tend to grow
individually, they grow in clumps, requiring cell-cell contact for growth.
3.2 CHARACTERISATION OF THE EPITHELIAL CELL LINES:
In order to show that both cells retained epithelial properties, they were stained with
a mouse anti-human cytokeratin antibody that is known to react with human
epithelial cells. The cells were then visualised by the immunoperoxidase method as
described in 2.2.5 and the nuclei were stained using nuclear fast red. Figures 2 and 3
show that both cell types stained positive for epithelial characteristics.
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Figure 2 Figure 3
Figures 2 and 3: A549 (figure 2) and 16HBE (figure 3) cells stained with the
cytokeratin antibody. (C) Corresponds to the cytokeratin and (N) to the nucleus.
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3.3 CELL CONFLUENCY.
Throughout this thesis the term confluency is used to describe a point in cell growth
when the well surface becomes completely covered by cells. In all experiments
described herein cells were treated at 70% confluency, which refers to the point at
which cells covered approximately 70% of the well surface. This measurement,
although subjective, ensured that cells were treated at approximately the same state
for each experiment. Figures 4 and 5 give an indication of the degree of confluency
for both cell types. Cells were grown in monolayers to each confluency level,
trypsinised and counted using a haemocytometer. This was carried out several times
to ensure that the level of confluency produced consistent cell numbers between
different experiments. Cell numbers were found to be similar for both cell types on
each occasion (Table 1).
Table 1 The Number of Cells at Different Confluency Points in both A549 and
16HBE cells.
% confluency Number ofA549 cells Number of 16HBE cells
70% 1.4 x 106 1.5 x 106
85% 1.7 x 106 1.6 x 106
95% 2.1 x 106 2.12 x 106
99% 2.4 x 106 2.3 x 106
For experimental purposes, cells were normally harvested before they reached 100%
confluency, i.e. they were harvested between 95 and 99% confluencies. This was
because once cells had formed a confluent monolayer they began to grow on top of
one another and floated off into the medium. Furthermore, intracellular GSH levels
decreased after cells had reached confluency.
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Figure 4 Figure 5
Figure 4 and 5: the appearance of A549 (figure 4) and 16HBE (figure 5) cells at a:
70% confluency, b: 85% confluency and c: 99% confluency.
3.4 REDUCED GSH LEVELS IN THE EPITHELIAL CELL LINES.
In preliminary studies total intracellular GSH levels varied considerably in these cell
lines from experiment to experiment. A number of experiments were therefore
carried out in both epithelial cell lines to determine if there was a period of time in
the growth of the cells when intracellular GSH levels were stable. Cells were seeded
at fairly low densities and harvested at different percentage confluences, counted
and total intracellular GSH levels measured. Cells were also grown in varying culture
conditions in order to determine if serum concentrations had any effect on GSH
levels. In these experiments, cells were grown in complete medium, harvested and
subcultured into 6 well plates, again in complete medium. When the cells had
reached 30% confluency the medium was removed and replaced with complete
medium (10% FBS), or medium supplemented with 2% BSA. Cells were then
harvested at different percentages of confluency and the intracellular GSH levels
measured. Figures 6 and 7 show the effects of different culture conditions and
different confluences on GSH levels. 110% represents cells grown to confluency
and left for a further 24 hours. GSH levels increased in both cell types to 70%
confluency, at which point they remained relatively stable until they had formed a
confluent monolayer (99%), and thereafter dropped significantly (110%). No
significant difference was observed between cells grown in 10% FBS and 2% BSA.
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% Confluency
Figure 6: The effect of different culture conditions and confluency on intracellular
GSH levels in A549 cells. The symbols represent the means, SEMs are absent for
clarity. GSH levels below 70% confluency were significantly different to those at
70% confluency (p<0.05), 85% (p<0.05), 95% (p<0.01) and 100% (p<0.01). Cells
grown to 110% confluency were significantly different (p<0.05) compared to 100%
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Figure 7: The effect of different culture conditions and confluency on intracellular
GSH levels in 16HBE cells. The symbols represent the means, SEMs are absent for
clarity. GSH levels below 70% confluency were significantly different to those at
70% confluency (p<0.01), 85% (p<0.01), 95% (p<0.01) and 100% (p<0.01). Cells
grown to 110% confluency were not significantly different compared to 100%
confluency. There was no significant difference in GSH levels between 70% and
100% confluency but there is a significant difference (p<0.05) between 95% and
110% confluency.
It is a normal experimental procedure to quiesce cells for 24 hours before using them
for experimental manipulation. I therefore measured GSH levels in cells following
replacement of the serum-supplemented medium with serum free medium. Figures 8
and 9 show the effects of growing cells to 70% confluency in 2% serum (BSA)
supplemented medium, followed by removal of medium over a 24 hours period.
GSH levels decreased significantly in both cell types following removal of serum,
although this effect was more significant in A549 cells. Removal of serum also
resulted in a decrease in cell proliferation; cells containing serum reached 95%
confluency after 24 hours whereas cells without serum only reached approximately






Figure 8: The effect of 2% BSA supplemented medium and serum free medium on
intracellular GSH in A549 cells at different time points after serum removal. The
points represent means and bars SEMs. (**p<0.01, *p<0.05 compared to serum free





Figure 9: The effect of 2% BSA supplemented medium and serum free medium on
intracellular GSH in 16HBE cells at different time points after serum removal. The
points represent means and bars SEMs. (*p<0.05 compared to serum free at the same
time.)
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It has also been observed that at different passage numbers, cells had different
intracellular non-protein thiol (NPSH) levels. GSH constitutes 90% of the intra
cellular non-protein thiol (NPSH) levels, and therefore NPSH levels reflect
intracellular GSH levels. Figures 10 and 11 show the NPSH levels of both A549 and
16HBE cells for different passage numbers. Based on these results, which were
obtained by Dr. B. Mulier, A549 cells were always used between passage numbers















Fig 10: The levels of intracellular NPSH for different passage numbers in A549
cells. Histograms represent means and bars SEMs. (***p<0.001 compared to p37,
#p<0.05 compared to p41).
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Fig 11: The levels of intracellular NPSH for different passage numbers in 16HBE
cells. Flistograms represent means and bars SEMs. (***p<0.001 compared to plO,
• # p<0.05 compared to all other passages)
3.5 SUMMARY.
• Both A549 and 16HBE cells retain epithelial properties, as shown by cytokeratin
positivity.
• GSH levels are at their most stable between 70 and 99% confluency in both A549
and 16HBE cells.
• The removal of serum from cell medium results in intracellular GSH levels
decreasing over time and this decrease is also associated with a decrease in cell
proliferation.
• To obtain stable intracellular NPSH levels, and hence GSH levels, A549 cells
should be used between passage 41 to 80, and 16HBE cells should be used
between passage 10 to 25.
3.6 DISCUSSION.
Previous studies have shown that intracellular GSH levels are affected by culture
conditions (Kang and Enger, 1990; Post et ah, 1983). Post et al (Post et al., 1983)
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showed that GSH levels of A549 cells vary after they are passaged, levels increasing
up to 24 hours and decreasing thereafter. Post and colleagues also showed that serum
levels in the medium affect intracellular GSH levels, increased serum concentrations
increased GSH levels, and the absence of serum correlated with decreased GSH
levels. My results show that cells grown in serum supplemented medium have fairly
stable intracellular GSH levels between 70% and 99% confluency, which can occur
up to 48 hours after passaging, and no significant difference was observed between
cells grown in 10% serum and 2% serum. However, the data described here and that
of Post et al cannot be directly compared since cell densities were not recorded by
Post et al. My data show that once cells had formed a confluent monolayer however,
GSH levels decreased, possibly due to cells entering the Gi or Go plateau phase, i.e.
the cells cease to proliferate. Cells grown in medium lacking serum did, however,
have lower GSH levels compared to cells grown in serum supplemented medium.
These cells also had a much slower growth rate, taking up to 2 days longer to reach
confluency, possibly, again, due to cells being in a Gi or Go plateau growth phase.
Cells grown in serum free medium are known as quiesced cells, and it is thought that
cells contain several molecules which are critical in allowing cells to pass through
the restriction stage in the cell cycle, the Gi stage. Serum deprivation is thought to
destroy these molecules and hence the cells remain in the Gi stage, which, in
quiesced cells is referred to as the Go stage (Alberts et al., 1989). It has also been
shown (Harris and Teng, 1997) that GSH levels are fairly constant through the cell
cycle except when cells are grown to a Gi or Go plateau phase in either exhausted or
serum deficient medium1; Furthermore Kang and Enger (Kang and Enger, 1990)
observed that A549 cells contained a higher amount of GSH in the early portion of
the exponential phase of growth, and lower levels at the plateau phase of growth.
These studies (Harris and Teng, 1997; Kang and Enger , 1990; Post et al., 1983)
suggest that GSH is involved in the regulation of cell growth. In support of this,
treatment of A549 cells with butathione sulphoximine (BSO), which depletes GSH
levels, is also associated with a decrease in cell growth (Kang and Enger , 1990) and
this decrease is dose dependent. BSO is not toxic to the cells since removal of BSO
results in cell proliferation (Kang and Enger, 1992). This is consistent with results
described herein since intracellular GSH levels begin to fall after 100% confluency, a
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point at which cell growth is much slower, suggesting that GSH levels and
proliferation are related. However, it has been shown that the decrease in GSH does
not correlate with proliferation, (Kang, 1993) and it is thought that BSO actually
inhibits proliferation by inhibiting cysteine uptake, which is necessary for cell
growth and de novo GSH synthesis. Addition of extracellular GSH can partially
overcome the effects of BSO on GSH levels, and for extracellular GSH to have this
effect it needs to be broken down into its constitutive amino acids, one of which is
cysteine. Poot et al (Poot et al., 1995) have shown that the decrease in proliferation
following BSO treatment results in cells arresting in the S and G2 phase of the cell
cycle, which is consistent with the hypothesis that GSH synthesis is required for cell
growth. Cells sub-cultured during exponential growth also contain higher levels of
GSH. The critical role of thiols, especially GSH, in cell proliferation, has also been
observed in human bronchial epithelial cells, (Atzori et al., 1994) where GSH is
thought to play a part in transmembrane signal transduction by modifying the redox
status of critical proteins which are involved in proliferation. Thus, it is possible that
GSH is a candidate for one of the essential molecules that are required for cell
cycling (Alberts et al., 1989), since removal of serum causes both a decrease in
intracellular GSH levels, and an arrest of cells in the Gi plateau phase known as Go-
My results, taken together with other studies, suggest that lung epithelial cells should
be grown in serum supplemented medium and used at a stage in which they are still
proliferating. This should ensure that GSH levels are relatively stable during
experimental interventions. Since I wish to observe changes in GSH in both cell
types following various treatments, I treated cells at 70% confluency, harvested them
at between 90-99% confluency and always treated them in serum supplemented
medium.
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Chapter 4 Induction of Nitric Oxide in Both A549 and 16HBE Cells
and the Effect of Nitric Oxide Induction on GSH Levels.
4.1 INTRODUCTION.
NO can be induced in many different cell types, including epithelial cells (Robbins
et al., 1994;), macrophages (Steuhr and Marietta, 1987), hepatocytes (Geller et ah,
1993) and endothelial cells (Murphay et al., 1991) using a variety of stimuli such as
TNF-a, IL1—P, IFN-y, and LPS. Inducible nitric oxide synthase (iNOS), unlike the
constitutive cNOS is switched on by these stimuli, resulting in an increase in NO
release from cells. This increase can be measured in cell medium using the Greiss
assay which measures nitrite levels. NO reacts with molecular oxygen, abstracting a
single electron, resulting in the formation of nitrite (NO2), a product which is easily
measured in the cell medium. However, the assay appears to be limited and only
indicates that iNOS has been switched on, resulting in an increase in nitrite in the
medium. In the results that follow, the assay does not appear to show differences
above a certain level (approximately 0.6pM/million cells). This may be due to nitrite
itself being oxidised to give nitrate and a further assay can be carried out in order to
determine levels of both nitrite and nitrate (Green et al., 1982). This was not carried
out in our experiments, however, since we carried out further assays (PCR) in order
to assess iNOS induction. The oxidation of nitrite to nitrate may therefore be a
limitation in the accuracy of the Greiss assay in measuring NO release.
4.2 INDUCTION OF NO AND NITRITE PRODUCTION IN EPITHELIAL
CELLS IN RESPONSE TO CYTOKINES AND LPS.
NO induction, as measured by both nitrite levels in the medium and iNOS mRNA
has previously been shown for A549 cells (Robbins et al., 1994) using cytomix
(TNF-a, IL1-P, and IFN-y, lOng/ml of each). I therefore determined the
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concentration of cytomix required in our system to induce nitrite production in both
A549 and 16HBE cells. Figures 12 and 13 show the effects of cytomix at
concentrations of both lOng/ml and 20ng/ml of each cytokine. Cytomix was diluted
in 2% medium and added to the cells once they had reached 70% confluency. Nitrite
levels were measured 24 hours later. Ten ng/ml appears to be sufficient for the
induction of nitrite production (causing a 300% increase) and there is no added effect
of using the higher concentration of 20ng/ml in either cell type. This concentration of
cytomix (lOng/ml) was thus used throughout the thesis unless otherwise stated.
control cytomix lOng/ml cytomix20ng/ml
Treatment
Figure 12: The effect of different concentrations of cytomix on nitrite production by
A549 cells at 24hrs. Histograms represent means and bars SEMs. (**p <0.01, ***p<


















Figure 13: The effect of different concentrations of cytomix on nitrite production
byl6HBE cells at 24hrs. Histograms represent means and bars SEMs.
0.001,compared with control).
The time course of nitrite production was carried out to determine the optimal time
for measuring nitrite following treatment with cytomix. Cells were treated with
cytomix and nitrite levels were measured at 8 hourly intervals. The earliest time
point at which nitrite production was significantly different from control was 24
hours. Figures 14 and 15 show the time course of nitrite production over 24hrs in




Figure 14: The effect of cytomix on nitrite production in A549 cells over a period of




Figure 15: The effect of cytomix on nitrite production in 16F1BE cells over a period
of 24hrs. Symbols represent means and bars SEMs. (***p<0.001 compared with
control).
Since cytomix has been used previously to induce NO in A549 cell, (Adcock et al.,
1994; Robbins et al., 1994). I examined the effects of the individual cytokines on
nitrite production. Figures 16 and 17 show the effect of the single cytokines (TNF-a,
ILl-p, IFN-y, all at lOng/ml) on nitrite production in both cell types. TNF-a causes
a significant increase in nitrite production in both A549 and 16HBE cells, although
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nitrite levels were significantly lower than those observed with cytomix. There was
no significant increase in nitrite levels following addition of the other cytokines
(IL1—P and IFN-y) and there was a significantly higher level of nitrite following
cytomix than each individual cytokine. The combination of cytomix was therefore
used throughout this thesis since it was a significantly stronger signal than TNF-a
alone.
#
control cytomix TNF-a ILl-p IFN-y
Treatment
Figure 16: The effect of individual cytokines on nitrite production in A549 cells.
Histograms represent means and bars SEMs.(***p<0.001, **p<0.01, compared to
control, #p<0.05, ##p<0.01, compared to cytomix).
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control cytomix TNF-a IL1-P IFN-y
Treatment
Figure 17: The effect of individual cytokines on nitrite production in 16HBE cells.
Histograms represent means and bars SEMs. (**p<0.01, *p<0.05, compared to
control, ##p<0.01, ###p<0.001 compared to cytomix).
LPS has also been used in a variety of cell types to induce iNOS and NO release
(Chesrown et al., 1994; Steuhr and Marietta, 1987). I therefore examined the effect
of LPS alone and in combination with cytomix. Figures 18 and 19 show the effect of
LPS (lpg/ml) on nitrite production in both cell types. There was no significant
increase in nitrite levels following addition of LPS to A549 cells, but there was a
significant increase in nitrite levels in 16HBE cells following addition of LPS. There




Figure 18: The effect of LPS on nitrite production in A549 cells. Histograms
represent means and bars SEMs. (**p<0.01 compared to control).
control cytomix LPS LPS +cytomix
Treatment
Figure 19: The effect of LPS on nitrite production in 16HBE cells. Histograms
represent means and bars SEMs.(**p<0.01, *p<0.05, compared to control).
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4.3 INHIBITION OF NO RELEASE BY THE NOS INHIBITOR LNG-
MONOMETHYL-L-ARGININE (L-NMMA).
In order to show that the data presented above are as a result of nitrite production,
and hence induction of NOS, the inhibitor L-NMMA was used. L-NMMA is an
analogue of L-arginine and prevents NO formation by competitive inhibition of the
enzyme NOS. Cells were pre-treated with L-NMMA for 1 hour followed by
treatment with cytomix for a further 24 hours. Figures 20 and 21 show that pre-
treatment with L-NMMA significantly decreased nitrite production in both cell types
following cytokine treatment.
control cvtomix L-NMMA L-NMMA +
Treatment cytomix
Figure 20: The effect of pre-treating A549 cells for lhr with L-NMMA followed by
treatment with cytomix for 24hrs. Histograms represent means and bars SEMs.












control cytomix L-NMMA L-NMMA +
cytomix
Treatment
Figure 21: The effect of pre-treating 16HBE cells for lhr with L-NMMA followed
by treatment with cytomix for 24hrs. Histograms represent means and bars SEMs.
(**p< 0.01, compared with control, #p < 0.05,## p< 0.01, compared with cytomix.)
4.4 INDUCTION OF NO USING THE OXIDANT H202.
In the airway an initial response to oxidant stress is thought to be the induction of
NF-kB responsive genes such as iNOS. I therefore examined the effect of H202 on
NO release. H202 is an oxidant and can cause cell damage in high concentrations
(Mulier et ah, 1998). Three concentrations were chosen, of which the highest
(lOpM) has previously been shown to be non-toxic in A549 cells. Toxicity was
previously measured as the amount of LDH release (Mulier et al., 1998), which gives
an indication of cell membrane destruction and cell death. Trypan blue exclusion was
also carried out in the three treatments. Figures 22 and 23 show a dose response
ranging from lOOnM to lOpM, of H202, in 2% medium on nitrite production in both
A549 and 16HBE cells. Nitrite production increased significantly in both cells
following treatment with all three concentrations of H202. In subsequent experiments
I used 1 p.M of H202 since this concentration, although not significantly different to




H202 lOOnM H202 lgM H202 lOpM
Treatment
Figure 22: Dose response of H2O2 on nitrite production in A549 cells. Flistograms
represent means and bars SEMs. (*p<0.05,**p<0.01 compared to control)
■
H202 lOfaM
Figure 23: Dose response of H2O2 on nitrite production in 16HBE cells. Histograms
represent means and bars SEMs. (*p<0.05,**p<0.01 compared to control)
Figures 24 and 25 show the additive effect of both H2O2 and cytomix on nitrite
release. No significant additive effect was observed in either cell type following this
combination ofNO inducers. This may either be due to limitations of the assay, or


















control cytomix H202 H202 +
cytomix
Treatment
Figure 24: The effect of cytomix, H2O2 and a combination of cytomix and H2O2 on
nitrite production in A549 cells. Histograms represent means and bars SEMs.
(***p<Q 001 compared to control)
0.8 T
control cytomix H202 H202 +
cytomix
Treatment
Figure 25: The effect of cytomix, H2O2 and a combination of cytomix and H2O2 on
nitrite production in 16HBE cells. Histograms represent means and bars SEMs.
(**p<0.001 compared to control).
The NOS inhibitor L-NMMA was used to show that the observed effects of H2O2 on
nitrite prodcution was due to the induction of iNOS and subsequent NO release.
Figures 26 and 27 show the effect of pre-treatment with L-NMMA for 1 hour
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followed by H2O2 treatment for 24 hours in both cell types. In both cell types, pre-
treatment with L-NMMA significantly decreased nitrite production following H2O2
treatment.
control H2O2 L-NMMA L-NMMA
rp . . + H202Treatment
Figure 26: The effect of pre-treating A549 cells for lhr with L-NMMA followed by
treatment with H2O2 for 24hrs. Histograms represent means and bars SEMs. (**p<
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control H2O2 L-NMMA L-NMMA
Treatment + H2<-)2
Figure 27: The effect of pre-treating 16HBE cells for lhr with L-NMMA followed
by treatment with H2O2 for 24hrs. Histograms represent means and bars SEMs.
(**p< 0.01, compared with control, #p < 0.05, ##p<0.01 compared with H2O2.)
4.5 INTRACELLULAR GSH LEVELS FOLLOWING CYTOMIX AND H202.
The hypothesis to be tested in this thesis is that the intracellular redox status of the
cell, in particular GSH levels, may be important in iNOS induction. GSH levels of
both cells were therefore measured following the treatments described above. Figures
28 and 29 show the effect of cytomix at concentrations of 1 Ong/ml and 20ng/ml on
GSH levels in both cell types at 24 hours. In both cell types there is a significant
decrease (approximately 20%) in GSH levels following treatment with cytomix. In
the 16HBE cells there is also a significant difference between cells treated with the
two different concentrations of cytomix, although no difference was observed in
nitrite levels between these two concentrations in the 16HBE cells (see figure 13).
These results show that a decrease in GSH levels occurs concomitantly with NO
release under these conditions. This decrease may be due to either an increase in the
oxidant burden of the cell (such as that produced by the action of TNF-a on the








Figure 28: The effect of different concentrations of cytomix on intracellular GSH
levels in A549 cells. Histograms represent means and bars SEMs. (**p < 0.01,
***p< 0.001 compared with control)
##
40 T I
control cytomix lOng/ml cytomix20ng/ml
Treatment
Figure 29: The effect of different concentrations of cytomix on intracellular GSH
levels in 16HBE cells. Histograms represent means and bars SEMs. (**p < 0.01,
***p< 0.001 compared with control, ##p<0.01 compared with cytomix lOng/ml).
Figures 30 and 31 show the effect of the individual cytokines on GSH levels in both
cell types. TNF-a causes a significant decrease in GSH levels in both A549 and
16HBE cells, having also produced a significant increase in nitrite levels (see figures
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16 and 17). The other two cytokines (ILl-(3 and IFN-y) had no significant effect on
GSH levels in either cell type.
30 -
control cytomix TNF-a ILl-p IFN-y
Treatment
Figure 30: The effect of individual cytokines on intracellular GSH levels in A549














control cytomix TNF-a IL1 -(3 IFN-y
Treatment
Figure 31: The effect of individual cytokines on intracellular GSH levels in 16HBE
cells. Histograms represent means and bars SEMs. (*p < 0.05, compared to control).
Figures 32 and 33 show the effect of LPS on GSH levels in both cell types. LPS
caused a significant decrease in GSH levels in 16HBE cells only (having only caused
a significant increase in nitrite production in 16HBE cells (see figures 18 and 19)).
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control cytomix LPS LPS +
T . . cytomixTreatment J
Figure 32: The effect of cytomix and LPS on intracellular GSH levels in A549 cells
at 24hrs. Histograms represent means and bars SEMs. (**p< 0.01, *p< 0.05
compared with control)
control cytomix LPS LPS +
rr . . cytomixTreatment J
Figure 33: The effect of cytomix and LPS on intracellular GSH levels in 16HBE
cells at 24hrs. Histograms represent means and bars SEMs. (**p < 0.01, *p< 0.05
compared with control)
Figures 34 and 35 show the effect of H2O2 on GSH levels in both cell types. A
significant decrease in GSH was demonstrated in these cells concomitant with the
production ofNO . Again there is no additive effect of using cytomix and H2O2.
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control cytomix H202 cytomix +
h2o2
Treatment
Figure 34: The effect of cytomix and H2O2 on intracellular GSH levels in A549 cells
at 24hrs. Histograms represent means and bars SEMs. (**p< 0.01, *p< 0.05
compared with control)
control cytomix h2o2 cytomix +
h2o2
Treatment
Figure 35: The effect of cytomix and H2O2 on intracellular GSH levels in 16HBE
cells at 24hrs. Histograms represent means and bars SEMs. (**p< 0.01, *p< 0.05
compared with control).
Figures 36 and 37 show the effect of L-NMMA pre-treatment for 1 hour followed by
cytomix and H2O2 for 24 hours on GSH levels. In both cell types GSH levels are
decreased following pre-treatment with L-NMMA followed by either cytomix or
H2O2. This would suggest that the decrease in GSH following treatment with
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cytomix or H2O2 is not due to the formation of GSNO or peroxynitrite but due to an
increase in oxidant burden caused by the treatments themselves.
control cytomix H202 L-NMMA L-NMMA L-NMMA
+ cytomix + H20,
Treatment
Figure 36: The effect of cytomix, H2O2 and L-NMMA on intracellular GSH levels in
A549 cells at 24hrs. Cells were pre-treated with L-NMMA for 1 hour followed by
treatment with either cytomix or H2O2 for 24hrs. Histograms represent means and
bars SEMs. (*p< 0.05 compared with control)
35 T
control cytomix H2O2 L-NMMA L-NMMA 1-NMMA
Treatment + cytomix + H202
Figure 37: The effect of cytomix, H2O2 and L-NMMA on intracellular GSH levels in
16HBE cells at 24hrs. Cells were pre-treated with L-NMMA for 1 hour followed by
treatment with either cytomix or H2O2 for 24hrs. Histograms represent means and
bars SEMs. (*p< 0.05, **p<0.01 compared with control)
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4.6 PCR ANALYSIS OF iNOS
In order to verify that the formation of nitrite was due to the upregulation of iNOS in
these cells, iNOS mRNA levels were assessed using the technique of RT-PCR. The
housekeeping gene GAPDH was also assessed to allow semi-quantitative analysis of
iNOS mRNA expression in the cells. iNOS can be induced at 1- 16 hours (data not
shown) and the the ratio of iNOS to GAPDH determined. This ratio does not,
however, represent the levels ofNO produced following the same treatment since it is
representitive of only one time-point. RT-PCR is therefore only used to indicate
whether or not iNOS induction has occured. Both iNOS and GAPDH levels were
quantified using densitometry and levels of iNOS were determined by comparison to
levels of GAPDH. A 1 KB DNA ladder was used to determine the band sizes which
were 380 bp for iNOS and 600 bp for GAPDH. The first figure shows a positive
control for GAPDH to ensure the correct size band is being observed. However since
GAPDH is a housekeeping gene its only function in this assay is to determine that the
experiment has worked, and hence a positive control was not required for subsequent
experiments.
Figure 38 shows the effect of cytomix, H2O2 and LPS on iNOS and GAPDH mRNA
levels measured by RT-PCR in a) A549 cells and b) 16HBE cells at 4 hours. Both
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Figure 38: The effect of cytomix, H2O2 and LPS on iNOS and GAPDH mRNA
levels at 4 hours in a) A549 cells and b) 16HBE cells, -ve control, +ve control,
Lane 1: control cells, Lane 2: cytomix, Lane 3: H2O2, Lane 4: LPS.
Figure 39 shows the effect of treating both a) A549 and b) 16HBE cells with
cytomix, ILl-(3, TNF-a and IFN-y for 4 hours on iNOS and GAPDH mRNA levels.
In both cell types both cytomix and TNF-a increase iNOS mRNA levels, but IL1—P
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Figure 39: The effect of cytomix, IL1~P, TNF-a and IFN-y on iNOS and GAPDH
mRNA levels at 4 hours in a) A549 cells and b) 16HBE cells. -ve control, +ve
control, Lane 1: control cells, Lane 2: cytomix, Lane 3: IL1—[3, Lane 4: TNF-a,
Lane 5: IFN-y.
Figure 40 shows the ratio of iNOS to GAPDH following the above treatments.
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control cytomix H2O2 LPS cytomix IL1-J3 TNF-a IFN-y
Treatment
Figure 40: The ratio of iNOS mRNA to GAPDH in both A549 and 16HBE cells.
following cytomix, H2O2, LPS, cytomix, IL1—P, TNF-a and IFN-y treatment.
Differences in the ratios observed do not represent differences in levels of NO
produced (n=l).
4.7 SUMMARY
• Cytomix, TNF-a and H2O2 induce NO release, as measured by nitrite
production in the cell medium, in both A549 and 16HBE cells following 24 hour
treatments. IL1-|3 and IFN-y have no effect on nitrite production.
• LPS induces NO release in 16HBE cells but not in A549 cells following 24 hour
treatment.
• INOS induction can be observed between 1-16 hours (data not shown) and 4
hours was chosen as a time point to examine iNOS induction in both cell types.
• Cytomix, TNF-a and H2O2 induced iNOS in both A549 and 16HBE cells, LPS
also induced iNOS in 16HBE cells.
• L-NMMA decreased NO release in both A549 and 16HBE cells following
cytomix and H2O2 treatment.
• GSH levels are decreased in epithelial cells concomitant with increased NO*
release.
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• GSH levels are decreased in cells pre-treated with L-NMMA followed by
cytomix or H2O2 suggesting that the decrease in GSH is not due to NO
formation.
4.8 DISCUSSION
Nitric oxide can protect against cell damage and cytotoxicity caused by ROS by
inhibiting ROS release from inflammatory cells such as neutrophils, by reacting with
ROS to reduce their activity and by killing bacteria (Clancy et al., 1992; Granger and
Kubes, 1996; Rubbo et al., 1994). iNOS is continuously expressed in airway
epithelial cells in vivo, possibly to protect cells against general oxidant stress
incurred in the lungs such as cigarette smoke, ozone and pollutants. However cells
lose the ability to continually express iNOS upon culture (Nathan and Xie, 1994).
Different cells are able to induce NOS following different stimuli, such as human
hepatocytes which require LPS, IL1 —(3, TNF-a, and IFN-y (Geller et al., 1993;
Nussler et al., 1994), and human chrondocytes which only require ILl-p (Maier et
al., 1994). It has previously been reported (Robbins et al., 1994) that both A549 and
primary human bronchial epithelial cells stimulated with cytomix (TNF-a, IL1—P
and IFN-y) release significant amounts of NO at 24 hours, and express increased
amounts of iNOS mRNA also at 24 hours. My results show that both A549 and
16HBE cells are able to produce significant amounts of nitrite in the cell medium on
addition of cytomix for 24 hours. Both cell types also produce significant levels of
nitrite at 24 hours with the addition of TNF-a alone, and 16HBE cells produce
nitrite with the addition of LPS. However, IFN-y and IL1—p have no effect on nitrite
production in either cell type at 24 hours. It as also been reported (Adcock et al.,
1994) that A549 cells release significant levels ofNO at 24 hours and have increased
levels of iNOS mRNA at 2 hours on addition of the oxidant generator pyrogallol,
suggesting that oxidants can also induce NO'. My results showed that both A549 and
16HBE cells were able to produce significant levels of nitrite at 24 hours on addition
of a non-toxic dose of H2O2, which served as a general oxidant stress. The dose of
H2O2 was determined to be non-toxic in 2 ways. Cells were counted in the
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experiments using trypan blue, and trypan blue exclusion by more than 95% of the
cells indicates cells have maintained their integrity and the dose is non-toxic. The
second measurement was made by Dr. B. Mulier, who measured the amount of
lactate dehydrongenase (LDH) release from the cells into the medium. LDH release
indicates that the cell membrane is no longer intact due to cell death, and the dose of
H2O2 used herein did not cause cells to release LDH above control cell levels,
indicating that the dose is non-toxic. Both these tests showed that the dose of H2O2
was non-toxic.
However, the addition of cytomix and H2O2 had no additive effect on NO production
in either cell type, nor did the addition of cytomix and LPS in 16HBE cells. This may
be due to the assay since nitrite can readily become nitrate (which is not measured in
the assay) or due to negative feedback. NO has been shown to inhibit its own
synthesis in a number of ways. Matthews et al (Matthews et al., 1997) showed that
NO can inhibit NF-kB binding to DNA. NO donors were used and were shown to
inhibit binding by S-nitrosylation of redox sensitive cysteine residues on the p50
subunit, the necessary subunit for DNA binding. Peng et al (Peng et ah, 1995) also
showed by immunoprecipitation studies and NO donors that NO stabilised the
inhibitory subunit ofNF-kB, IkB a by preventing its degradation from NF-kB. NO
was also able to increase mRNA levels for IkBoc, and transfection experiments
suggested that NO can transcriptionaly induce IkB a. Evidence therefore suggests
that cellular NO can provide a control mechanism for modulating the expression of
NF-kB responsive genes, such as the induction of further iNOS, hence it provides a
negative feedback mechanism for itself.
The induction of iNOS has been previously shown to occur between 1 and 24 hours
in various cell types (Adcock et ah, 1994; Assreuy et ah, 1993; Chesrown et ah,
1994; Robbins et ah, 1994), and my own data shows that iNOS mRNA can be
observed clearly at 4 hours when measured by RT-PCR in both cell types. iNOS
mRNA was increased in both A549 and 16HBE cells following cytomix, H2O2 and
TNF-a. iNOS mRNA was also increased in 16HBE cells following LPS. Neither
IL1—p or IFN-y had any effect on iNOS induction in either cell type.
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The glutathione redox system is important in cell protection during oxidant stress,
preventing oxidant-induced damage such as cell leakage, and maintaining membrane
integrity (Pietarinen et ah, 1995). There are several reports indicating that both NO
and GSH may regulate each other. Phelps et al (Phelps et al., 1995) reported that the
induction of NO in bovine lung endothelial cells by TNF-a, resulted in decreased
GSH levels at 6 hours via a protein kinase C pathway, due to the formation of
ONOO" and that this also results in an altered GSH:GSSG ratio. Both L-NMMA and
SOD, which prevent NO synthesis or superoxide formation respectively, could block
these effects suggesting that either NO formation, oxidants or ONOO" are necessary
for the decrease in GSH. In contrast to Phelps et al (Phelps et al., 1995), White et al
(White et al., 1995) showed that NO donors increased GSH in RFL6 cells (rat lung
fibroblasts), possibly by the upregulation of GSH synthesis. Inhibition of cytokine-
induced NO (Kuo and Abe, 1996a) in rat hepatocytes also resulted in decreased
GSH levels, which were restored by NO donors. These reports suggest that NO
may be involved in the regulation of GSH synthesis and this is a possible
mechanism by which NO could protect against oxidant-induced injury. Furthermore,
reduced GSH has been shown to be critical for the induction of iNOS (Duval et al.,
1995). Inhibition of GSH de novo synthesis by buthionine sulfoximine (BSO) or
inhibition of the reduction of GSSG by Bis-2 chloroethyl nitosourea (BCNU)
abolishes or reduces NOS induction by TNF-a (Duval et al., 1995). The enzyme
iNOS has several co-factors, one ofwhich, is GSH (Steuhr et al., 1990), and GSH is
therefore considered necessary for enzyme activation. Inhibition of GSH synthesis or
reduction may therefore prevent NO production.
Since the hypothesis of this thesis is that intracellular GSH levels may be involved in
NO induction, I measured the levels of intracellular GSH following cytokine and
oxidant treatments. My results show that NO production at 24 hours is concomitant
with a decrease in intracellular GSH, suggesting that in this system NO does not up-
regulate GSH synthesis. It was possible, however, that the decrease in intracellular
GSH was due to NO production. In order to determine if NO induction caused a
decrease in GSH, the NO inhibitor L-NMMA was used followed by cytomix or
H2O2. L-NMMA prevented cytomix and H2O2 induced NO production but did not
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prevent the decrease in GSH observed with cytomix or H2O2 alone. This suggests
that the decrease in intracellular GSH is due, not to NO production, but due to the
cytomix and H2O2 themselves.
TNF-a causes an increase in both ROS and NO production, and iNOS induction by
TNF-a can be inhibited by the addition of the mitochondria complex I inhibitor
rotenone in human hepatocytes (Duval et al., 1995). Rotenone inhibits the reduction
of oxygen to water by inhibiting electron flow in the electron transport chain, and
thus preventing the release of superoxide anions from the mitochondria. The use of
rotenone in preventing TNF-a induced iNOS activation provides evidence that
TNF-a works via the mitochondria, releasing ROS and suggests that oxidants are
necessary for iNOS induction. Exposure of the cell to extracellular ROS, generated
by the xanthine/xanthine oxidase system, also increases NOS activity, further
supporting the hypothesis that ROS are involved in iNOS induction (Duval et al.,
1995). It has also been shown that IFN-y and TNF-a (Kuo et al., 1996b) act
synergistically in mouse hepatocytes, and that IFN-y increases both TNF-a induced
iNOS activation and the generation of ROS. IFN-y also potentates the TNF-a
induced effects on GSH, causing a depletion in GSH and a flux of GSSG out of the
cells. The synergistic effect is thought to be due to IFN-y increasing TNF-a
receptors. Thus it is likely that ROS are involved in the decrease in GSH within the
cell and it is possible that both ROS and GSH are involved in NO induction.
As mentioned previously decreasing GSH with BSO and BCNU (Duval et al., 1995)
reduces NOS induction but it has also been shown that antioxidants decrease iNOS
induction (Hecker et al., 1996a; Hecker et al., 1996b). These reports (Duval et al.,
1995; Hecker et al., 1996a; Hecker et al., 1996b), although appearing to show
opposite results suggest that GSH may be involved in NOS induction. ROS have
been shown to decrease GSH (Duval et al., 1995), which is oxidized to GSSG,
suggesting there may be a complex link between oxidants, antioxidants and GSH in
the induction of iNOS. It has also been shown in J774 cells, (a murine macrophage
cell line), (Hothersall et al., 1997) that the addition of LPS and IFN-y causes a 45%
decrease in GSH at 48 hours and a decrease in the GSH:GSSG ratio from 12:1 to 2:1,
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and that this change is not due to the efflux of GSH. This suggests that there is either
a decrease in the de novo synthesis of GSH or there is an increase in its utilisation
and that this change may be important in iNOS induction.
There is conflicting evidence, however, about the decrease in GSH following iNOS
induction. Some reports suggest that the decrease in GSH following iNOS induction
is dependent on the production of NO, since the decrease can be prevented by
addition of the inhibitor L-NMMA (Hothersall et ah, 1997). A decrease in
intracellular GSH with compounds such as BSO also decreases the output of NO
following activation suggesting GSH is involved in NO induction (Hothersall et ah,
1997). In contrast, Kuo et al, (Kuo et ah, 1996b) suggest that TNF-a and IFN-y
cause an increase in oxidant stress within the cells, resulting in altered GSH levels
and an efflux of GSSG, independent of whether NO is produced or not. In these
studies the TNF-a and IFN-y induced GSSG efflux was not dependant on the
stimulation ofNOS, as shown by the studies using the inhibitor L-NMMA, and also,
the GSSG efflux occurred in the first 4 hours, a time point at which significant levels
ofNOS activation were not observed (Kuo et ah, 1996b). This report is similar to my
own results, where a decrease in GSH is observed in both A549 and 16HBE cells
following cytomix or H2O2 stimulation but the addition of L-NMMA followed by
cytomix or H2O2 stimulation does not prevent the decrease in GSH. This suggests
that the decrease is due to an increased oxidant burden, causing an increase in the
oxidation of GSH to GSSG which is subsequently removed from the cells. It is also
possible that an increase in the GSSG to GSH ratio is important in the induction of
iNOS. NO itself did not cause a decrease in GSH in my system at 24 hours but it is
possible that at later time points, NO may cause further decreases in GSH. NO can
rapidly bind to thiol receptor molecules such as GSH, forming nitrosothiols which
are not detected in the Griess assay, and this is a possible cause for the NO -
dependant decrease in GSH observed in other systems. NO also rapidly reacts with
superoxide anions, such as those produced by the mitochondria, to form
peroxynitrite, which is a potent oxidant, causing a decrease in GSH and is thus
another possible mechanism for the decrease in GSH. However, since the decrease in
GSH occurs with cytomix and H2O2 stimulation, independently ofNO release, it can
103
be assumed that the decrease in GSH observed in my studies is not due to the
formation of GSNO or due to peroxynitrite formation, but is due to the oxidant burst
induced by TNF-a or oxidant stress induced by H2O2.
Thus there is conflicting evidence concerning the role ofNO in GSH regulation and
the importance of GSH in NO induction. My data support the hypothesis that GSH
may be important in NO induction but that the involvement of GSH may be indirect.
It is possible that superoxides are important in induction ofNO, and the presence of
GSH is important in maintaining an antioxidant state within the cell to prevent NO
induction. Or, it may be that the ratio of GSH:GSSG is important since GSH levels
are decreased in NO induced cells and a decrease in GSH could result from the
oxidation of GSH to GSSG. Manipulation of GSH levels and its effect on NO
induction are studied in more detail in chapter 5.
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Chapter 5 The Effect ofManipulating GSH Levels on NO Induction
and Release In Both A549 and 16HBE Cells.
5.1 INTRODUCTION
GSH is an important antioxidant in the lungs, it both reacts with ROS and acts as a
substrate for glutathione peroxidase (GPx) as part of the GSH redox enzyme system
(Cantin and Begin, 1991). The redox balance of the cell is considered to be important
in lung inflammation, since changes in the redox balance may be critical in
modulating molecular events in the cell. These include initiating a cascade of events
such as the activation ofNF-kB, which, in turn, regulates gene expression for many
inflammatory mediators including NO (Adcock et al., 1994). The addition of
antioxidants to lung cells can protect against oxidant damage by either scavenging
ROS or by increasing both intra and extra-cellular GSH levels (Mulier et ah, 1998).
The previous chapter reports that NO and iNOS can be induced by a variety of
stimuli in both A549 and 16HBE cells and that this induction is concomitant with a
decrease in GSH levels, independently of the formation of NO. This suggests that
GSH may be involved, either directly or indirectly via ROS, in the induction ofNO .
This chapter examines the effects of manipulating GSH levels before cells are
stimulated in order to determine the effect ofmodulating GSH levels on NO levels.
5.2 MANIPULATION OF GSH LEVELS.
GSH was manipulated by:
• Decreasing GSH using the irreversible inhibitor of y-glutamylcysteine synthase
(y -GCS), buthionine sulfoximine (BSO). y -GCS is the rate-limiting enzyme
involved in GSH synthesis.
• Increasing GSH levels using 4 different thiol compounds:
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♦ N-acetylcysteine (NAC)
♦ N-acetylcysteine lysinate (NAL)
♦ Glutathione (GSH)
♦ Glutathione monoethylester (GSHMEE)
These 4 compounds all increase intracellular GSH levels but in slightly different
ways.
NAC and NAL are both precursors of the amino acid cysteine and are thought to
work by either intracellular or extracellular deacetylation to release cysteine (Phelps
et ah, 1992). Cysteine, which can be a rate limiting amino acid in GSH synthesis, is
then used for denovo synthesis of GSH in the cell. GSH is thought to increase GSH
by either being degraded extracellularly by the membrane bound y-glutamyl
transpeptidase, and its respective amino acids taken up for denovo synthesis of GSH,
or by reducing extracellular cystine to cysteine, which is then taken into the cell for
denovo synthesis (Deneke et ah, 1995). GSHMEE, in contrast to GSH, effectively
crosses the membrane due to its electrophillic surface and is converted to
intracellular GSH by esterases, which remove the ester group (Anderson et ah,
1985).
5.3 THE EFFECT OF DEPLETING INTRACELLULAR GSH WITH BSO ON
NO PRODUCTION.
A concentration of 50pM BSO was chosen for these studies since previous studies
have used this concentration and it has been found to be effective in decreasing GSH
without causing toxicity (Beasley et al., 1985; Poot et al., 1995) and trypan blue
exclusion was used to ensure this level was not toxic in either the A549 or 16HBE
cells. Cells were treated at 70% confluency with 50pM BSO and BSO plus cytomix
in 2% medium for 24 hours. GSH levels are depleted in both A549 and 16HBE cells
by approximately 90% compared to control in both cells treated with BSO and BSO
with cytomix (Figures 41 and 42). Cytomix also causes depletion of GSH (as
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previously shown in Figures 28 and 29). However there was no significant difference
between cells treated with BSO alone and BSO plus cytomix. BSO also significantly
decreased GSH compared to cytomix alone.
###
Control Cytomix BSO BSO + cytomix
Treatment
Figure 41: The effect of BSO on intracellular GSH levels in A549 cells at 24hrs.
Histograms represent means and bars SEMs. (**p<0.01, ***p<0.001 compared to
control, ###p<0.001, compared to cytomix).
###
control cytomix BSO BSO + cytomix
Treatment
Figure 42: The effect of BSO on intracellular GSH levels in 16HBE cells at 24hrs
Histograms represent means and bars SEMs. (**p<0.01, ***p<0.001 compared to
control, ###p<0.001, compared to cytomix).
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Figures 43 and 44 show the effect of BSO on nitrite levels in both A549 and 16HBE
cells at 24 hours. BSO produced a significant increase in nitrite levels in both cell
types at 24 hours. Although cells treated with BSO plus cytomix have significantly
higher levels of nitrite compared to cytomix and BSO alone in A549 cells, there was
no significant difference between BSO plus cytomix and BSO or cytomix alone.
Thus there is no additive effect of co-treating cells with both BSO and cytomix.
0.6 t **
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control cytomix BSO BSO + cytomix
Treatment
Figure 43: The effect of BSO on nitrite production in A549 cells at 24 hours.
Histograms represent means and bars SEMs. (*p<0.05, **p<0.01, compared to
control).
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Figure 44: The effect of BSO on nitrite production in 16HBE cells at 24 hours.
Histograms represent means and bars SEMs. (*p<0.05, **p<0.01, compared to
control).
Since cells were co-treated with cytomix and BSO the effect of BSO + cytomix on
cells may not have been observed because cytomix may already have induced NO
before GSH levels were decreased. Cells were therefore pre-treated with BSO for 16
hours at which point GSH levels were reduced to approximately 90% compared to
control cells (figure 45).
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Figure 45: The effect of BSO on GSH levels in both A549 and 16HBE cells at 16
hours. Histograms represent means and bars SEMs. (***p<0.001 compared to the
relevant control).
Cells were then treated with cytomix for 24 hours to determine if decreased GSH
levels had any effect on NO induction. Figures 46 and 47 show the effects of pre-
treating cells for 16 hours with BSO followed by cytomix for 24 hours on nitrite
levels in both A549 and 16HBE cells. Decreasing GSH levels had no effect on
























Figure 46: The effect of pre-treating cells for 16 hours with BSO followed by
cytomix for 24 hours on nitrite levels in A549 cells. Histograms represent means and













Figure 47: The effect of pre-treating cells for 16 hours with BSO followed by
cytomix for 24 hours on nitrite levels in 16HBE cells. Histograms represent means
and bars SEMs. (***p<0.001 compared to control).
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5.4 THE EFFECT OF INCREASING GSH LEVELS WITH THIOL
COMPOUNDS ON NO RELEASE.
Since decreasing GSH levels resulted in increased NO release I hypothesised that
increasing GSH levels with antioxidants would prevent NO release i.e. antioxidants
may have a protective effect. Cells were treated with the four thiol compounds
already mentioned, NAC, NAL, GSH, and GSHMEE to determine if they could
protect prevent NO induction following cytomix or H2O2 treatment. Cells were
treated with NAC, NAL, GSH and GSHMEE all at 5mM in 2% medium and GSH
levels were measured over a period of 24 hours (Figures 47 and 48). An increase in
GSH was observed in both cells between 4 and 6 hours, with a highly significant









Figure 47: The effect of the 4 thiol compounds on intracellular GSH levels in A549






Figure 48: The effect of the 4 thiol compounds on intracellular GSH levels in 16HBE
cells over 24hrs. Points represent means, SEMs are omitted to addiclarity.
The significant values of increasing GSH levels at 4 hours in both cell types with the
4 thiol compounds are shown in figures 49 and 50.
control NAC NAL GSH GSHMEE
Treatment
Figure 49: The effect of the 4 thiol compounds, NAC, NAL, GSH and GSHMEE on
GSH levels at 4hrs in A549 cells. Histograms represent means bars SEMs (**p<0.01,
***p<0.001 compared to control).
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Figure 50: The effect of the 4 thiol compounds, NAC, NAL, GSH and GSHMEE on
GSH levels at 4hrs in 16HBE cells. Histograms represent means bars SEMs
(*p<0.05, **p<0.01, ***p<0.001 compared to control).
I have previously shown (section 4.1) that NO induction by cytomix, as measured by
nitrite production, does not occur until 24 hours, the effect of the 4 thiol compounds
on nitrite production was examined at 4 hours, the time at which GSH levels are
increased. The 4 thiol compounds had no effect on nitrite production at 4 hours when
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Figure 51: The effect of thiol compounds on nitrite production in A549 cells at 4hrs.
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Figure 52: The effect of thiol compounds on nitrite production in 16HBE cells at
4hrs. Histograms represent means and bars SEMs.
Nitrite levels were also measured at 24 hours in both cell types following thiol
treatment (Figures 53 and 54) which showed that the four thiol compounds had no
effect on nitrite production over 24 hours. GSH levels have returned to control values
at this point but increasing GSH levels at 4 hours did not itself have any effect on
NO release from cells compared to cytomix.
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Figure 53: The effect of thiol compounds on nitrite prodcution in A549 cells at 24hrs.
Histograms represent means and bars SEMs. (***p<0.001, compared to control,
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Figure 54: The effect of thiol compounds on nitrite production in 16HBE cells at
24hrs. Histograms represent means and bars SEMs. (***p<0.001, compared to
control, #p<0.05, ##p<0.01, compared to cytomix).
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5.5 THE EFFECT OF PRE-TREATING CELLS WITH THIOL
COMPOUNDS ON CYTOMIX AND H202 INDUCED NO RELEASE.
Cells were pre-treated with the four thiol compounds for 4 hours, washed in PBS
three times (to ensure the antioxidants did not affect the cytomix), and treated with
cytomix for 24 hours in order to determine if increased intracellular GSH levels
could inhibit cytomix induced NO release. Figures 55 and 56 show the effect of pre-
treating cells with thiol compounds in both A549 and 16HBE cells followed by
cytomix for 24 hours. Increased GSH levels did not prevent cytomix induced NO
release.
0.5 T
control cytomix NAC + NAL + GSH + GSHMEE +
cytomix cytomix cytomix cytomix
Treatment
Figure 55: The effect of pre-treating A549 cells with 4 thiol compounds for 4hrs
followed by cytomix for 24hrs. Histograms represent means and bars SEMs.
(*p<0.05, **p<0.01, ***p<0.001, compared to control).
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Figure 56: The effect of pre-treating A549 cells with 4 thiol compounds for 4 hrs
followed by cytomix for 24hrs. Histograms represent means and bars SEMs.
(*p<0.05, **p<0.01, ***p<0.001, compared to control).
Cells were then pre-treated with the four thiol compounds for 4 hours followed by
H2O2 for 24 hours to determine if increasing GSH levels could prevent oxidant
induced NO release. Cells were again washed 3 times in PBS to ensure the thiol
compounds did not scavenge the H2O2. Figures 57 and 58 show that increasing
intracellular GSH levels in both A549 and 16HBE cells significantly decreased H2O2
induced NO release by at least 50%.
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Figure 57: The effect of pre-treating A549 cells with thiol compounds for 4 hrs
followed by H2O2 for 24hrs. Histograms represent means and bars SEMs.
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Figure 58: The effect of pre-treating 16HBE cells with thiol compounds for 4 hrs
followed by H2O2 for 24hrs. Histograms represent means and bars SEMs.
(***p<0.001 compared to control, ###p<0.001, compared to H2O2).
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5.6 PCR RESULTS
Since BSO resulted in increased NO levels, iNOS and GAPDH mRNA levels were
measured in both A549 and 16HBE cells. iNOS mRNA was not observed at the 4
hour time-point used for all other measurements (data not shown), in A549 cells and
therefore a later time-point of 6 hours was used. Figure 60 shows the effects of BSO
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Figure 60: The effect of BSO on iNOS and GAPDH mRNA in both A549 at 6 hours
and 16HBE cells at 4 hours, -ve control, +ve control, Lane 1: control, Lane 2:
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Treatment
Figure 61: The effect of treating both A549 (6hrs) and 16HBE cells (4hrs) with BSO
at 6 hours. Differences in the ratios observed do not represent differences in levels of
NO produced (n=l).
iNOS and GAPDH mRNA were measured in both A549 and 16HBE cells pre-treated
with the 4 thiol compounds, which had no effect on iNOS induction themselves (data
not shown), followed by either cytomix or H2O2. Figure 62 and 63 show the effect of
pre-treatment in both the cells types on iNOS mRNA. The thiol compounds have no
effect on cytomix induced iNOS but reduce H2O2 induced iNOS in both cells types.
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Figure 62: The effect of pre-treating A549 cells with the 4 thiol compounds, NAC,
NAL, GSH and GSHMEE followed by cytomix and H2O2. -ve, +ve control, Lane 1:
control, Lane 2: cytomix, Lane 3: NAC + cytomix, Lane 4: NAL + cytomix, Lane
5: GSH + cytomix, Lane 6: GSHMEE + cytomix, Lane 7: H2O2, Lane 8: NAC +
H202, Lane 9: NAL + H202, Lane 10: GSH + H202, Lane 11 GSHMEE + H202.
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Figure 63: The effect of pre-treating 16HBE cells with the 4 thiol compounds, NAC,
NAL, GSH and GSHMEE followed by cytomix and H2O2. -ve, +ve control, Lane 1:
control, Lane 2: cytomix, Lane 3: NAC + cytomix, Lane 4: NAL + cytomix, Lane
5: GSH + cytomix, Lane 6: GSHMEE + cytomix, Lane 7: H2O2, Lane 8: NAC +
H202, Lane 9: NAL + H202, Lane, 10: GSH + H202, Lane 11 GSHMEE + H202.
1.4
control cytomix NAC + NAL + GSH + GSHMEE H2O2 NAC + NAL + GSH + GSHMEE
cytomix cytomix cytomix + cytomix H2O2 H2O2 H2O2 H202
Treatment
Figure 64: The effect of pre-treating both A549 and 16HBE cells with the 4 thiol
compounds followed by cytomix and H2O2. Differences in the ratios observed are
not meant to represent differences in levels ofNO produced (n=l).
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5.7 SUMMARY
• Treatment of both A549 and 16HBE cells with BSO resulted in decreased GSH
levels at 24 hours.
• This treatment also resulted in an increase in NO and iNOS mRNA in both A549
and 16HBE cells.
• Pre-treatment of both cell types with BSO followed by cytomix did not have any
additional effect on NO release.
• The four thiol compounds; NAC, NAL, GSH and GSHMEE increased GSH
levels significantly in both A549 and 16HBE cells at 4 hours.
• Pre-treatment of both cell types with the 4 thiol compounds followed by cytomix
had no effect on NO release or iNOS induction.
• Pre-treatment of both cell types with the 4 thiol compounds followed by H2O2
produced a significant decrease in both NO release and iNOS compared to H2O2
alone.
5.8 DISCUSSION
Reduced glutathione (GSH) is a key intracellular antioxidant, protecting cells against
oxidant-mediated injury, in particular against oxidants produced during
inflammation. There is increasing evidence that GSH is also involved in the
induction of iNOS, (Hothersall et al., 1997) which causes the release of NO from
cells during oxidative stress. Alternatively (Kuo and Abe, 1996a; Luperchio et al.,
1996), it has been suggested that NO is involved in the regulation of GSH synthesis,
upregulating GSH synthesis during times of oxidative stress. The data in chapter 4
shows that inducing iNOS and increasing NO release is concomitant with a decrease
in GSH, but this decrease is independent of NO release, since inhibitors of NO
production do not prevent the decrease in intracellular GSH. It is therefore unlikely
that NO has any effect on the intracellular levels of GSH in our experimental system
at 24 hours, the time point at which nitrite can be measured in the medium. Later
time-points may, however, show decreases in GSH levels that are dependent on NO
release, since NO' can readily bind to thiol containing compounds such as GSH.
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GSH may be involved in the induction of iNOS either directly, affecting activation of
the transcription factors necessary for iNOS induction, or indirectly, by removing
excessive ROS which may themselves affect the transcription factors for iNOS
induction. It has been shown that activation of cells with TNF-a causes an increase
in intracellular ROS, through its action on the mitochondria, (Duval et ah, 1995),
which release superoxide anions. Super oxide anions are, in turn, converted to H2O2
by SOD. The addition of H2O2 to the cells has a similar effect as TNF-a on the
activation of iNOS. If ROS are involved in the induction of iNOS, then GSH could
also be involved since it is a cofactor in the breakdown of H2O2 by GPx. This chapter
has focused on the manipulation of GSH levels in both the A549 and 16HBE cells in
order to determine the effect of GSH on iNOS induction, by both cytokines and
H202.
Intracellular GSH can be decreased in cells by a variety of compounds. In this study
buthionine sulfoximine (BSO) was used. BSO has been widely used to decrease
GSH, especially in A549 cells, where it has been used to examine the importance of
GSH in cell proliferation (see chapter 3)(Beasley et al., 1985; Ling et ah, 1990). BSO
has been used at various concentrations (50pM to lOmM) and the effects on
intracellular GSH levels have been reported at time points ranging from 24 hours to 8
days (Kang, 1993; Kang, 1994; Ling et al., 1990; Poot et al., 1995). BSO has been
shown to inhibit cell proliferation at lOmM (Kang, 1994). I therefore used a low
concentration of 50pM BSO, in order to prevent inhibition of cell proliferation. My
data shows that this concentration decreased intracellular GSH by approximately
90% of control levels after 16 hours, and that the decrease remained for at least 24
hours (GSH levels were not measured after 24 hours). My data also show that
treatment of cells with BSO for 24 hours increased NO release from the cells to
levels similar to cytomix. This does not agree with Hothersal et al (Hothersall et al.,
1997), who reported that decreasing GSH with a variety of inhibitors, including
BSO, also decreased NO output following activation with LPS and IFN-y . In this
report cells were pre-treated for 12 hours with BSO, at which point GSH levels were
30% of control cells, which resulted in a 40% decrease in NO production. Hothersal
et al (Hothersall et al., 1997) hypothesised that this may be due to the L-arginine
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transport system requiring thiols such as GSH for its function, since N-
ethylmaleimide (NEM), a GSH-depleting compound can also inhibit L-arginine
transport. In addition GSSG levels were thought to be important since GSSG can
inhibit phosphorylation of proteins necessary for iNOS induction (Hothersall et ah,
1997). I therefore studied the effect of pre-treating cells with BSO for 16 hours (at
which point GSH levels were decreased by approximately 90%), followed by
cytomix. In these experiments NO levels were still increased in BSO-treated cells.
Thus I did not observe an inhibition of NO release by decreasing GSH levels. BSO
is likely to induce NO in my experimental system by depleting GSH and so
preventing it reacting with and removing excess ROS. Organelles within the cell
such as the mitochondria release ROS in aerobic conditions, and these are normally
quenched by directly reacting with GSH. Reducing intracellular GSH levels may
therefore result in an increase in the level of ROS above normal, which may switch
on iNOS induction by an oxidant-mediated pathway.
Thus GSH appears to have a complex role in NO induction. GSH may be necessary
for induction of NO', and decreasing GSH levels causes inhibition of induction
(Hothersall et ah, 1997). Alternately it has been suggested that inhibition of NO ,
causes a decrease in GSH levels, and NO may possibly have a role in the synthesis
of GSH at a transcriptional level (Baeuerle et ah, 1996). My data suggest that GSH
may be involved in NO induction either directly or indirectly in response to certain
stimuli. NO is induced by cytokines, one of which, TNF-a, has been shown to cause
an increase in intracellular ROS (Duval et ah, 1995). H2O2, which produces oxidant
stress, and BSO, whcih decreases intracellular GSH, are also likely to result in
increased intracellular ROS. It is therefore likely that NO can be induced by an
oxidant stress and that GSH may influence that induction indirectly by reducing
ROS. The level of GSSG, in particular the ratio of GSSG:GSH, may also be
important, by inhibiting the phosphorylation of proteins necessary for the induction
of transcription factors involved in iNOS induction (Droge et ah, 1994). The
importance of the ratio ofGSSG:GSH is discussed in more detail in Chapter 6.
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In view of the potential deleterious affects of high amounts of NO production by
iNOS during inflammation (Anggard, 1994), the prevention of iNOS expression
could be important therapeutically. Since evidence suggests that GSH is involved in
iNOS induction I examined the effect of increasing intracellular GSH levels in the
A549 and 16HBE lung epithelial cells.
Intracellular GSH was increased using the thiol compounds NAC, NAL, GSH, and
GSHMEE, all of which are thiol containing compounds with antioxidant properties.
Antioxidants are of interest in the treatment of diseases, particularly chronic
inflammatory respiratory disease due to their ability to react with ROS. Both NAC
and NAL have been shown to be potent scavengers of superoxide anions, H2O2,
hydroxyl radicals and hypochlorous acid, (Arouma et al., 1989; Vanderbist et al.,
1996), being equivalent in their scavenging abilities to GSH (Gillissen et al., 1997).
GSHMEE is taken up by cells and its ester group is cleaved, on entering the cell, to
release GSH. Increases in GSH levels produced by thiol compounds have previously
been reported using such compounds and these increases have occurred at between 2
and 6 hours for NAC (Phelps et al., 1992), 3 hours for GSH (Chen et al., 1992), and
2-3 hours for GSHMEE (Anderson et al., 1985). My results show that all 4 thiol
compounds significantly increased intracellular GSH levels at 4 hours to
concentrations similar to these previously reported. A variety of antioxidants have
previously been used (Hecker et al., 1996b) to inhibit cytokine induction of iNOS in
vascular smooth muscle cells. However, although the antioxidants were capable of
inhibiting superoxide anion production (by PMA), suggesting they were effective
antioxidants, they did not necessarily inhibit IL-1|3 induction of iNOS. This suggests
that not all antioxidants are able to inhibit iNOS induction and that different
antioxidants may act on different parts of the pathway involved in iNOS induction.
In addition, simulation of RAW 264.7 macrophages with LPS and IFN-y has a
synergistic effect on iNOS induction, and this effect can be inhibited by antioxidants
that prevent activation of transcription factors (Hecker et al., 1996a). Thus it is likely
that iNOS induction by certain cytokines contains a redox-sensitive step which can
be inhibited by antioxidants. Production of oxidants is not always necessary for the
induction of iNOS, since PMA (which induces superoxide anion production) had no
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effect on NO levels (Hecker et al., 1996a), suggesting that although there may be a
redox sensitive step in the induction of iNOS, this may not be sufficient for NO
release.
Cells were therefore pre-treated with the thiol compounds, followed by cytomix or
H2O2 to determine if increased GSH levels could inhibit iNOS induction. Cells pre-
treated with 4 thiol compounds for 4 hours followed by cytomix for 24 hours
released NO at levels similar to those observed with cytomix alone. This suggests
that either cytomix does not induce NO by an oxidant mediated pathway or that
GSH, at the levels produced by these thiol compounds does not diminish ROS
activity sufficiently to interfere with ROS mediated NO release. Pre-treating the
cells with the 4 thiol compounds followed by H2O2 did, however, decrease NO
release compared to those observed with H2O2 alone. This suggests that NO can be
induced by an oxidant mediated pathway, and that this pathway can be inhibited by
antioxidants which increase intracellular GSH levels. It is possible from these results
that NO can be induced in 2 ways, one by a direct effect of oxidants and one by an
effect of cytokines which may bypass the oxidant step. Although TNF-a induces
ROS release from the mitochondria, it may also act on another pathway
synergistically with the other cytokines.
There are very few reports on the effect of GSH, or other antioxidants, and oxidants
on NO induction that do not focus on NF-kB activation. The effect of antioxidants
on NF-kB activation and hence NO induction are discussed in more detail in
Chapter 6. The ratio of GSSG:GSH is also determined, in order to verify if it is
important in iNOS induction.
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Chapter 6 The effect of cytokines, H202 and modulating GSH levels
on NF-kB activation.
6.1 INTRODUCTION
The transcription factor NF-kB is present in the cytosol of cells in an inactivated
form, due to its association with the inhibitory subunit IkB. Activation of NF-kB
requires the phosphorylation and ubiquitination of IkB, which then dissociates from
NF-kB and is degraded. NF-kB can then move to the cytosol, where it binds to
DNA switching on gene transcription for a large number of molecules including
iNOS and pro-inflammatory cytokines (Baeuerle and Baichwal, 1997; Baldwin,
1996; Rahman and MacNee, 1998) (see Figure 7 of introduction). NO synthesis
has been shown to require NF-kB activation for induction of iNOS (Ignarro and
Murad, 1995; Wong et al., 1996; Droge et al., 1994), and although other transcription
factors such as IRF-1 are thought to be required for optimal induction (Ignarro and
Murad, 1995; Salkowski et al., 1996), NF-kB is a key player in the induction of
iNOS (Amoah-Apraku et al., 1995; Flodstrom et al., 1996). I therefore examined the
effect of cytokines and H202 on NF-kB activation in the cell. Increased ROS are
thought to be involved in the activation of NF-kB, since NF-kB activation can be
inhibited by antioxidants (Flohe et al., 1997; Sen and Packer, 1996). GSH may be
involved in NF-kB activation and in particular the ratio of GSSG:GSH may be
critical (Droge et al., 1994; Gaiter et al., 1997). I therefore examined the effect of
antioxidants which increase intracellular GSH on NF-kB activation by oxidants
(H202) and cytokines. The effect of a mitochondrial inhibitor, rotenone was also
examined, to determine if blocking mitochondrial release of superoxide anions had
any effect on oxidant and cytokine induced NF-kB activation.
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6.2 A TYPICAL GEL SHIFT
All the results ofNF-kB activation are captured images of original autoradiographs,
allowing density of the bands to be determined by densitometry. Densitometry
provides an idea of the level of activation above control levels, but huge variations
occurred from gel to gel, and hence standard errors are often large and statistical
analysis is therefore not carried out. In some figures below, bands have been cut out
of the gel in order to be placed next to appropriate bands for that figure. In all cases,
the bands are from the same gel, but gels contain up to 15 samples, many of which
are irrelevant to that particular figure. Although differences may appear in some
figures, this is due to the film background, which is not always uniform. Some
autoradiographs were computer enhanced due to backgrounds being dark and images
being unclear. Enhancement, however, only involved changing of background
brightness and contrast in order to make the images clearer and was carried out on
the whole autoradiograph before gels were cut. Figure 65 shows an example of a
'typical' gel shift autoradiograph.
Figure 65: An example of a typical gel shift. A corresponds to the wells into which
the samples are loaded, B corresponds to NF-kB double shift bands, C corresponds
to a non-specific band (see later), D corresponds to excess unbound radiolabeled
NF-kB oligonuclotide.
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Since several bands were present on the gel shift, several methods were used to try
and distinguish which bands were NF-kB. Firstly rabbit polyclonal antibodies
directed to the nuclear location sequence on the p50 and p65 subunits of NF-kB
were used. The antibody was added to samples treated with cytomix before the
addition of the labeled oligonuclotide. The antibody binds to the relevant sub-unit,
and due to the net increase in the overall molecular weight, 'super-shifts' to a
different part of the gel are observed. Figure 66 shows the effect of addition of either
the p50 or p65 antibody to A549 cells treated with cytomix. The intensity of the
band that is increased in cytomix-treated cells is decreased in both p65 and p50
antibody treated reactions, more so in the p65 antibody treated reactions, and the
band appears to have 'supershifted'. This suggests that the band thought to be
NF-kB contains both the p65 and p50 subunits ofNF-kB. Two bands are present in
this gel, the p65 seems to decrease the top band, and the p50 the bottom band,
suggesting that the protein may degrade slightly to give two bands. There are also
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Figure 66: the effect of using antibodies against the p50 and p65 subunits ofNF-kB
in cytomix treated A549 cells, -ve control; Lane 1: control; Lane 2: cytomix; Lane
3: cytomix with the p65 antibody; Lane 4: cytomix with the p50 antibody.
In order to clarify that these two bands (which often appear as one large band)
represented the activated NF-kB, recombinant IkBcx was used. IkBoc will bind to the
p65 subunit of NF-kB, and therefore inhibit binding of NF-kB to the
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oligonucleotide by masking the DNA binding sequence. Excess IkBcc was added to
the samples prior to addition of the radiolabeled oligonucleotide. Figure 67 shows the
effect of the addition of the IkBoc protein to both control and cytomix-treated A549
cell samples. The intensity of the band induced by cytomix is reduced to that of
control cells without the protein. Control cells with the IkBoc protein show no
difference to control cells without. This suggests that the increase in the intensity of
the band observed with cytomix contains a p65 subunit, and could be either a
p65/p50 NF-kB or a p65/p65 homodimer. The band remaining could be a p50
subunit, or a p50/p50 homodimer, since hcBa does not bind to the p50 subunit.
0 §p : i|p <—NF-kB
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Figure 67: The effect of adding excess, unlabeled IkBoc recombinant protein to
samples prior to addition of labeled NF-kB oligonuclotide. Lane 1: control; Lane 2:
cytomix; Lane 3: control with h<Ba; Lane 4: cytomix with IkBcc, -ve control.
The bottom band that appears in the gels is not altered in any of the gels following
addition of the antibodies or recombinant IkBoc protein, suggesting that it is not a
NF-kB protein, or is a product of denaturation. In a cold displacement assay (which
involves incubation with excess unlabelled oligonuclotide) this band has been shown
to be a product of non-specific binding (Mark Lawson, Rayne Laboratory).
Densitometry was therefore measured on the top 2 bands, which are often
indistinguishable from one another.
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6.3 THE EFFECT OF CYTOMIX, INDIVIDUAL CYTOKINES AND LPS ON
NF-kB ACTIVATION.
Both cells lines were treated for 30 minutes with cytomix, TNF-a, IL1—P and IFN-y
(all at lOng/ml). Figures 68 and 69 show the effect of treating both A549 and 16HBE
cells with cytomix and individual cytokines. Cytomix, TNF-a and ILl-(3 all
increased NF-kB activation above control levels in both A549 and 16HBE cells.
IFN-y did not have any obvious effect on NF-kB activation by itself. Figure 70
shows the relative densitometry ofNF-kB activation in cytokine treated cells.
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Figure 68 : The effect of cytomix and individual cytokines on NF-kB activation in
A549 cells. Lane 1: control; Lane 2: cytomix; Lane 3: TNF-a lOng/ml; Lane 4:
IL1—p lOng/ml; Lane 5: IFN-y lOng/ml.
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Figure 69: The effect of cytomix and individual cytokines on NF-kB activation in
16HBE cells. Lane 1: control; Lane 2: cytomix; Lane 3: TNF-a lOng/ml; Lane 4:
IL1—P lOng/ml; Lane 5: IFN-y lOng/ml.
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Figure 70: The effect of treating A549 and 16HBE cells with cytomix and the
individual cytokines on NF-kB activation as measured by densitometry.
Both cell lines were also treated with LPS at 1 |ig/ml for 30 minutes. Figure 71 shows
the effect of LPS on NF-kB activation in both A549 and 16HBE cells. LPS had no
effect on NF-kB activation in A549 cells but increased NF-kB activation in 16HBE
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Figure 71: The effect of LPS on NF-kB activation in both A549 and 16HBE cells at
30 minutes. Lane 1: control A549 cells; Lane 2: LPS A549 cells, Lane 3: control
16HBE cells; Lane 4: LPS 16HBE cells.
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Figure 72: The effect of treating A549 and 16HBE cells with LPS on NF-kB
activation as measured by densitometry.
Both A549 and 16HBE cell lines were treated with lp.M H2O2 (the concentration
used to increase nitrite production significantly in both cell types) to investigate the
effect of oxidants on NF-kB activation. A 2 hour time point was chosen since in our
laboratory it has previously been shown that this time-point is the earliest time point
at which there is an increase in NF-kB activation following this concentration of
H2O2. Figure 73 shows the relative densitometry ofNF-kB activation by H2O2 at 30
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Figure 73: The effect of treating A549 and 16HBE cells with H2O2 on NF-kB
activation at 30 minutes and 2 hours, as measured by densitometry (n=4).
Both A549 and 16HBE cells were thus treated with H2O2 for 2 hours to determine
the effect on NF-kB activation (figure 74). NF-kB nuclear binding is increased in
both A549 and 16FIBE cells by H2O2 at 2 hours. Figure 75 shows the relative




Figure 74: The effect of H2O2 on NF-kB activation in both A549 and 16HBE cells at
2 hours. Lane 1: control A549 cells; Lane 2: H2O2 A549 cells; Lane 3; control
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Figure 75: The effect of treating A549 and 16FIBE cells with H2O2 on NF-kB
activation as measured by densitometry.
6.4 THE EFFECT OF MODULATING INTRACELLULAR GSH LEVELS BY
BSO AND THIOL COMPOUNDS ON NF-kB ACTIVATION.
Since the compound BSO resulted in both an increase in nitrite production and an
induction of iNOS mRNA, I examined the effects of BSO on NF-kB activation in
both A549 and 16HBE cells. NF-kB activation was investigated at different time
points, from 30 minutes to 4 hours. Figures 76 and 77 show the effect of BSO at
different time points on NF-kB activation in both A549 and 16HBE cells. BSO
activates NF-kB in A549 cells at 4 hours in 16HBE cells at 2 and 4 hours. Figure 78
shows the relative densitometry ofNF-kB activation in BSO treated cells.
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Figure 76 : The effect of BSO on NF-kB activation in A549 cells. Lane 1: control;
Lane 2: BSO 30 minutes; Lane 3: BSO 1 hour; Lane 4; BSO 4 hours; Lane 5:
control; Lane 6: BSO 2 hours; Lane 7: BSO 4 hours.
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Figure 77: The effect of BSO on NF-kB activation in 16HBE cells. Lane 1: control;
Lane 2: BSO 30 minutes; Lane 3: control; Lane 4: BSO 1 hours; Lane 5: control;
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Figure 78: the effect of treating A549 and 16HBE cells with BSO at various time
points on NF-kB activation as measured by densitometry.
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The 4 thiol compounds used previously to increase intracellular GSH levels were
also used in order to study the effect of increasing GSH on cytokine and H2O2
induced NF-kB activation. Figures 79 and 80 show the effect of treating both cell
lines with NAC, NAL, GSH and GSHMEE, on NF-kB activation at the 4 hour time
point, the time at which intracellular GSH levels are increased. The 4 thiol
compounds have no effect on NF-kB activation alone. Figure 81 shows the relative
densitometry ofNF-kB treated with the 4 thiol compounds.
Figure 79: The effect of the 4 thiol compounds, NAC, NAL, GSH, and GSHMEE on
NF-kB activation in A549 cells. Lane 1: control; Lane 2: NAC; Lane 3: NAL;
Lane 4: GSH; Lane 5: GSHMEE.
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Figure 80: The effect of the 4 thiol compounds, NAC, NAL, GSH, and GSHMEE on
NF-kB activation in 16HBE cells. Lane 1: control; Lane 2: NAC; Lane 3: NAL;
Lane 4: GSH; Lane 5: GSHMEE.
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Figure 81: The effect of treating A549 and 16HBE cells with the 4 thiol compounds
on NF-kB activation as measured by densitometry.
The cells were then pre-treated with the 4 thiol compounds for 4 hours followed by
cytomix or TNF-a for 30 minutes or by H2O2 for 2 hours to determine the effect of
increased GSH levels on cytokine and oxidant induced NF-kB activation. Figures 82
and 83 show the effect of pre-treating cells with thiol compounds for 4 hours
followed by cytomix for 30 minutes on NF-kB activation in both A549 and 16HBE
cells. Cytomix increases NF-kB activation at 30 minutes. There is no difference
between cytomix alone and cells pre-treated with thiol compounds followed by
cytomix, indicating that the increase in GSH levels produced by these compounds do
not prevent cytomix induced NF-kB activation. Figure 84 shows the relative
densitometry of NF-kB activation in cells pre-treated with thiol compounds
followed by cytomix.
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Figure 82: The effect or pre-treating A549 cells for 4 hours with the 4 thiol
compounds followed by cytomix for 30 minutes on NF-kB activation. Lane 1:
control; Lane 2: cytomix; Lane 3: NAC + cytomix; Lane 4: NAL + cytomix; Lane
5: GSH + cytomix; Lane 6: GSHMEE + cytomix.
1 2 3 4 5 6
Figure 83: The effect of pre-treating 16E1BE cells with the 4 thiol compounds
followed by cytomix for 30 minutes on NF-kB activation. Lane 1: control; Lane 2:
cytomix; Lane 3: NAC + cytomix ; Lane 4: NAL + cytomix ; Lane 5: GSH +
cytomix ; Lane 6: GSHMEE + cytomix .
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Figure 84: The effect of treating A549 and 16HBE cells with the 4 thiol compounds
followed by cytomix on NF-kB activation as measured by densitometry .
Cells were then pre-treated with the 4 thiol compounds followed by H2O2. Figures 85
and 86 show the effect of pre-treating cells with 4 thiol compounds for 4 hours
followed by H2O2 for 2 hours on NF-kB activation in both A549 and 16HBE cells.
In both cell types, H2O2 induced NF-kB activation was decreased following pre-
treatment with the thiol compounds. Figure 87 shows the relative densitometry of
NF-kB activation in cells pre-treated with thiol compounds followed by H202.
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Figure 85: The effect or pre-treating A549 cells for 4 hours with the 4 thiol
compounds followed by H202 for 2 hours on NF-kB activation. Lane 1: control;
Lane 2: H202; Lane 3: NAC + H202; Lane 4: NAL + H202; Lane 5: GSH + H202;
Lane 6: GSHMEE + H202.
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Figure 86: The effect or pre-treating 16HBE cells for 4 hours with the 4 thiol
compounds followed by H2O2 for 2 hours on NF-kB activation. Lane 1: control;
Lane 2: H2O2; Lane 3: NAC + H2O2; Lane 4: NAL + H2O2; Lane 5: GSH + H2O2;










Figure 87: The effect of treating A549 and 16HBE cells with the 4 thiol compounds
followed by H2O2 on NF-kB activation as measured by densitometry .
Since increased GSH levels did not decrease cytokine induced NF-kB activation I
investigated the effect of pre-treating cells with the 4 thiol compounds followed by
TNF-a. TNF-a has been shown to induce NF-kB activation by increasing
intracellular ROS levels due to its action on the mitochondria. Figures 88 and 89
show the effect of pre-treating cells with the 4 thiol compounds followed by TNF-a
alone at lOng/ml for 30 minutes on NF-kB activation in both A549 and 16HBE














cells pre-treated with NAL and GSH, and in 16HBE cell pre-treated with NAL.
Other pre-treatments, however, did not decrease NF-kB activation induced by
TNF-a in either cell type. Figure 90 shows the relative densitometry of NF-kB
activation in cell pre-treated with thiol compounds followed by TNF-a.
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Figure 88: The effect of pre-treating A549 cells with the 4 thiol compounds followed
by TNF-a for 30 minutes on NF-kB activation. Lane 1: control; Lane 2: TNF-a;
Lane 3: NAC + TNF-a; Lane 4: NAL + TNF-a ; Lane 5: GSH + TNF-a; Lane 6:
GSHMEE + TNF-a.
1 2 3 4 5 6
Figure 89: The effect of pre-treating 16HBE cells with the 4 thiol compounds
followed by TNF-a for 30 minutes on NF-kB activation. Lane 1: control; Lane 2:
TNF-a; Lane 3: NAC + TNF-a; Lane 4: NAL + TNF-a; Lane 5: GSH + TNF-a;




















Figure 90: The effect of treating A549 and 16HBE cells with the 4 thiol compounds
followed by TNF-a on NF-kB activation as measured by densitometry .
6.5 THE EFFECT OF ROTENONE ON CYTOKINE AND H202 INDUCED
NF-kB ACTIVATION.
Rotenone is a mitochondrial inhibitor, inhibiting complex I of the electron transport
system, and thus inhibits the flow of electrons that reduce oxygen to water. Rotenone
can therefore inhibit the production of superoxide anions, since oxygen is not
partially reduced, and hence inhibits H202 production, which is produced by
superoxide anions and SOD. IfNF-kB activation is due to superoxide anion release
from the mitochondria, then rotenone will inhibit this NF-kB activation. Rotenone
was dissolved in chloroform and the cells were pre-treated for 30 minutes followed
by either cytomix or TNF-a for 30 minutes or H202 for 2 hours. The expression of
iNOS mRNA was also assessed when the cells were pre-treated for 30 minutes with
rotenone followed by cytomix TNF-a or H202 for 4 hours.
Figure 91 shows the effect on NF-kB activation of pre-treating both A549 and
16HBE cells with rotenone followed by cytomix. Rotenone had no effect on cytomix
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induced NF-kB activation in either cell type. Figure 92 shows the relative
densitometry of NF-kB activation in cells pre-treated with rotenone followed by
cytomix.
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Figure 91: The effect of pre-treating both A549 and 16HBE cells with rotenone
followed by cytomix for 30 minutes. Lane 1: control A549 cells; Lane 2: cytomix
A549 cells; Lane 3: rotenone A549 cells; Lane 4: rotenone + cytomix A549 cells;
Lane 5: control 16F1BE cells; Lane 6: cytomix 16HBE cells; Lane 7: rotenone













Figure 92: The effect of pre-treating both A549 and 16HBE cells with rotenone
followed by cytomix for 30 minutes on NF-kB activation as measured by
densitometry.
147
Figure 93 shows the effect of pre-treating both A549 and 16FIBE cells with rotenone
followed by H2O2. Rotenone had no effect on H2O2 activation of NF-kB in either
cell type. Figure 94 shows the relative densitometry of NF-kB activation in cells
pre-treated with rotenone followed by FI2O2.
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Figure 93: The effect of pre-treating both A549 and 16HBE cells with rotenone
followed by H2O2 for 2 hours. Lane 1: control A549 cells; Lane 2: H2O2 A549 cells;
Lane 3: rotenone A549 cells; Lane 4: rotenone + H2O2 A549 cells; Lane 5: control
16FIBE cells; Lane 6: H2O2 16HBE cells; Lane 7: rotenone 16E1BE cells; Lane 8:








Figure 94: The effect of pre-treating both A549 and 16HBE cells with rotenone
followed by H2O2 for 2 hours on NF-kB activation as measured by densitometry .
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Figure 95 shows the effect of pre-treating both A549 and 16HBE cells with rotenone
followed by TNF-a for 30 minutes on NF-kB activation. Rotenone reduces TNF-a
induced NF-kB activation in both cell types. Figure 96 shows the relative
densitometry of NF-kB activation in cells pre-treated with rotenone followed by
Figure 95: The effect of pre-treating both A549 and 16HBE cells with rotenone
followed by TNF-a for 30 minutes. Lane 1: control A549 cells; Lane 2: TNF-a
A549 cells; Lane 3: rotenone A549 cells; Lane 4: rotenone + TNF-a A549 cells;
Lane 5: control 16HBE cells; Lane 6: TNF-a 16FIBE cells; Lane 7: rotenone
16HBE cells; Lane 8: rotenone + TNF-a 16HBE cells.
TNF-a.









Figure 96: The effect of pre-treating both A549 and 16HBE cells with rotenone
followed by TNF-a for 30 minutes on NF-kB activation as measured by
densitometry .
The above densitrometry graphs are representative of the gel shown. Tables 2-5
show the densitometries of the above experiments for 3 separate experiments. Since
the measurement is only semi-quantitative and values can vary hugely between
different gels, statistical analysis is not carried out. Flowever, the trend for each
experiment is the same and the mean and SEM was measured for each experiment.
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Table 2 The effect of cytokines, LPS and H2O2 on NF-kB activation in both A549
and 16HBE cells.
Treatment (30 minutes) A549 cells 16HBE cells
Control 100 100
Cytomix 282,312, 291 177, 161, 351
Average ± SEM 295 ±9 230 ±60
TNF-a 381,219, 261 198, 165,200
Average ± SEM 287 ±48 187 ± 11
IL1-P 241,315,257 141, 163, 135
Average ± SEM 271 ±22 146 ±9
IFN-y 74, 110, 135 126,61, 112
Average ± SEM 106 ±18 99 ±20
LPS 94, 103,91 153,140, 124
Average ± SEM 96 ±4 139 ±8
EI2O2 (30 minutes) 115, 74, 131, 77, 135, 113
Average ± SEM 106 ± 17 108 ±16
H2O2 ( 2 hours) 214, 256, 150 142, 146, 158
Average ± SEM 206 ±31 149 ±5
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Table 3 The effect of BSO on NF-kB activation in both A549 and 16HBE cells at
different time points.


























Table 4 The effect of the 4 thiol compounds on cytomix, TNF-a and H2O2 induced
NF-kB activation in both A549 and 16E1BE cells







































Treatment A549 cells 16HBE cells
NAL + cytomix 192,122, 424 198,218, 2370
Average ± SEM 246 ± 72 928 ± 720
GSH + cytomix 184, 272, 282 174, 204, 984
Average ± SEM 279 + 31 424 ± 265
GSHMEE + cytomix 182,343,4 + 7435 152, 149, 2000
Average ± SEM 320 ± 74 767 + 616
H202 204, 166,214 190, 384, 158
Average ± SEM 194+14 244 ± 70
NAC + H202 120, 101, 66 85, 139, 77
Average ± SEM 96 ± 15 133 + 27
NAL + H202 51, 104, 97 126, 159, 97
Average ± SEM 84+16 127+17
GSH + H202 31,77, 46 78, 127, 116
Average ± SEM 52+13 107+14
GSHMEE + H202 54,142, 49 75, 136, 118
Average ± SEM 82 ±30 109+18
TNF-a 381, 140, 144 198. 167, 1504
Average ± SEM 221+80 623 ± 440
NAC + TNF-a 419, 134, 137 208, 148, 1900
Average ± SEM 230 ± 94 725 ± 574
NAL + TNF-a 296, 122, 133 153, 127, 1038
Average ± SEM 183 + 56 439 ± 299
GSH + TNF-a 276, 125, 125 197, 153, 813
Average ± SEM 175 + 50 387 + 213
GSHMEE + TNF-a 376, 136, 124 211, 149, 1305
Average ± SEM 212 + 82 555 + 375
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Table 5 The effect of rotenone on cytomix, TNF-a and H2O2 induced NF-kB
activation in both A549 and 16HBE cells.
T reatment A549 cells 16HBE cells
Control 100 100
Cytomix 164, 129, 126 351,385,481
Average ± SEM 139 ± 12 405 ± 39
TNF-a 261, 153,470 203, 198, 165
Average ± SEM 295 ± 93 188112
H202 150, 166, 166 158, 384, 146
Average ± SEM 160 ±5 230 ± 77
Rotenone 91, 87, 130 128,68, 101
Average ± SEM 102 ± 14 991 17
Rotenone + cytomix 187, 124, 125 431, 801, 875
Average ± SEM 144 + 23 7021 137
Rotenone + TNF-a 65, 58, 100 42, 149, 89
Average 74 ± 13 93 131
Rotenone + H2O2 154, 132, 197 123,446, 149
Average ± SEM 161 ± 19 2391 103
6.6 THE EFFECT OF ROTENONE ON iNOS mRNA LEVELS.
Both A549 and 16FIBE cells were pre-treated with rotenone for 30 minutes, followed
by cytomix, TNF-a and H2O2 for 4 hours and iNOS mRNA levels measured.
Unfortunately cell death was quite high in the 16HBE cells, (many cells were
floating in the medium) possibly due to the effect of rotenone and chloroform for 4
1/2 hours, and therefore no results were obtained for rotenone and iNOS in 16HBE
cells. The effects of rotenone on iNOS induction was measured, however, in A549
cells and figure 97 shows the effect of pre-treating cells with rotenone followed by
cytomix, TNF-a and H2O2 for 4 hours. Cytomix, TNF-a, and H2O2 all induce iNOS
mRNA, rotenone by itself has no effect; rotenone with cytomix and H2O2 has no
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effect on cytomix and H2O2 induced iNOS; but rotenone and TNF-a prevents
TNF-a induced iNOS supporting the evidence observed with NF-kB activation.
Figure 98 shows the ratio of iNOS to GAPDFI.
iNOS
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GAPDH
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Figure 97: The effect of pre-treating A549 cells with rotenone followed by cytomix,
TNF-a and H2O2 on iNOS and GAPDH mRNA levels.-ve control; +ve control;
Lane 1: control; Lane 2: cytomix; Lane 3: TNF-a; Lane 4: H2O2; Lane 5:
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Figure 98: The ratio of iNOS to GAPDH in A549 cells pre-treated with rotenone
followed by cytomix, TNF-a and H2O2. (n=l).
6.7 INTRACELLULAR GSSG:GSH RATIO IN BOTH A549 AND 16HBE
CELLS AT TIME POINTS WHEN NF-kB IS ACTIVATED.
It is possible that the levels of intracellular GSH are important in the induction of
iNOS, in particular the ratio of GSSG:GSH, since GSSG has been shown to both
activate NF-kB and inhibit its binding to DNA (Droge et al., 1994a; Hodge-Jahngen
et al., 1997). I have also shown that decreased GSH levels are concomitant with
iNOS induction. I therefore measured the ratio of GSSG to GSH in both A549 and
16HBE cells at 30 minutes, 1 hour, 2 hours, and 4 hours. As mentioned in Materials
and Methods, the pH of the samples is important in the assay and adjustment of pH
was not possible due to the small volumes of the samples (lOOpl). Data shown below
is expressed as the mean of 3 separate experiments but standard errors are absent due
to variations within the assay. However a similar trend is shown in each separate
experiment. Due to variations I was also unable to measure statistical significance.
Figures 99 and 100 show the effect of treating A549 and 16HBE cells with cytomix,
H2O2 and BSO for 30 minutes, 1 hour, 2 hours and 4 hours. In both A549 and
16HBE cells cytomix increases the GSSG:GSH ratio at 1 hour, and the trend persists
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to 4 hours. H2O2 appears to change the ratio of GSSG:GSH in both cell lines at 1
hour, and the trend persists to 4 hours, although the change is much higher at 2 and 4
hours in A549 cells. BSO appears to change the GSSG:GSH ratio at 4 hours in A549




























Figure 99: The effect of cytomix, H2O2 and BSO on the GSSG:GSH ratio in A549
cells at 30 minutes, 1 hour, 2 hours and 4 hours. Histograms represent the means, and
























Figure 100: The effect of cytomix, H2O2 and BSO on the GSSG:GSH ratio in 16HBE
cells at 30 minutes, 1 hour, 2 hours and 4 hours. Histograms represent the means, and
SEMs are absent due to a high level of variation between experiments (n=3).
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6.8 SUMMARY
• Nuclear binding of NF-kB is increased, indicating NF-kB is activated, in both
A549 and 16HBE cells at 30 minutes by treatment with cytomix, TNF-a, and
IL1—13. IFN-y did not have any effect on NF-kB activation. Treatment with LPS
for 30 minutes activates NF-kB in 16HBE cells only.
• NF-kB is activated in both A549 and 16HBE cells treated with H2O2 at 2 hours
but not at 30 minutes.
• NF-kB is activated by BSO at 4 hours in A549 cells and at 2 and 4 hours in
16HBE cells.
• The four thiol compounds, NAC, NAL, GSH, and GSHMEE have no effect on
NF-kB activation at 4 hours in either A549 or 16HBE cells.
• Pre-treatment of both A549 and 16HBE cells with the 4 thiol compounds
followed by cytomix treatment for 30 minutes had no effect on cytomix-induced
NF-kB activation.
• Pre-treatment of both A549 and 16HBE cells with thiol compounds followed by
H2O2 for 2 hours decreased FLCL-induced NF-kB activation.
• Pre-treatment of both A549 and 16HBE cells with thiol compounds followed by
TNF-a for 30 minutes had a variable effect on TNF-a-induced NF-kB
activation. A549 cells pre-treated with NAL and GSFI decreased TNF-a-induced
NF-kB activation, and 16HBE cells pre-treated with NAL also had decreased
TNF-a-induced NF-kB activation. The other thiol compounds had no effect on
TNF-a-induced NF-kB activation in either cell type.
• Rotenone had no effect on cytomix induced NF-kB activation in either A549 or
16HBE cells.
• Rotenone had no effect on H2O2 induced NF-kB activation in either A549 or
16HBE cells.
• Rotenone inhibited TNF-a induced NF-kB activation in both A549 and 16HBE
cells.




Activation of the nuclear transcription factor NF-kB is considered to be a key
element in cellular inflammatory responses and ROS are considered to be important
mediators ofNF-kB activation (Marietta, 1993; Matthews et al., 1992; Schreck and
Baeuerle, 1994). Oxidant stress (thought to be mediated by H2O2 which can function
as a signaling molecule in the activation of gene expression (Kretx-Remy et al.,
1996)) has been shown to be involved in NF-kB activation and this activation can
often be inhibited by antioxidants (Flohe et al., 1997; Meyer et al., 1993; Sato et al.,
1996; Schreck et al., 1991). However, the pathways involved in NF-kB activation
are not fully evaluated and elucidation of the mechanisms involved are likely to be
important in the development of strategies for therapeutic intervention in
inflammatory diseases including those in the lungs.
The NF-kB family consists of a variety of proteins (Baldwin, 1996) but the most
studied protein is the p50/p65 heterodimer, which is normally present in an inactive
form in the cytosol due to its association with the inhibitory protein, IkB. Activation
of NF-kB involves the phosphorylation and degradation of the IkB subunit, which
masks the DNA binding sites of NF-kB, enabling NF-kB to move into the nucleus
where it can bind to DNA. NF-kB activation can be measured by the electrophoretic
mobility shift assay (EMSA), which demonstrates NF-kB binding in the cell nucleus
using a radiolabeled oligonucleotide which binds to the DNA binding site ofNF-kB.
Demonstration ofNF-kB binding by EMSA often produces 3 bands on the gel and I
therefore tried to determine the nature of these bands. This was achieved in 2 ways.
The first was to use polyclonal anitbodies against the p50 and p65 subunits. This is
known as a supershift assay, where binding of the antibodies to the relevant
radiolabeled subunit of NF-kB increases the molecular weight of that subunit and
thus retards its progress, or causes it to 'shift' on the gel from its original position.
My results show a supershift of the 2 bands thought to be p50 and p65, both
antibodies causing a decrease in intensity of the 2 bands which are normally
observed. These results indicate that the two top bands (which actually often appear
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as one large band) contain the p50 and p65 subunits ofNF-kB. In order to confirm
this further, a recombinant IicBa protein was used. The protein is unlabelled and
added to samples prior to addition of the labeled oligonucleotide, and it can therefore
bind to NF-kB, masking the DNA binding site, and prevent the oligonucleotide
binding. Addition of the recombinant protein therefore decreases the NF-kB band
observed in activated cells. The results show that addition of the recombinant protein
reduces the intensity of the 2 bands produced with cytomix treatment, suggesting that
the bands observed are NF-kB. The use of the FcBa-protein also suggests that the
ikba subunit is a likely candidate for inhibition of NF-kB in these cell lines. The
bottom band is thought to be either a product of denaturation or a non-NF-kb
protein since it has been shown by Mr M. Lawson of the Rayne Laboratory to be a
non-specific product in a cold displacement assay.
Regulation of NF-kB involves cascades of phosphorylation and dephosphorylation
(Baldwin, 1996; MacKichan et al., 1996). Many enzymes are involved in the
pathway leading to NF-kB activation and may be the target of redox regulation
involving oxidants. Most active sites of enzymes contain sulphide bonds, and both
oxidising and reducing agents can modify their activity. It has also been suggested
that different forms of the inhibitory unit, IkB, are regulated by different types of
kinases, which are likely to play a part in the activation ofNF-kB (Marietta, 1993)
and these kinases are also likely to be susceptible to redox regulation. Taking into
account the multiple pathways leading to the transcriptional activation of NF-kB
dependent genes, the modulating effects of redox processes are likely to be variable
and the pathway for NF-kB activation may be both cell specific and dependant on
the stimulus involved (Flohe et al., 1997). Evidence for the role of ROS in NF-kB
activation arises from the fact that many of the agents that activate NF-kB, also
release ROS or are themselves oxidants (Flohe et al., 1997).
In both the A549 and 16HBE cells cytomix, H2O2, TNF-a and IL1—p activated NF-
kB. IFN-y did not have any obvious effect on NF-kB activation and LPS induced
activation of NF-kB in 16HBE cells only. The gene for iNOS has been shown to
160
contain 5 NF-kB binding sites (Taylor et al., 1998). Binding ofNF-kB to the iNOS
gene has previously been observed in A549 cells stimulated with TNF-a and IL1—(3,
but not IFN-y (Taylor et al., 1998). NF-kB activation is considered to be necessary
for cytokine induction of iNOS (Amoah-Apraku et al., 1995; Xie et al., 1994)
although differences have been observed between murine and human iNOS (Spitsin
et al., 1997). Although NF-kB activation is sufficient for iNOS induction by LPS in
murine RAW 264.7 cells, it is not sufficient for iNOS induction in human A549
cells. NF-kB activation is thus essential, but its activation alone is not necessarily
sufficient for iNOS activation, other transcription factors may be necessary in the
induction of iNOS (Amoah-Apraku et al., 1995; Spitsin et al., 1997).
ROS have been implicated in the activation ofNF-kB (Flohe et al., 1997; Hecker et
al., 1996b; Meyer et al., 1993; Schreck et al., 1991). Antioxidants have been used to
prevent ROS induced NF-kB activation. Therefore the antioxidant status of the cells,
such as GSH levels, may be important in modulating NF-kB activation by ROS.
BSO, as discussed previously, is often used to decrease GSH levels in cells by
blocking GSH synthesis. It has been reported (Ginn-Pease and Whisler, 1996), that in
Jurkat T cells, pre-treatment with BSO decreased NF-kB activation by H2O2. This
suggests that GSH may play a role in preventing NF-kB activation by oxidants. My
results, in contrast, show that in airspace epithelial cells, BSO activates NF-kB and
induces iNOS. Pre-treatment of cells with BSO had no effect on cytomix-induced
NO levels. This suggests that decreasing GSH levels could be involved in NF-kB
activation, so that decreased GSH levels may activate NF-kB activation. The
mechanism may be through a general increase in ROS levels, (which would normally
be quenched by GSH) or due to a change in the ratio of GSSG:GSH. A change in the
intracellular redox state, particularly that of GSH may result in the modification of
sulfhydryl groups present on the cascade of enzymes involved in NF-kB activation
thus causing activation. Changes in the redox state may also inhibit NF-kB binding
to DNA, since the DNA binding site of NF-kB contains critical cysteine residues
which need to be in a reduced state for binding to occur.
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Antioxidants, particularly thiol containing compounds, are in widespread use to
prevent activation of transcription factors such as NF-kB, and thus inhibition of the
release of inflammatory mediators such as cytokines and NO (Flohe et al., 1997;
Hecker et al., 1996a; Hecker et al., 1996b; Meyer et al., 1993; Sato et al., 1996;
Schreck et al., 1991). NAC and NAL are potent scavenger's of the hydroxyl radical
(Vanderbist et al., 1996) and NAC has been shown to protect against the toxic effects
of H2O2 (Lyons et al., 1992; Mulier et al., 1998). Thiol containing antioxidants are
also able to increase intracellular GSH levels. Different antioxidants have, however,
been shown to have different effects on iNOS induction at both pre and post-
transcriptional levels (Hecker et al., 1996b). It has been reported (Hecker et al.,
1996b) that in vascular smooth muscle cells, although a variety of antioxidants are
able to inhibit superoxide production by Phorbol 12-myrisate 13-acetate (PMA),
indicating they are working efficiently within the cell, they don't necessarily inhibit
iNOS induction by IL1—13, suggesting that ROS are not necessary for cytokine
induced NF-kB activation and iNOS induction.
I examined the effects of thiol antioxidants on NF-kB activation (the 4 antioxidants
themselves having no effect on NF-kB activation (data not shown)) by cytomix,
TNF-a and H2O2. Both A549 and 16HBE cells were pre-treated with the 4 thiol
antioxidants NAC, NAL, GSH, and GSHMEE for 4 hours, the time point at which
intracellular GSH levels are increased. The cells were then washed thoroughly (to
avoid scavenging of ROS) and treated with cytomix, TNF-a or H2O2. The data show
that pre-treatment of both A549 and 16HBE cells with the thiol compounds followed
by cytomix for 30 minutes had no effect on cytomix induced NF-kB activation. This
suggests that increasing GSH by these compounds does not effect NF-kB activation
by cytokines. Pre-treatment of the cells with the thiol compounds followed by H2O2
for 2 hours did, however, decrease H2O2 induced NF-kB activation, suggesting that
oxidant-induced NF-kB activation can be inhibited by increasing GSH levels. Pre-
treatment of the cells with thiol compounds followed by TNF-a for 30 minutes, gave
variable results. Pre-treatment of A549 cells with NAL and GSH decreased NF-kB
activation compared to TNF-a alone. A similar result was observed in 16HBE cells
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pre-treated with NAL. The result shown with TNF-a was surprising since TNF-a is
known to increase superoxide anion release from the mitochondria and increased
GSH levels would therefore likely inhibit NF-kB activation by TNF-a. The results
observed may therefore be explained in 2 ways. One is that the level of TNF-a used
to activate NF-kB was too high, and partial protection may be observed with lower
levels of TNF-a. Since results show that there is a huge increase in NF-kB
activation with lOng/ml of TNF-a, I may not be able to observe any partial
inhibition that is occurring. The second explanation is that although TNF-a releases
oxidants that activate NF-kB, it may also activate a separate pathway that does not
involve oxidants.
Rotenone was therefore used to distinguish between these two theories. Rotenone is
an inhibitor of complex 1 of the mitochondrial electron transport chain and prevents
superoxide anion release upon stimulation by compounds such as TNF-a.
Cells were pre-treated for 30 minutes with rotenone followed by cytomix or TNF-a
for 30 minutes, or H2O2 for 2 hours. A549 cells treated with rotenone followed by
cytomix or H2O2 showed no decrease in NF-kB activation following either stimuli.
This result was also observed in 16HBE cells. In both cell types, cells pre-treated
with rotenone followed by TNF-a, had reduced activation of NF-kB by TNF-a.
This suggests that TNF-a may activate NF-kB by increasing ROS release from the
mitochondria. INOS mRNA expression was also assessed following pre-treatment
with rotenone followed by cytomix, TNF-a and H2O2. Results were only obtained
for the A549 cells however, since rotenone and chloroform caused cell death in the
16HBE cells at 4 hours. Using RT-PCR, pre-treatment of cells with rotenone had no
effect on cytomix or H2O2 induced iNOS levels, but inhibited TNF-a induced iNOS.
Thus it is likely that TNF-a activates NF-kB and induces NO by an oxidant-
mediated pathway. It is therefore likely that inhibition of TNF-a induced NF-kB
activation by increased GSH levels is not observed with all compounds due to the
dose of TNF-a being to high and the increase in intracellular GSH by the
antioxidants my not be sufficient to reduce the amount of ROS produced by TNF-a.
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A direct oxidant (H202) mediated pathway of NF-kB activation can therefore be
blocked by increasing GSH levels with thiol antioxidants, but increasing GSH levels
has no effect on cytomix induced NF-kB activation, suggesting that cytomix may
activate NF-kB by a different pathway. This is further supported by results observed
with rotenone. Rotenone had no effect on cytomix induced NF-kB and iNOS
induction, suggesting that production of oxidants by cytomix do not play an essential
role in cytokine induced NF-kB activation.
Although it is widely accepted that NF-kB is activated by ROS and that this
activation can be inhibited by antioxidants, particularly thiol-containing antioxidants,
there is growing controversy that more than one pathway exists in the activation of
NF-kB. In support of the data presented herein there are now several reports
showing evidence that NF-kB may be activated by a pathway that is unaffected by
antioxidants and may not rely on oxidants.
In studies of NF-kB activation by ROS in Jurkat T cells, KB epidermal cells, and
EL4.NOB-1 T cells, (Brennan and O'Neill, 1994) both H202 and TNF-a activated
NF-kB in Jurkat T cells and this activation was inhibited by NAC. However, NAC
did not offer protection against H202 and TNF-a in the other two cells types. This
suggests that the ROS model ofNF-kB activation is dependant on the cell type and
may not be necessary for NF-kB activation by TNF-a. Further evidence against the
hypothesis that ROS are always necessary for the activation of NF-kB has been
reported by MacKichie et al (MacKichie et al., 1996), who found that the pi05 Rel
protein, which contains the p50 subunit of NF-kB and the IkB inhibitor, requires
phosphorylation for proteolytic processing into the p50 and IkB subunits, and hence
NF-kB activation. Compounds that block IkB phosphorylation and degradation, also
block phosphorylation of the pi05 protein, but antioxidants do not block
phosphorylation, suggesting that a redox insensitive pathway may exist. The
insensitivity of the pi 05 protein to antioxidants demonstrates that each IkB inhibitor
is independently regulated, and the response induced reflects the specific role of the
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inhibitor in determining the response ofNF-kB to stimuli (MacKichan et ah, 1996).
Suzuki et al (Suzuki et al., 1994) reported that 2 activators of NF-kB, calyculin A
and okadaic acid, were not inhibited by NAC, even though calyculin A was inhibited
by rotenone (suggesting oxidant involvement). Both calyculin A and okadaic acid are
phosphatase inhibitors and therefore target signal transduction. It is thought that they
may either target the pathway downstream from an antioxidant sensitive step or work
via a different signaling pathway, since inhibition of phosphatases is not a step in
TNF-a induced NF-kB activation (Suzuki et al., 1994).
Thus it is possible that cytomix and H2O2 activate NF-kB via different pathways.
H2O2 by an oxidant-induced pathway and cytomix by a signaling pathway
independent of oxidants. TNF-a produces oxidants from the mitochondria and this
may enhance cytomix induced NF-kB activation but is probably not essential for
activation.
Although there are many reports suggesting that ROS are involved in NF-kB
activation and that antioxidants can inhibit this activation, few have focused on the
role of the redox state of the cell, in particular GSH.
Thioredoxin (TRX) is an important cellular protein with antioxidant properties and is
important in NF-kB activation since it is involved in the binding ofNF-kB to DNA
(Hayashi et al., 1993). It is possible that redox regulation ofNF-kB by TRX occurs
at a point after the dissociation of IkB from NF-kB. The DNA binding motif of
NF-kB contains cysteine residues which need to be reduced for DNA binding of
NF-kB to occur, and TRX ensures that they remain reduced. Thus a redox
mechanism exists, mediated by TRX which regulates NF-xB-mediated gene
expression (Hayashi et al., 1993). GSSG, which is formed by oxidation of GSH, acts
as an oxidant and it is possible that levels of GSSG play an important role in
preventing the activation of NF-kB, by competing with TRX for the cysteine
residues, oxidising them and ensuring NF-kB does not bind to DNA. Droge et al
(Droge et al., 1994) reported that low levels of GSSG prevented NF-kB activation
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where as too high levels of GSSG inhibited DNA binding ofNF-kB and effects of
GSSG were antagonised by TRX. NF-kB is thought to be activated by a cascade of
membrane bound and cytoplasmic protein kinases including tyrosine kinases of the
src family, 2 of which are activated by H2O2. GSSG may play a role in stabilizing
phosphorylation of the kinases, (and thus activation of NF-kB), by oxidising the
active sites of phosphatases and therefore inhibiting their phosphatase activity.
Evidence that GSSG is involved in NF-kB activation is also shown by the fact that a
potent inducer of NF-kB teradecanoylphorbolacetate (TPA) is associated with
increased GSSG levels and a change in the GSSG:GSH ratio. Droge et al (Droge et
al., 1994) reported that BSO inhibited TPA activation of NF-kB, and decreased
GSSG levels. BCNU, a compound that inhibits glutathione reductase and therefore
increases GSSG levels, increased TPA induced activation of NF-kB. It is therefore
possible that GSSG levels are important in NF-kB activation and that H2O2 or
oxidants activate NF-kB by altering the redox state of the cell, in particular the level
of GSSG. However high levels of GSSG can inhibit NF-kB binding to DNA, and
this inhibition occurs even in the presence of an excess of thiols, and only by
increasing levels of TRX is this inhibition overcome (Droge et al., 1994a). Cells
containing higher levels of TRX also require increased levels of GSSG for activation
of NF-kB producing further evidence that GSSG is involved. DNA binding of
NF-kB can be inhibited by thiol modulating agents and enhanced by reducing agents
as shown by mutating cysteine residues in the binding site (Matthews et al., 1992).
Thus it is likely that an optimal level of GSSG is required for NF-kB activation, and
this is likely to occur during an oxidant stress (Droge et al., 1994; Gaiter et al., 1997).
I therefore measured the levels of GSSG in cells treated with cytomix, H2O2 and
BSO at various time points ranging from 30 minutes to 4 hours, and determined if
the ratio of GSSG:GSH had any effect on NF-kB activation. The data show that the
ratio of GSSG:GSH increases with cytomix at 1 and 2 hours in both cell types.
Although TNF-a increases ROS levels at less than 30 minutes, it is unlikely that the
GSSG:GSH ratio is involved in cytomix induced NF-kB activation, since the ratio
changed at a time point after NF-kB activation occurs. The increase observed at
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these later time points (1-4 hours) is probably due to the increased ROS levels caused
by TNF-a. This change in the ratio may contribute to NF-kB activation but is
probably not essential to cytomix-mediated NF-kB activation. H2O2, however,
produced an increased GSSG:GSH ratio at 1 and 2 hours, and this may be important
in the activation of NF-kB by ROS. Likewise, BSO produces an increased
GSSG:GSH ratio at time points when NF-kB activation occurs (4 hours in A549
cells and 2 hours in 16HBE cells). It is therefore possible that oxidant mediated
activation ofNF-kB is due, at least in part, to the levels of GSSG, in particular the
ratio of GSSG:GSH, which activates NF-kB at lower levels, and inhibits activation
at higher levels. Inhibition ofNF-kB activation by high levels of GSSG is observed
with BSO, which increases the ratio of GSSG:GSH at 24 hours by a much larger
amount (data not shown) than that observed at 4 hours but NF-kB activity is not
observed at 24 hours. The change in ratio at these time points is also likely to be the
cause for the decrease in GSH observed with the treatments at 24 hours.
In conclusion, NF-kB is activated by stimuli that induce NOS but data suggests that
NF-kB is activated by 2 pathways, one an oxidant mediated pathway, which can be
inhibited by thiol-containing antioxidants that increase intracellular GSH levels. This
activation is also associated with a shift in the ratio of GSSG:GSH. The other
pathway appears to be independent of oxidants in that thiol-containing antioxidants
and increased GSH levels have no effect on NF-kB activation and the ratio of
GSSG:GSH in not associated with NF-kB activation. Thus it is likely that NF-kB





• Intracellular GSH is relatively stable in both A549 and 16HBE cells at between
70 and 99% confluency in the presence of serum.
• NO is induced by cytomix, TNF-a, and H2O2 in both A549 and 16HBE cells,
and is also induced by LPS in 16HBE cells as measured by both nitrite
production and iNOS mRNA levels.
• This induction is concomitant with a decrease in GSH levels in both A549 and
16HBE cells.
• This induction is also concomitant with NF-kB activation, as measured by the
electromobility shift assay in both A549 and 16HBE cells.
• BSO causes a decrease in GSH levels, which is both accompanied by an increase
in NO release, iNOS mRNA and NF-kB activation in both A549 and 16HBE
cells.
• The thiol compounds NAC, NAL, GSH, and GSHMEE cause a significant
increase in GSH at 4 hours in both A549 and 16HBE cells.
• Pre-treatment of cells with thiol compounds followed by cytomix had no effect
on cytomix-induced NO release, iNOS mRNA or NF-kB activation in both
A549 and 16HBE cells.
• Pre-treatment of cells with thiol compounds followed by H2O2 resulted in a
decrease in H202-induced NO release, iNOS mRNA and NF-kB activation in
both A549 and 16HBE cells.
• Pre-treatment of cells with thiol compounds followed by TNF-a had no effect on
TNF-a-induced NF-kB activation in both A549 and 16HBE cells.
• Rotenone inhibited TNF-a induced NF-kB activation but had no effect on
cytomix or H2O2 induced activation in A549 or 16HBE cells. This effect was also
observed in A549 iNOS mRNA levels.
• The ratio of GSSG:GSH is increased in cells following treatment with cytomix,
H2O2 and BSO. The ratio is increased in both H2O2 and BSO treated cells at time
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points when NF-kB activation occurs, but occurs after the time at which cytomix
induces NF-kB activation.
• There are no obvious differences between the two cell types used, the A549 cell
line and the 16HBE cell line, other than the effects observed with LPS in 16HBE
cells.
7.2 CONCLUSIONS
I should emphasise that the use of cell lines are a very useful tool in investigating the
metabolic and molecular pathways of individual cells but they cannot mimic the
complexities of the situation in vivo where interactions between cell types, metabolic
products and the environment occur. The use of cell lines, however, allows the
investigation to focus on individual mechanisms, in vitro, (Gille and Joenje, 1992).
The data obtained will therefore give insight into pathways which need to be
elucidated in order to understand certain pathologic conditions but results need to be
validated both in primary cell cultures and in vivo. Harvesting of cells from the body
leads to changes within the cells, such as antioxidants whose levels change within 30
minutes of removal of type II cells from the lung (Kinnula et ah, 1992), and thus,
even in primary cultures, the antioxidant response is likely to be different from that
seen in vivo. Transformation of cells in order to facilitate their growth is also likely
to change some cellular characteristics. The cells used herein, however, do retain
many of the characteristics of the original cell and since there are no obvious
differences between cell lines, results will hopefully resemble those in vivo.
Are intracellular GSH levels affected by culture conditions, and if so
when are they relatively stable?
Intracellular GSH levels were measured in both A549 and 16HBE cells at various
confluencies. The cells were seeded at low densities in medium complemented with
10% serum. GSH was found to increase as cells proliferated. A relatively stable
level of GSH was obtained from 70% to 100% confluency in both cell types, GSH
decreased once cells had formed a confluent monolayer. Cells grown in serum free
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medium had lower GSH levels than those grown in serum supplemented medium,
and therefore cells were treated at 70% confluency in serum supplemented medium.
Can NO' be induced in both A549 and 16HBE cells with cytomix,
individual cytokines, LPS and H2O2?
NO was successfully induced at 24 hours in both cell lines following cyomix,
TNF-a and H2O2. LPS has no effect in A549 cells, but increased NO levels in
16HBE cells. mRNA levels for iNOS were also observed in both cell types, and
iNOS was switched on in both cell types following cytomix, TNF-a, H2O2, and LPS
in 16HBE cells. Cells stimulated with increased cytomix levels (20ng/ml) or with co-
incubation of cytomix and H2O2 did not show increased levels of NO release
compared to cytomix, lOng/ml. This is possibly due to negative feedback by NO
itself or due to the top of the concentration response being reached.
Does NO' induction affect intracellular GSH levels?
Intracellular GSH levels were measured at 24 hours, the time point at which NO was
released from the cell. An increase in NO was concomitant with a decrease in
intracellular GSH levels. The decrease in GSH was not, however, due to NO
formation, since inhibitors of NO did not prevent the decrease in GSH. Decreased
GSH levels were therefore likely to be due to the effects of the stimuli themselves,
such as TNF-a, and H2O2. TNF-a causes the release of superoxide anions from the
mitochondria, which are converted to H2O2 by SOD in the cytosol. H2O2, the likely
ROS involved in NF-kB activation, (Kretx-Remy et ah, 1996) and hence NO
induction is broken down by GPx and GSH to form GSSG and this is likely to result
in a decrease in intracellular GSH since GSSG is exported from the cells.
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Does decreasing intracellular GSH affect NO" induction?
BSO was used to decrease GSH since GSH is thought to be involved in NO
induction. I found that decreasing GSH with BSO resulted in the induction of iNOS
and NO release. The increase in NO following addition ofBSO is likely to be due to
an increase in the intracellular ROS concentrations. ROS are released from cellular
reactions and organelles and are normally effectively quenched by GSH. However if
GSH levels are decreased, then these oxidants may activate NF-kB and hence induce
iNOS and NO release.
Does increasing GSH affect NO' induction?
The four thiol compounds NAC, NAL, GSH, and GSHMEE were used to increase
GSH levels in both A549 and 16HBE cells. Cells were then pre-treated with the 4
thiol compounds followed by cytomix and H2O2. Pre-treatment of cells with thiol
compounds followed by cytomix had no effect on cytomix induced NO induction or
iNOS mRNA levels, suggesting that the redox status of the cell, in particular that of
GSH is not involved in the induction of iNOS by cytomix. Pre-treatment of cells with
thiol compounds followed by H2O2 however, decreased H2O2 induced NO induction
and iNOS mRNA levels, suggesting that GSH is involved in oxidant induced NO.
GSH may therefore be acting as an antioxidant, scavenging ROS, or may be involved
directly in the induction ofNO.
Is NF-kB activated in cells treated with cytomix, individual cytokines,
LPS and H202?
NF-kB is activated in both A549 and 16HBE cells following cytomix, TNF-a,
ILl-p and H202. IFN-y had no obvious effect on NF-kB activation and LPS
activates NF-kB in 16HBE cells only. Activation occurs at 30 minutes for cytokines
and LPS and 2 hours for H202. H202 may take longer than cytomix since it is
possible that NF-kB activation by H202 requires changes in the redox state of the
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cell, whereas cytokines activate NF-kB independently of the redox state of the cells.
It is possible that H2O2 activation ofNF-kB requires a shift in the GSSG:GSH ratio.
Does increasing intracellular GSH levels affect cytomix, TNF-a and
H2O2 induction of NF-kB activation?
Pre-treatment of both cell types with thiol compounds, followed by cytomix had no
effect on cytomix induced NF-kB activation. It did however decrease H2O2 induced
activation of NF-kB and had a varied effect on TNF-a induced activation. This
suggests that increased GSH levels can prevent oxidant induced NF-kB activation.
TNF-a works via increasing ROS within the cell. Thus NF-kB activation by
TNF-a would therefore be expected to be decreased by increased GSH levels, but it
was only partially decreased by some thiol compounds, and not at all by other thiol
compounds. To determine if TNF-a was having its effect via oxidant induced
activation, I examined the effects of rotenone on TNF-a, cytomix and H2O2 induced
NF-kB activation and iNOS mRNA induction. Rotenone inhibits complex I of the
electron transport chain, and therefore prevents ROS release from the mitochondria.
Cells pre-treated with rotenone followed by cytomix and H2O2 had no effect on
cytomix or H2O2 induced NF-kB activation, suggesting that H2O2 is working as a
direct oxidant, independent of the mitochondria, and cytomix is working via a
pathway that does not rely on increased ROS for NF-kB activation. Cells pre-treated
with rotenone followed by TNF-a, however, showed reduced levels of NF-kB
activation, compared to TNF-a alone, suggesting that TNF-a is working via an
oxidant mediated pathway. This data was further supported by similar observations
on TNF-a-induced iNOS mRNA levels in rotenone treated A549 cells. The dose of
TNF-a used was lOng/ml which produced a huge increase in the activation of
NF-kB. The increase in GSH levels produced by the thiol compounds may therefore
not be completely sufficient in blocking ROS released by TNF-a and hence only
partially prevent NF-kB activation. TNF-a induced NF-kB activation using lower
doses of TNF-a may be inhibited by increased GSH levels. Since rotenone had no
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effect on cytomix induced NF-kB activation or iNOS induction, it can be assumed
that cytomix is not working via superoxide anion production from the mitochondria
and hence its concentration is not important in protection studies.
Does the GSSG:GSH ratio affect NF-kB activation by cytokines, H2O2
and BSO?
GSSG levels were measured in both A549 and 16HBE cells between 30 minutes and
4 hours in order to determine if the ratio of GSSG:GSH was increased at the time of
NF-kB activation. Cytomix activates NF-kB at 30 minutes and there is not a large
difference in the GSSG:GSH ratio in either cell type at 30 minutes, suggesting
cytomix is not working via a mechanism which depends on the GSSG:GSH ratio.
H2O2, however, produced an increased GSSG:GSH ratio at 1 hour, continuing to 4
hours, suggesting that an increase in the GSSG:GSH ratio may play a part in
H202induction. Activation of NF-kB was not measured at 1 hour, but H2O2
increased NF-kB activation at 2 hours, a time point at which the GSSG:GSH ratio
was high in both cell types. BSO increases the GSSG:GSH levels at 4 hours in A549
cells and 2 hours in the 16HBE cells, and this increase continues to 24 hours (data
not shown), and is likely to be involved in BSO activation of NF-kB and iNOS
induction. The ratio of GSSG:GSE1 in cytomix and H2O2 treated cells returns to that
of control at 24 hours, suggesting that the decrease in GSH observed at 24 hours is
due to the oxidation of GSSG:GSE1 at earlier time points, and an efflux of GSSG
from the cell as it accumulates.
7.3 TO CONCLUDE:
Both A549 and 16HBE cells were treated in the same manner throughout the thesis
and there were no obvious differences between the cells in these experiments, other
than the effect of LPS on 16HBE cells. It has been reported (Amoah-Apraku et al.,
1995) that LPS is only a weak inducer of NF-kB in non-immune cells, and it is
insufficient to activate NF-kB and iNOS in human A549 cells, (Spitsin et al., 1997)
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which require a mixture of cytokines. 16HBE cells are therefore more susceptible to
LPS, and bronchial epithelial cells may therefore play a bigger role in the immune
response in vivo.
NO is induced in both A549 and 16HBE cells by cytomix, TNF-a, EI2O2 and BSO
and this increase is concomitant with a decrease in GSH. The decrease in GSH is
not, however dependent on NO release, but is likely to be caused by an increased
oxidant burden which alters the GSSG:GSH ratio. Both H2O2 and BSO increase the
GSSG:GSH ratio at the time point at which they activate NF-kB, suggesting that the
GSSG:GSH ratio may play a part in oxidant induced NF-kB activation and iNOS
induction. Cytomix, however, is likely to activate NF-kB and induce iNOS by a
different pathway, which may or may not involve oxidants, since the ratio of
GSSG:GSE1 is not increased at the time point at which NF-kB is activated. This is
supported by the data using the thiol compounds to increase GSH levels. Increased
GSH levels can reduce H2O2 induced NF-kB activation and NO release, they
cannot, however reduce cytokine induced NF-kB activation or NO release. Thus
separate pathways are likely to exist in the induction of NO , and further
investigation into these pathways may provide a mechanism for selectively inhibiting
NO induction during inflammation. During inflammation NO can be induced in
large amounts by NF-kB activation, and may itself cause lung damage due to the
formation of peroxynitrite (Ignarro and Murad, 1995; Xie et al., 1994).
Peroxynitrite, is formed in large amounts during inflammation due to the availability
or ROS and NO and inhibition of its formation may be beneficial in preventing lung
damage such as that observed in asthma, COPD, ARDS and emphysema (Kharitonov
et al., 1996; Kooy et al., 1995; Royall.JA. and Kooy, 1997; Saleh et al., 1997).
7.4 FUTURE STUDIES
• Since cell lines were used throughout this thesis it would be interesting to carry
out the key experiments in primary cell cultures, to determine if the effects
observed in this thesis also occur in primary culture. This would indicate that the
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pathways determined herein are also the pathways that occur in vivo and may
therefore provide insight into mechanisms for modulating the activation of
NF-kB and NO induction selectively in inflammatory conditions of the lungs. It
would therefore be ideal to:
♦ Investigate the effects of cytomix, H2O2 and TNF-a on NO induction in
primary cell cultures and to examine the effect ofNO induction on GSH levels.
♦ Investigate the effects of cytomix, H2O2 and TNF-a on NF-kB activation
in primary cell cultures, and to determine if increased GSH levels prevent
NF-kB induced activation.
• Since it is likely that GSH and GSSG levels are important in NF-kB activation,
and possibly are more important than ROS themselves, future studies should
examine the effect of changing intracellular GSSG levels and the GSH:GSSG
ratio by compounds such as BCNU, and determine the effect of altered GSSG
levels on cytomix and H2O2 induced NF-kB activation. The assay used herein
for measuring GSSG levels does not seem to be sensitive enough for accurate
measurements, although results show a trend throughout, statistical analysis was
not possible. It would therefore be beneficial to either find a different assay for
GSSG measurement, or to increase the volumes used from lOOpl to a few
millilitres, which would enable the adjustment of the pH of the samples.
• NF-kB has been shown to be necessary in the induction of iNOS and NO but not
necessarily sufficient in some circumstances. Further studies should therefore
investigate:
♦ Other transcription factors such as IRF-1, the interferon regulatory
factor, which is activated by IFN-y, and will possibly give insight into a non-
oxidative pathway induced by cytomix. Since IFN-y does not have a large effect
on NF-kB activation itself, it is likely to be working in a synergistic manner with
TNF-a and IL1-P in the induction ofNO.
Different parts of the pathway involved in iNOS induction should be examined such
as:
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♦ IkB levels, degradation indicating NF-kB activation, and comparison of
IkB levels to GSH and GSSG levels, in particular the GSH:GSSG ratio.
♦ Investigation of kinase phosphorylation which is implicated in the
activation of NF-kB in order to determine if varying levels of GSSG affects
phosphorylation and NF-kB activation.
• To determine an alternative method for dissolving rotenone (such as DMSO) to
ensure future experiments using rotenone do not result in cell death.
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